0000875320-24-000139.txt : 20240507 0000875320-24-000139.hdr.sgml : 20240507 20240507161428 ACCESSION NUMBER: 0000875320-24-000139 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 80 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240507 DATE AS OF CHANGE: 20240507 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA CENTRAL INDEX KEY: 0000875320 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 043039129 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-19319 FILM NUMBER: 24922041 BUSINESS ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 6173416393 MAIL ADDRESS: STREET 1: 50 NORTHERN AVENUE CITY: BOSTON STATE: MA ZIP: 02210 10-Q 1 vrtx-20240331.htm 10-Q vrtx-20240331
VERTEX PHARMACEUTICALS INC / MA000087532012/312024Q1falseP1M372442339468427340382xbrli:sharesiso4217:USDiso4217:USDxbrli:sharesvrtx:segmentvrtx:targetxbrli:pure00008753202024-01-012024-03-3100008753202024-04-3000008753202023-01-012023-03-3100008753202024-03-3100008753202023-12-310000875320us-gaap:CommonStockMember2022-12-310000875320us-gaap:AdditionalPaidInCapitalMember2022-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000875320us-gaap:RetainedEarningsMember2022-12-3100008753202022-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000875320us-gaap:RetainedEarningsMember2023-01-012023-03-310000875320us-gaap:CommonStockMember2023-01-012023-03-310000875320us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000875320us-gaap:CommonStockMember2023-03-310000875320us-gaap:AdditionalPaidInCapitalMember2023-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000875320us-gaap:RetainedEarningsMember2023-03-3100008753202023-03-310000875320us-gaap:CommonStockMember2023-12-310000875320us-gaap:AdditionalPaidInCapitalMember2023-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000875320us-gaap:RetainedEarningsMember2023-12-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000875320us-gaap:RetainedEarningsMember2024-01-012024-03-310000875320us-gaap:CommonStockMember2024-01-012024-03-310000875320us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-310000875320us-gaap:CommonStockMember2024-03-310000875320us-gaap:AdditionalPaidInCapitalMember2024-03-310000875320us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000875320us-gaap:RetainedEarningsMember2024-03-310000875320vrtx:TRIKAFTAKAFTRIOMember2024-01-012024-03-310000875320vrtx:TRIKAFTAKAFTRIOMember2023-01-012023-03-310000875320vrtx:OtherCysticFibrosisProductsMember2024-01-012024-03-310000875320vrtx:OtherCysticFibrosisProductsMember2023-01-012023-03-310000875320country:US2024-01-012024-03-310000875320country:US2023-01-012023-03-310000875320srt:EuropeMember2024-01-012024-03-310000875320srt:EuropeMember2023-01-012023-03-310000875320vrtx:OtherNonU.S.Member2024-01-012024-03-310000875320vrtx:OtherNonU.S.Member2023-01-012023-03-310000875320us-gaap:NonUsMember2024-01-012024-03-310000875320us-gaap:NonUsMember2023-01-012023-03-310000875320vrtx:CRISPRTherapeuticsAGMember2019-01-012019-12-310000875320vrtx:CRISPRJDCAMember2024-01-012024-01-310000875320vrtx:CRISPRMember2024-03-310000875320vrtx:CRISPRJDCAMember2024-01-012024-03-310000875320vrtx:CRISPRJDCAMember2021-12-310000875320vrtx:CRISPRJDCAMembervrtx:CRISPRMember2021-12-310000875320vrtx:CRISPRJDCAMember2023-01-012023-03-310000875320vrtx:CRISPRT1DMember2023-03-012023-03-310000875320vrtx:EntradaTherapeuticsMember2023-02-012023-02-280000875320vrtx:EntradaTherapeuticsMember2024-01-012024-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000875320us-gaap:EmployeeStockOptionMember2024-01-012024-03-310000875320us-gaap:EmployeeStockOptionMember2023-01-012023-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-03-310000875320us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310000875320us-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2024-03-310000875320us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:USTreasurySecuritiesMember2023-12-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CertificatesOfDepositMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CertificatesOfDepositMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2024-03-310000875320us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2023-12-310000875320us-gaap:EquitySecuritiesMember2024-03-310000875320us-gaap:FairValueInputsLevel3Member2019-12-310000875320us-gaap:FairValueInputsLevel3Membersrt:MinimumMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310000875320us-gaap:FairValueInputsLevel3Membersrt:MaximumMemberus-gaap:MeasurementInputDiscountRateMember2024-03-310000875320us-gaap:USTreasurySecuritiesMember2024-03-310000875320us-gaap:USTreasurySecuritiesMember2023-12-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMember2024-03-310000875320us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-12-310000875320us-gaap:AssetBackedSecuritiesMember2024-03-310000875320us-gaap:AssetBackedSecuritiesMember2023-12-310000875320us-gaap:CertificatesOfDepositMember2024-03-310000875320us-gaap:CertificatesOfDepositMember2023-12-310000875320us-gaap:CorporateDebtSecuritiesMember2024-03-310000875320us-gaap:CorporateDebtSecuritiesMember2023-12-310000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2024-03-310000875320us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember2023-12-310000875320vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember2024-03-310000875320vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember2023-12-3100008753202023-01-012023-12-310000875320us-gaap:CashAndCashEquivalentsMember2024-03-310000875320us-gaap:CashAndCashEquivalentsMember2023-12-310000875320vrtx:MarketableSecuritiesMember2024-03-310000875320vrtx:MarketableSecuritiesMember2023-12-310000875320vrtx:MarketableSecuritiesNoncurrentMember2024-03-310000875320vrtx:MarketableSecuritiesNoncurrentMember2023-12-310000875320us-gaap:OtherAssetsMember2024-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-01-012024-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-01-012024-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2024-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-03-310000875320us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000875320us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-03-310000875320us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000875320us-gaap:CashFlowHedgingMembersrt:MinimumMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000875320us-gaap:CashFlowHedgingMembersrt:MaximumMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:EURus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CADus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:GBPus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:GBPus-gaap:ForeignExchangeForwardMember2023-12-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2024-03-310000875320currency:AUDus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CHFus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMembercurrency:CHFus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000875320us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2024-01-012024-03-310000875320us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedTranslationAdjustmentMemberus-gaap:NondesignatedMemberus-gaap:ForeignExchangeForwardMember2023-01-012023-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2024-03-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:PrepaidExpensesAndOtherCurrentAssetsMemberus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:ForeignExchangeForwardMember2023-12-310000875320us-gaap:RestrictedStockMember2024-01-012024-03-310000875320us-gaap:RestrictedStockMember2023-01-012023-03-310000875320us-gaap:EmployeeStockMember2024-01-012024-03-310000875320us-gaap:EmployeeStockMember2023-01-012023-03-310000875320us-gaap:CostOfSalesMember2024-01-012024-03-310000875320us-gaap:CostOfSalesMember2023-01-012023-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-03-310000875320us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-03-310000875320us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-03-3100008753202023-02-280000875320us-gaap:RevolvingCreditFacilityMember2022-07-310000875320us-gaap:LetterOfCreditMember2022-07-310000875320us-gaap:BaseRateMembersrt:MinimumMemberus-gaap:RevolvingCreditFacilityMember2022-07-012022-07-310000875320us-gaap:BaseRateMemberus-gaap:RevolvingCreditFacilityMembersrt:MaximumMember2022-07-012022-07-310000875320srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembervrtx:SecuredOvernightFinancingRateSOFRMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMembervrtx:SecuredOvernightFinancingRateSOFRMembersrt:MaximumMember2022-07-012022-07-310000875320us-gaap:RevolvingCreditFacilityMember2022-07-012022-07-310000875320vrtx:AlpineMemberus-gaap:SubsequentEventMember2024-04-012024-04-300000875320vrtx:EMorrowMorreyAtkinsonIIIMember2024-01-012024-03-310000875320vrtx:EMorrowMorreyAtkinsonIIIMember2024-03-310000875320vrtx:JonathanBillerMember2024-01-012024-03-310000875320vrtx:JonathanBillerMember2024-03-310000875320vrtx:CarmenBozicMember2024-01-012024-03-310000875320vrtx:CarmenBozicMember2024-03-310000875320vrtx:ReshmaKewalramaniMember2024-01-012024-03-310000875320vrtx:ReshmaKewalramaniMember2024-03-310000875320vrtx:OuraniaNiaTatsisMember2024-01-012024-03-310000875320vrtx:OuraniaNiaTatsisMember2024-03-310000875320vrtx:CharlesFWagnerJrMember2024-01-012024-03-310000875320vrtx:CharlesFWagnerJrMember2024-03-310000875320vrtx:BruceSachsMember2024-01-012024-03-310000875320vrtx:BruceSachsMember2024-03-31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
________________________________________________________
FORM 10-Q
☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2024
or
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM    TO   
Commission file number 000-19319
____________________________________________
Vertex Pharmaceuticals Incorporated
(Exact name of registrant as specified in its charter)

Massachusetts
(State or other jurisdiction of incorporation or organization)

50 Northern Avenue, Boston, Massachusetts
(Address of principal executive offices)

04-3039129
(I.R.S. Employer Identification No.)

02210
(Zip Code)

Registrant’s telephone number, including area code (617) 341-6100
____________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which registered
Common Stock, $0.01 Par Value Per Share
VRTX
The Nasdaq Global Select Market
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer ☒ Accelerated filer ☐ Non-accelerated filer ☐ Smaller reporting company ☐ Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒ 
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
Common Stock, par value $0.01 per share
258,053,387
Outstanding at April 30, 2024


VERTEX PHARMACEUTICALS INCORPORATED
FORM 10-Q
FOR THE QUARTER ENDED MARCH 31, 2024

TABLE OF CONTENTS
Page
Condensed Consolidated Statements of Income - Three Months Ended March 31, 2024 and 2023
Condensed Consolidated Statements of Comprehensive Income - Three Months Ended March 31, 2024 and 2023
Condensed Consolidated Balance Sheets - March 31, 2024 and December 31, 2023
Condensed Consolidated Statements of Shareholders' Equity - Three Months Ended March 31, 2024 and 2023
Condensed Consolidated Statements of Cash Flows - Three Months Ended March 31, 2024 and 2023
Item 1A.

“Vertex,” “we,” “us,” and “our” as used in this Quarterly Report on Form 10-Q refer to Vertex Pharmaceuticals Incorporated, a Massachusetts corporation, and its subsidiaries.
“Vertex®,” “KALYDECO®,” “ORKAMBI®,” “SYMDEKO®,” “SYMKEVI®,” “TRIKAFTA®,” “KAFTRIO®,” and CASGEVY™” are registered trademarks of Vertex. Other brands, names and trademarks contained in this Quarterly Report on Form 10-Q are the property of their respective owners.
We use the brand name for our products when we refer to the product that has been approved and with respect to the indications on the approved label. Otherwise, including in discussions of our development programs, we refer to our compounds and therapies by their scientific (or generic) name or VX developmental designation.


Part I. Financial Information
Item 1.  Financial Statements
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Income
(in millions, except per share amounts)(unaudited)
Three Months Ended March 31,
20242023
Product revenues, net$2,690.6 $2,374.8 
Costs and expenses:
Cost of sales342.6 266.9 
Research and development expenses789.1 742.6 
Acquired in-process research and development expenses76.8 347.1 
Selling, general and administrative expenses342.7 241.1 
Change in fair value of contingent consideration(0.1)(1.9)
Total costs and expenses1,551.1 1,595.8 
Income from operations1,139.5 779.0 
Interest income181.2 122.6 
Interest expense(10.4)(11.4)
Other (expense) income, net(31.2)1.3 
Income before provision for income taxes1,279.1 891.5 
Provision for income taxes179.5 191.7 
Net income$1,099.6 $699.8 
Net income per common share:
Basic$4.26 $2.72 
Diluted$4.21 $2.69 
Shares used in per share calculations:
Basic258.2 257.4 
Diluted261.1 260.3 
The accompanying notes are an integral part of these condensed consolidated financial statements.

2
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Comprehensive Income
(in millions)(unaudited)
Three Months Ended March 31,
20242023
Net income$1,099.6 $699.8 
Other comprehensive income (loss):
Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $5.4 and $(0.8), respectively
(19.7)2.9 
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(12.3) and $7.4, respectively
44.5 (26.8)
Foreign currency translation adjustment6.8 10.0 
Total other comprehensive income (loss)
31.6 (13.9)
Comprehensive income$1,131.2 $685.9 
The accompanying notes are an integral part of these condensed consolidated financial statements.

3
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Balance Sheets
(in millions, except share data)(unaudited)
March 31, 2024December 31, 2023
Assets
Current assets:
Cash and cash equivalents$9,158.0 $10,369.1 
Marketable securities1,013.3 849.2 
Accounts receivable, net1,793.2 1,563.4 
Inventories813.1 738.8 
Prepaid expenses and other current assets
511.1 623.7 
Total current assets
13,288.7 14,144.2 
Property and equipment, net1,172.8 1,159.3 
Goodwill1,088.0 1,088.0 
Other intangible assets, net
834.9 839.9 
Deferred tax assets
1,963.0 1,812.1 
Operating lease assets
312.9 293.6 
Long-term marketable securities4,381.4 2,497.8 
Other assets
875.7 895.3 
Total assets
$23,917.4 $22,730.2 
Liabilities and Shareholders’ Equity
Current liabilities:
Accounts payable$351.4 $364.9 
Accrued expenses2,795.9 2,655.3 
Other current liabilities
648.6 527.2 
Total current liabilities
3,795.9 3,547.4 
Long-term finance lease liabilities361.5 376.1 
Long-term operating lease liabilities359.8 348.6 
Other long-term liabilities
853.6 877.7 
Total liabilities
5,370.8 5,149.8 
Commitments and contingencies— — 
Shareholders’ equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding
— — 
Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively
2.6 2.6 
Additional paid-in capital7,284.7 7,449.7 
Accumulated other comprehensive income (loss)17.3 (14.3)
Retained earnings
11,242.0 10,142.4 
Total shareholders’ equity
18,546.6 17,580.4 
Total liabilities and shareholders’ equity
$23,917.4 $22,730.2 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Shareholders’ Equity
(in millions)(unaudited)
Three Months Ended
Common StockAdditional Paid-in CapitalAccumulated Other Comprehensive Income (Loss)Retained EarningsTotal Shareholders’ Equity
SharesAmount
Balance at December 31, 2022257.0 $2.6 $7,386.5 $0.8 $6,522.8 $13,912.7 
Other comprehensive loss, net of tax— — — (13.9)— (13.9)
Net income
— — — — 699.8 699.8 
Repurchases of common stock(0.5)(0.0)(135.6)— — (135.6)
Common stock withheld for employee tax obligations(0.6)(0.0)(166.6)— — (166.6)
Issuance of common stock under benefit plans1.6 0.0 13.1 — — 13.1 
Stock-based compensation expense
— — 122.8 — — 122.8 
Balance at March 31, 2023257.5 $2.6 $7,220.2 $(13.1)$7,222.6 $14,432.3 
Balance at December 31, 2023257.7 $2.6 $7,449.7 $(14.3)$10,142.4 $17,580.4 
Other comprehensive income, net of tax— — — 31.6 — 31.6 
Net income
— — — — 1,099.6 1,099.6 
Repurchases of common stock(0.3)(0.0)(140.4)— — (140.4)
Common stock withheld for employee tax obligations(0.6)(0.0)(233.5)— — (233.5)
Issuance of common stock under benefit plans1.5 0.0 15.9 — — 15.9 
Stock-based compensation expense
— — 193.0 — — 193.0 
Balance at March 31, 2024258.3 $2.6 $7,284.7 $17.3 $11,242.0 $18,546.6 
The accompanying notes are an integral part of these condensed consolidated financial statements.

5
VERTEX PHARMACEUTICALS INCORPORATED
Condensed Consolidated Statements of Cash Flows
(in millions)(unaudited)
Three Months Ended March 31,
20242023
Cash flows from operating activities:
Net income$1,099.6 $699.8 
Adjustments to reconcile net income to net cash provided by operating activities:
Stock-based compensation expense191.9 122.4 
Depreciation and amortization expense53.5 38.8 
Deferred income taxes(158.3)(113.4)
Losses (gains) on equity securities27.0 (6.4)
Decrease in fair value of contingent consideration(0.1)(1.9)
Other non-cash items, net(36.3)21.7 
Changes in operating assets and liabilities:
Accounts receivable, net(251.6)(90.5)
Inventories(80.1)(82.6)
Prepaid expenses and other assets99.2 46.2 
Accounts payable0.1 35.7 
Accrued expenses194.1 140.7 
Other liabilities167.6 89.4 
Net cash provided by operating activities1,306.6 899.9 
Cash flows from investing activities:
Purchases of available-for-sale debt securities(2,598.5)(1,816.6)
Sales and maturities of available-for-sale debt securities710.5 50.0 
Purchases of property and equipment(68.4)(42.1)
Net payments related to finite-lived intangible assets(180.0)— 
Investment in equity securities— (24.9)
Net cash used in investing activities(2,136.4)(1,833.6)
Cash flows from financing activities:
Issuances of common stock under benefit plans16.9 14.2 
Repurchases of common stock(131.2)(132.8)
Payments in connection with common stock withheld for employee tax obligations(233.5)(166.6)
Payments on finance leases(13.2)(10.6)
Other financing activities3.5 1.1 
Net cash used in financing activities(357.5)(294.7)
Effect of changes in exchange rates on cash(15.6)12.0 
Net decrease in cash, cash equivalents and restricted cash(1,202.9)(1,216.4)
Cash, cash equivalents and restricted cash—beginning of period10,372.3 10,512.0 
Cash, cash equivalents and restricted cash—end of period$9,169.4 $9,295.6 
Supplemental disclosure of cash flow information:
Cash paid for income taxes$34.8 $120.3 
Cash paid for interest$10.0 $11.1 
The accompanying notes are an integral part of these condensed consolidated financial statements.
6
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)

A.Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2024 and 2023.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023, which are contained in our 2023 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted Accounting Standards
As noted in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K, we did not adopt any accounting standards that had a significant impact on our consolidated financial statements in the three years ended December 31, 2023.
Recently Issued Accounting Standards
Segment Reporting
In 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose significant segment expenses and other segment items. ASU 2023-07 also requires public entities to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for the interim periods starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-07 will have on our segment disclosures.
Income Tax Disclosures
In 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 becomes effective for the annual period starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-09 will have on our income tax disclosures.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K.


7
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
B.Revenue Recognition
Disaggregation of Revenue
Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended March 31,
20242023
(in millions)
TRIKAFTA/KAFTRIO$2,483.6 $2,096.7 
Other CF products207.0 278.1 
Total product revenues, net$2,690.6 $2,374.8 
Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20242023
(in millions)
United States$1,519.9 $1,403.8 
Outside of the United States
Europe967.4 807.2 
Other
203.3 163.8 
Total product revenues outside of the United States1,170.7 971.0 
Total product revenues, net
$2,690.6 $2,374.8 
Contract Liabilities
We had contract liabilities of $275.8 million and $170.3 million as of March 31, 2024 and December 31, 2023, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive for our cystic fibrosis (“CF”) products. Upon exceeding the annual reimbursement amount provided by the customer’s contract with us, our CF products are provided free of charge, which is a material right. These contracts include upfront payments and fees. If we estimate that we will exceed the annual reimbursement amount under a contract, we defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” Once the reimbursement limit has been reached, we recognize the deferred amount as revenue when we ship the free products. Our CF product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with CF annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.

C.Collaboration, License and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $76.8 million and $347.1 million for the three months ended March 31, 2024 and 2023, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including

8
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2024 and 2023, or were new or materially revised during the three months ended March 31, 2024, are described below. Additional agreements were described in Note B, “Collaboration, License and Other Arrangements,” of our 2023 Annual Report on Form 10-K.
In-license Agreements
CRISPR Therapeutics AG
CRISPR-Cas9 Gene-editing Therapies Agreements
In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including CF, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR were co-developing and preparing to co-commercialize CASGEVY for the treatment of hemoglobinopathies, including treatments for severe sickle cell disease (“SCD”) and transfusion-dependent beta thalassemia.
Pursuant to the CRISPR JDCA, we lead global development, manufacturing and commercialization of CASGEVY, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.
CASGEVY was approved by the U.S. Food and Drug Administration in December 2023 for the treatment of SCD. In connection with this approval, we made a $200.0 million milestone payment to CRISPR in January 2024, which we accrued to “Other current liabilities” and recorded within “Other intangible assets, net” on our consolidated balance sheet as of December 31, 2023. Subsequent to receiving marketing approval for CASGEVY, we continue to lead the research and development activities under the CRISPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40% share of these research and development activities, subject to certain adjustments, and we record this reimbursement from CRISPR as a credit within “Research and development expenses.” We also share with CRISPR 40% of the net commercial profits or losses incurred with respect to CASGEVY, subject to certain adjustments, which is recorded to “Cost of sales.” The net commercial profits or losses equal the sum of the product revenues, cost of sales and selling, general and administrative expenses that we have recognized related to the CRISPR JDCA.
In the three months ended March 31, 2024, we recognized net reimbursements from CRISPR pursuant to the CRISPR JDCA as credits to “Cost of sales” of $15.8 million, related to CRISPR’s share of the CRISPR JDCA’s net commercial loss, and to “Research and development expenses” of $11.7 million, related to CRISPR’s share of the CRISPR JDCA’s research and development activities.
Prior to receiving marketing approvals for CASGEVY in various markets beginning in December 2023, we accounted for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to CASGEVY allocated 60% to us and 40% to CRISPR, subject to certain adjustments. In the three months ended March 31, 2023, we recognized net reimbursements from CRISPR as credits to “Research and development expenses” of $17.9 million and to “Selling, general and administrative expenses” of $5.8 million, related to CRISPR’s share of the CRISPR JDCA’s operating expenses.
CRISPR-Cas9 Gene-editing Hypoimmune Cell Therapies Agreement
In March 2023, we entered into a non-exclusive license agreement (the “CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes (“T1D”). Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR, and we determined that substantially all the fair value of our upfront payment was attributable to in-process research and development, for which there is no alternative future use, and that no substantive processes were acquired that would

9
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
constitute a business. CRISPR is eligible to receive up to an additional $160.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales.
Entrada Therapeutics, Inc.
In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. We determined that substantially all the fair value of our upfront payment was attributable to in-process research and development, for which there is no alternative future use, and that no substantive processes were acquired that would constitute a business. We recorded the upfront payment to “Acquired in-process research and development expenses” in the three months ended March 31, 2023. We recorded the investment in Entrada’s common stock at fair value on our condensed consolidated balance sheet within “Marketable securities.” In the first quarter of 2024, Entrada earned a $75.0 million milestone, which we recorded to “Acquired in-process research and development expenses” in the three months ended March 31, 2024 and accrued to “Other current liabilities” as of March 31, 2024. Entrada is eligible to receive up to an additional $335.0 million in development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales.
Cystic Fibrosis Foundation
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record expenses related to these royalty obligations to “Cost of sales.”

D.Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20242023
(in millions, except per share amounts)
Net income$1,099.6 $699.8 
Basic weighted-average common shares outstanding258.2 257.4 
Effect of potentially dilutive securities:
Restricted stock units (including performance-based restricted stock units (“PSUs”))
1.7 1.6 
Stock options1.2 1.3 
Employee stock purchase program
0.0 0.0 
Diluted weighted-average common shares outstanding261.1 260.3 
Basic net income per common share$4.26 $2.72 
Diluted net income per common share$4.21 $2.69 

10
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20242023
(in millions)
Unvested restricted stock units (including PSUs)— 0.6 

E.Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy:
As of March 31, 2024As of December 31, 2023
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents$5,865.3 $4,921.3 $944.0 $— $7,033.9 $5,397.3 $1,636.6 $— 
Marketable securities:
Corporate equity securities43.4 43.4 — — 46.0 46.0 — — 
U.S. Treasury securities1,389.4 1,389.4 — — 546.5 546.5 — — 
U.S. government agency securities
356.7 — 356.7 — 425.2 — 425.2 — 
Asset-backed securities792.6 — 792.6 — 306.0 — 306.0 — 
Certificates of deposit42.6 — 42.6 — 33.7 — 33.7 — 
Corporate debt securities2,632.2 — 2,632.2 — 1,802.8 — 1,802.8 — 
Commercial paper137.8 — 137.8 — 186.8 — 186.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts26.3 — 26.3 — 1.8 — 1.8 — 
Total financial assets
$11,286.3 $6,354.1 $4,932.2 $— $10,382.7 $5,989.8 $4,392.9 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(1.4)$— $(1.4)$— $(33.7)$— $(33.7)$— 
Other long-term liabilities:
Contingent consideration(77.3)— — (77.3)(77.4)— — (77.4)
Total financial liabilities
$(78.7)$— $(1.4)$(77.3)$(111.1)$— $(33.7)$(77.4)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment. Our cash equivalents primarily include money market funds and time deposits.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based

11
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.
As of March 31, 2024, one of our investments in publicly traded corporate equity securities was subject to a contractual sales restriction expiring partially in 2024 and partially in 2025 with a total fair value of $23.0 million. We purchased this investment directly from the publicly traded company in the first quarter of 2023, and do not anticipate any circumstances that would cause this restriction to lapse prior to the periods listed above.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy (“DMD”) and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to gene therapies and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.1% and 5.3% as of March 31, 2024, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2024
(in millions)
Balance at December 31, 2023$77.4 
Decrease in fair value of contingent payments
(0.1)
Balance at March 31, 2024$77.3 

F.Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable debt and equity securities, which are recorded at fair value, is shown below:
As of March 31, 2024As of December 31, 2023
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents
$5,865.3 $— $— $5,865.3 $7,033.9 $— $— $7,033.9 
Marketable securities:
U.S. Treasury securities1,395.1 1.1 (6.8)1,389.4 544.5 3.0 (1.0)546.5 
U.S. government agency securities
357.7 0.1 (1.1)356.7 424.8 0.9 (0.5)425.2 
Asset-backed securities793.5 0.7 (1.6)792.6 304.9 1.4 (0.3)306.0 
Certificates of deposit42.6 0.0 (0.0)42.6 33.7 0.0 (0.0)33.7 
Corporate debt securities
2,637.4 4.3 (9.5)2,632.2 1,794.0 10.5 (1.7)1,802.8 
Commercial paper
137.9 0.0 (0.1)137.8 186.8 0.1 (0.1)186.8 
Total marketable available-for-sale debt securities
5,364.2 6.2 (19.1)5,351.3 3,288.7 15.9 (3.6)3,301.0 
Corporate equity securities
72.1 — (28.7)43.4 72.1 — (26.1)46.0 
Total marketable securities
5,436.3 6.2 (47.8)5,394.7 3,360.8 15.9 (29.7)3,347.0 
Total cash equivalents and marketable securities$11,301.6 $6.2 $(47.8)$11,260.0 $10,394.7 $15.9 $(29.7)$10,380.9 

12
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
Amounts in the table above at fair value were classified on our condensed consolidated balance sheets as follows:
As of March 31, 2024As of December 31, 2023
(in millions)
Cash and cash equivalents$5,865.3 $7,033.9 
Marketable securities
1,013.3 849.2 
Long-term marketable securities4,381.4 2,497.8 
Total
$11,260.0 $10,380.9 
Marketable available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2024As of December 31, 2023
(in millions)
Matures within one year$969.9 $803.2 
Matures after one year through five years
4,273.3 2,495.6 
Matures after five years108.1 2.2 
Total
$5,351.3 $3,301.0 
We did not record any allowances for credit losses to adjust the fair value of our marketable available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2024 and 2023. Additionally, we did not record any realized gains or losses that were material to our condensed consolidated statements of income during the three months ended March 31, 2024 and 2023. As of March 31, 2024, we held marketable available-for-sale debt securities with a total fair value of $4.0 billion that were in unrealized loss positions totaling $19.1 million. Included in this amount were marketable available-for sale debt securities with a total fair value of $53.8 million and total unrealized loss of $0.4 million that had been in unrealized loss positions for greater than twelve months. We intend to hold these investments until maturity and do not expect to incur realized losses on these investments when they mature.
We record changes in the fair value of our investments in corporate equity securities to “Other (expense) income, net” in our condensed consolidated statements of income. During the three months ended March 31, 2024 and 2023, our net unrealized (losses) gains on corporate equity securities with readily determinable fair values held at the conclusion of each period were as follows:
Three Months Ended March 31,
20242023
(in millions)
Net unrealized (losses) gains
$(2.7)$6.4 
        
As of March 31, 2024, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $74.3 million. During the three months ended March 31, 2024, we reduced the carrying value of one of our equity investments without a readily determinable fair value by $24.3 million based on an observable change in price.


13
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
G.Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2023$1.1 $9.6 $(25.0)$(14.3)
Other comprehensive income (loss) before reclassifications6.8 (20.5)47.2 33.5 
Amounts reclassified from accumulated other comprehensive income (loss)— 0.8 (2.7)(1.9)
Net current period other comprehensive income (loss)6.8 (19.7)44.5 31.6 
Balance at March 31, 2024$7.9 $(10.1)$19.5 $17.3 
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications10.0 2.9 (9.6)3.3 
Amounts reclassified from accumulated other comprehensive income (loss)— — (17.2)(17.2)
Net current period other comprehensive income (loss)10.0 2.9 (26.8)(13.9)
Balance at March 31, 2023$(15.0)$2.8 $(0.9)$(13.1)

H.Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2024, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2024 and December 31, 2023, credit risk did not change the fair value of our foreign currency forward contracts.

14
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2024As of December 31, 2023
Foreign Currency(in millions)
Euro$1,305.5 $1,720.6 
Canadian dollar
190.0 229.5 
British pound sterling
186.4 225.0 
Australian dollar
122.1 153.3 
Swiss Franc50.5 63.9 
Total foreign currency forward contracts
$1,854.5 $2,392.3 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other (expense) income, net” in our condensed consolidated statements of income each period. As of March 31, 2024, we did not have any outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP was not applied.
During the three months ended March 31, 2024 and 2023, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended March 31,
20242023
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$3.4 $22.0 
Not designated as hedging instruments
Other (expense) income, net$(2.4)$3.6 
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,690.6 $2,374.8 
Other (expense) income, net$(31.2)$1.3 
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2024
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$26.3 Other current liabilities$(1.4)
As of December 31, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$1.8 Other current liabilities$(33.7)

15
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
As of March 31, 2024, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of March 31, 2024
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$26.3 $— $26.3 $(1.4)$24.9 
Total liabilities(1.4)— (1.4)1.4 — 
As of December 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$1.8 $— $1.8 $(1.8)$— 
Total liabilities(33.7)— (33.7)1.8 (31.9)

I.Inventories
Inventories consisted of the following:
As of March 31, 2024As of December 31, 2023
(in millions)
Raw materials$95.7 $78.7 
Work-in-process601.8 525.1 
Finished goods
115.6 135.0 
Total
$813.1 $738.8 
During the first quarter of 2024, following positive results we announced related to our two Phase 3 trials for suzetrigine (formerly VX-548) for acute pain and vanzacaftor/tezacaftor/deutivacaftor for CF, we began capitalizing inventories produced in preparation for our planned product launches. We made these determinations based on our evaluation, among other factors, the safety and efficacy results, and expected likelihood of regulatory approval and commercial success. Prior to the first quarter of 2024, we expensed inventoriable and related costs associated with these product candidates as “Research and development expenses.” As of March 31, 2024, these inventories were not material to our condensed consolidated financial statements.


16
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
J.Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2024 and 2023, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20242023
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$187.2 $115.9 
ESPP share issuances5.8 5.5 
Stock options— 1.4 
Stock-based compensation expense related to inventories
(1.1)(0.4)
Total stock-based compensation expense included in “Total costs and expenses”
$191.9 $122.4 
Stock-based compensation expense by line item:
Cost of sales$1.8 $1.9 
Research and development expenses119.4 76.3 
Selling, general and administrative expenses70.7 44.2 
Total stock-based compensation expense included in costs and expenses
191.9 122.4 
Income tax effect(79.0)(40.6)
Total stock-based compensation expense, net of tax
$112.9 $81.8 
Share repurchase program
In February 2023, our Board of Directors approved a share repurchase program, pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. The program does not have an expiration date and can be discontinued at any time. During the three months ended March 31, 2024 and 2023, we repurchased 335,773 and 459,017 shares of our common stock under the program, respectively, for aggregate repurchases of $140.4 million and $135.6 million, respectively. As of March 31, 2024, we had $2.4 billion remaining authorization under this program.

K.Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2024 and 2023, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20242023
(in millions, except percentages)
Income before provision for income taxes$1,279.1 $891.5 
Provision for income taxes$179.5 $191.7 
Effective tax rate14.0 %21.5 %
Our effective tax rate for the three months ended March 31, 2024 was lower than the U.S. statutory rate primarily due to changes in our unrecognized tax positions as well as excess tax benefits related to stock-based compensation.
Our effective tax rate for the three months ended March 31, 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax positions partially offset by excess tax benefits related to stock-based compensation.

17
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2024 and December 31, 2023, we had $301.6 million and $288.7 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2015 in jurisdictions that have a material impact on our consolidated financial statements. In 2023, we came to settlement with the United Kingdom’s HM Revenue & Customs (“HMRC”) with respect to our tax positions for 2015 through 2020 and subsequently received Closure Notices for those periods during the three months ended March 31, 2024. Due to the nature of the adjustments, we will be asserting our rights under the U.S./U.K. Income Tax Convention pursuant to the mutual agreement procedures for the relief of double taxation for these matters.
In December 2022, European Union member states reached an agreement to implement the minimum tax component (“Pillar Two”) of the Organization for Economic Co-operation and Development’s (the “OECD’s”), global international tax reform initiative with effective dates of January 1, 2024 and 2025. In July 2023, the OECD published Administrative Guidance proposing certain safe harbors that effectively extend certain effective dates to January 1, 2027. The assessment of our potential 2024 exposure for the global per-country minimum tax of 15%, based on our forecasted 2024 results, is immaterial to our condensed consolidated financial statements as the effective tax rates in most of the jurisdictions in which we operate are above 15%.

L.Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of March 31, 2024, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.

18
VERTEX PHARMACEUTICALS INCORPORATED
Notes to Condensed Consolidated Financial Statements (unaudited)
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2024 or December 31, 2023.

M.Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20242023
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,369.1 $9,158.0 $10,504.0 $9,289.9 
Prepaid expenses and other current assets
3.2 11.4 8.0 5.7 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,372.3 $9,169.4 $10,512.0 $9,295.6 

N.Subsequent Event
In April 2024, we entered into an agreement and plan of merger (the “Alpine Merger Agreement”) to acquire all of the issued and outstanding shares of common stock of Alpine Immune Sciences, Inc. (“Alpine”), a publicly traded biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, for approximately $4.9 billion in cash. Alpine’s lead molecule, povetacicept, is a highly potent and effective dual antagonist of BAFF (“B cell activating factor”) and APRIL (“a proliferation inducing ligand”). Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA nephropathy (“IgAN”), a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. The transaction is expected to close in the second quarter of 2024, subject to certain customary closing conditions, including the completion of a tender offer, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other conditions. We will account for the acquisition in the period that it closes. We intend to fund the acquisition with our cash and cash equivalents.

19
Item 2.     Management’s Discussion and Analysis of Financial Condition and Results of Operations
OVERVIEW
We are a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases, with a focus on specialty markets. We have four approved medicines that treat the underlying cause of cystic fibrosis (“CF”), a life-threatening genetic disease, and one approved therapy that treats severe sickle cell disease (“SCD”) and transfusion dependent beta thalassemia (“TDT”), life-shortening inherited blood disorders. Our pipeline includes clinical-stage programs in CF, sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, alpha-1 antitrypsin deficiency, and autosomal dominant polycystic kidney disease.
Our four approved CF medicines, led by TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), are being used to treat nearly three quarters of the approximately 92,000 people with CF in North America, Europe, and Australia. We are evaluating our CF medicines in additional patient populations, including younger children, with the goal of having small molecule treatments for all people who have at least one mutation in their cystic fibrosis transmembrane conductance regulator (“CFTR”) gene that is responsive to our CFTR modulators. We also are pursuing messenger ribonucleic acid (“mRNA”) and genetic therapies for people with CF who do not make full-length CFTR protein and, as a result, cannot benefit from our current CF medicines.
In late 2023 and early 2024, CASGEVY (exagamglogene autotemcel or “exa-cel”), an ex-vivo, non-viral CRISPR/Cas9 gene-edited cell therapy, was approved in the U.S., the E.U., the United Kingdom (“U.K.”), the Kingdom of Saudi Arabia (“Saudi Arabia”), and the Kingdom of Bahrain (“Bahrain”) for the treatment of people 12 years of age and older with SCD or TDT. We estimate approximately 35,000 people with severe SCD or TDT could be eligible for CASGEVY in the U.S. and Europe, with additional people in Saudi Arabia and Bahrain. In addition, we are preparing for near-term launches of potential new products in CF and acute pain.
Financial Highlights
Revenues
In the first quarter of 2024, our net CF product revenues increased to $2.7 billion as compared to $2.4 billion in the first quarter of 2023. The increase was primarily due to the continued strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets with recently achieved reimbursements and label extensions in younger age groups and performance of TRIKAFTA in the U.S., following the launch of TRIKAFTA in children with CF 2 to 5 years of age.
Expenses
Our total research and development (“R&D”), acquired in-process research and development (“AIPR&D”), and selling, general and administrative (“SG&A”) expenses decreased to $1.2 billion in the first quarter of 2024 as compared to $1.3 billion in the first quarter of 2023. The decrease was primarily due to decreased AIPR&D. Cost of sales was 13% in the first quarter of 2024 as compared to 11% in the first quarter of 2023, primarily due to cost of sales associated with CASGEVY.
Cash
Our total cash, cash equivalents and marketable securities increased to $14.6 billion as of March 31, 2024 as compared to $13.7 billion as of December 31, 2023 primarily due to our cash from operations driven by our net product revenues, partially offset by business development payments and repurchases of our common stock.
MD&A Chart v4.jpg
Note: Charts above may not add due to rounding.

20
Business Updates
Marketed Products
Cystic Fibrosis
We expect to grow our CF business with (i) continued uptake by patients in countries where we are early in our launch, (ii) label expansions, including into younger patient groups, and (iii) growth in the number of people living with CF. Recent progress in activities supporting continued uptake and label expansions is included below:
•The European Commission approved KALYDECO for the treatment of infants with CF from 1 month to less than 4 months of age with specific mutations in the CFTR gene.
Sickle Cell Disease and Beta Thalassemia
•CASGEVY is approved in the U.S., the E.U., the U.K., Saudi Arabia, and Bahrain for people 12 years of age and older with SCD or TDT.
•We completed regulatory submissions for CASGEVY in both SCD and TDT in Switzerland and Canada, and our regulatory submission in Canada has been granted priority review.
•We have activated more than 25 authorized treatment centers globally, and multiple patients have initiated cell collection.
•We entered into multiple agreements with commercial and government health insurance providers in the U.S. to provide access to CASGEVY. We have also secured reimbursed access for people with SCD or TDT in Saudi Arabia and Bahrain, as well as for people with TDT in France through an early access program.
Potential Near-Term Launch Opportunities
We are preparing for the following near-term launches of potential new products:
Vanzacaftor/tezacaftor/deutivacaftor in CF
•In February 2024, we announced positive results from the pivotal program for our next-generation triple combination of vanzacaftor/tezacaftor/deutivacaftor (the “vanzacaftor triple”) for people with CF 6 years of age and older.
•We submitted regulatory marketing applications for the vanzacaftor triple in people with CF 6 years of age and older to the U.S. Food and Drug Administration (“FDA”), using a priority review voucher, and to the European Medicines Agency (the “EMA”). We expect to complete additional global regulatory submissions for people with CF 6 years of age and older in 2024.
Suzetrigine in Acute Pain
•In January 2024, we announced positive results from our Phase 3 clinical trials evaluating our lead compound, suzetrigine (formerly VX-548), a selective NaV1.8 inhibitor for the treatment of moderate-to-severe acute pain.
•In the U.S., the FDA has granted rolling submission to the new drug application (“NDA”) for suzetrigine for the treatment of moderate-to-severe acute pain and we have begun the NDA submission process. We expect to complete the submission in the second quarter of 2024. Suzetrigine has been granted Fast Track and Breakthrough Therapy designations by the FDA in moderate-to-severe acute pain.
Pipeline
We continue to advance a diversified pipeline of potentially transformative medicines for serious diseases utilizing a range of modalities. Recent and anticipated progress in activities supporting these efforts is included below:
Cystic Fibrosis
•In the second half of 2024, we plan to initiate a new cohort in the Phase 3 clinical trial, RIDGELINE, evaluating the vanzacaftor triple in children with CF 2 to 5 years of age who have at least one F508del mutation or a mutation responsive to triple combination CFTR modulators.

21
•In collaboration with Moderna, Inc. (“Moderna”), we are developing VX-522, a nebulized mRNA therapy for the treatment of people with CF who do not produce full-length CFTR protein. We continue to enroll and dose patients in the multiple ascending dose portion of the Phase 1/2 clinical trial of VX-522 in people with CF. We expect to share data from this clinical trial in late 2024 or early 2025.
Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
•We have completed enrollment in two global Phase 3 clinical trials evaluating CASGEVY in children 5 to 11 years of age with SCD or TDT.
•We continue to work on preclinical assets for myeloablative conditioning agents that would have milder side-effects and could be used in connection with CASGEVY, which could broaden the eligible patient population.
Acute Pain
•We expect to initiate a Phase 2 clinical trial evaluating the oral formulation of VX-993, a next-generation selective NaV1.8 inhibitor, for the treatment of moderate-to-severe acute pain in 2024.
•The FDA cleared the investigational new drug application (“IND”) for an intravenous formulation of VX-993 for the treatment of moderate-to-severe acute pain. We have initiated the Phase 1 clinical trial.
•We are advancing multiple NaV1.7 inhibitors through research and earlier stages of development, which could be used alone or in combination with NaV1.8 inhibitors for the treatment of acute and peripheral neuropathic pain.
Peripheral Neuropathic Pain
•Following a successful end-of-Phase 2 meeting with the FDA, we expect to initiate the Phase 3 pivotal program evaluating suzetrigine in people with diabetic peripheral neuropathy, a common form of chronic peripheral neuropathic pain, in the second half of 2024. The FDA has granted suzetrigine Breakthrough Therapy designation in this indication.
•We continue to enroll and dose patients in the Phase 2 clinical trial evaluating suzetrigine in people with lumbosacral radiculopathy, a second type of peripheral neuropathic pain. We expect to complete enrollment in the Phase 2 clinical trial by the end of 2024.
•We expect to initiate a Phase 2 clinical trial evaluating the oral formulation of VX-993 for the treatment of peripheral neuropathic pain in 2024.
APOL1-Mediated Kidney Disease
•Inaxaplin is our small molecule for the treatment of APOL1-mediated kidney disease (“AMKD”), including APOL1-mediated focal segmental glomerulosclerosis (“FSGS”). Based on the totality of the unblinded data reviewed by the Independent Data Safety Monitoring Committee (“IDMC”), we have advanced into the Phase 3 portion of the global Phase 2/3 pivotal clinical trial in people with AMKD. The trial has been expanded to include adolescents 10 to 17 years of age with AMKD.
•The clinical trial is designed to have a pre-planned interim analysis at Week 48 evaluating eGFR slope, supported by a percentage change from baseline in proteinuria, in the inaxaplin arm versus placebo. If positive, we expect that the interim analysis may serve as the basis to seek accelerated approval in the U.S.
Type 1 Diabetes
•VX-880 is an allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell replacement therapy, using standard immunosuppression to protect the implanted cells. We are evaluating VX-880 as a potential treatment for type 1 diabetes (“T1D”) in a sequential, three-part Phase 1/2 clinical trial. Based on the totality of the data reviewed by the IDMC, we have resumed dosing in the Phase 1/2 clinical trial in people with T1D and impaired awareness of hypoglycemia and recurrent hypoglycemic events. Enrollment in Parts A, B and C of the global 17-patient clinical trial is complete and we expect to complete dosing in the coming months.
•Our second Phase 1/2 program in T1D evaluates VX-264, which encapsulates the same VX-880 islet cells in a novel device designed to eliminate the need for immunosuppression. This trial is a sequential, multi-part study to evaluate the safety, tolerability and efficacy of VX-264. We have completed Part A of the clinical trial and initiated Part B.

22
•Our hypoimmune islet cell program uses CRISPR/Cas9 technology to gene-edit the same allogeneic stem cell-derived, fully differentiated islet cells used in the VX-880 and VX-264 programs. The goal is to cloak the cells from the immune system to explore another possible path to eliminate the need for immunosuppressive therapy. This program continues to progress through the research stage.
Myotonic Dystrophy Type 1
•Our lead approach for myotonic dystrophy type 1 (“DM1”), VX-670, was in-licensed from Entrada Therapeutics, Inc. (“Entrada”). VX-670 is an oligonucleotide connected to a cyclic peptide to promote effective delivery into cells, which holds the potential to address the underlying cause of DM1.
•Our IND in the U.S. for VX-670 has cleared, as have the clinical trial applications in Canada, the U.K. and the E.U, and the clinical trial notification in Australia. Enrollment and dosing are underway.
Autosomal Dominant Polycystic Kidney
•We have initiated a Phase 1 clinical trial in healthy volunteers evaluating VX-407, our first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (“ADPKD”) in people with a subset of PKD1 variants.
Investment in External Innovation
•In April 2024, we entered into an agreement and plan of merger (the “Alpine Merger Agreement”) to acquire all of the issued and outstanding shares of common stock of Alpine Immune Sciences, Inc. (“Alpine”) for approximately $4.9 billion. Pursuant to the Alpine Merger Agreement, we commenced a tender offer to purchase all of the outstanding shares of common stock of Alpine for $65 per share in cash. We expect the transaction to close in the second quarter of 2024, subject to certain customary conditions, including the completion of the tender offer, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other conditions.
•Alpine’s lead molecule, povetacicept, is a highly potent and effective dual antagonist of BAFF (“B cell activating factor”) and APRIL (“a proliferation-inducing ligand”). Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA nephropathy (“IgAN”), a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. There are no approved therapies that target the underlying cause of IgAN, which is the most common cause of primary (idiopathic) glomerulonephritis worldwide, affecting approximately 130,000 people in the U.S. We expect povetacicept will enter Phase 3 clinical development in IgAN in the second half of 2024. Phase 1b/2 clinical trials in autoimmune renal diseases and cytopenias are ongoing with data expected in 2024.
•We achieved a clinical milestone for VX-670 in DM1 in the first quarter of 2024, resulting in a $75 million milestone payable to Entrada.
Our Business Environment
In the first quarter of 2024, our net product revenues came from the sale of our medicines for the treatment of CF. Our CF strategy involves continuing to develop and obtain approval and reimbursement for treatment regimens that will provide benefits to all people with CF and increasing the number of people with CF eligible and able to receive our medicines, including through label expansions, expanded reimbursement, and the development of new medicines. We are advancing our pipeline of product candidates for the treatment of serious diseases outside of CF, including CASGEVY, which has received marketing approvals in the U.S., the E.U., the U.K., Saudi Arabia, and Bahrain for the treatment of SCD and TDT.
Our strategy is to combine transformative advances in the understanding of causal human biology and the science of therapeutics to discover and develop innovative medicines. This approach includes advancing multiple compounds or therapies from each program, spanning multiple modalities, into early clinical trials to obtain patient data that can inform selection of the most promising therapies for later-stage development, as well as to inform discovery and development efforts. We aim to rapidly follow our first-in-class therapies that achieve proof-of-concept with potential best-in-class candidates to provide durable clinical and commercial success.
In pursuit of new product candidates and therapies in specialty markets, we invest in research and development. We believe that pursuing research in diverse areas allows us to balance the risks inherent in product development and may provide product candidates that will form our pipeline in future years. To supplement our internal research programs, we acquire technologies and programs and collaborate with biopharmaceutical and technology companies, leading academic

23
research institutions, government laboratories, foundations and other organizations, as needed, to advance research in our areas of therapeutic interest and to access technologies needed to execute on our strategy.
Discovery and development of a new pharmaceutical or biological product is a difficult and lengthy process that requires significant financial resources along with extensive technical and regulatory expertise. Across the industry, most potential drug or biological products never progress into development, and most products that do advance into development never receive marketing approval. Our investments in product candidates are subject to considerable risks. We closely monitor the results of our discovery, research, clinical trials and nonclinical studies and frequently evaluate our product development programs in light of new data and scientific, business and commercial insights, with the objective of balancing risk and potential. This process can result in rapid changes in focus and priorities as new information becomes available and as we gain additional understanding of our ongoing programs and potential new programs, as well as those of our competitors.
Our business also requires ensuring appropriate manufacturing and reimbursement of our products. As we advance our product candidates through clinical development toward commercialization and market and sell our approved products, we build and maintain our supply chain and quality assurance resources. We rely on a global network of third parties, including some in China, and our internal capabilities to manufacture and distribute our products for commercial sale and post-approval clinical trials and to manufacture and distribute our product candidates for clinical trials. In addition to establishing supply chains for each new approved product, we adapt our supply chain for existing products to include additional formulations or to increase scale of production for existing products as needed. Our foreign third-party manufacturers and suppliers may be subject to U.S. legislation, including the BIOSECURE Act, sanctions, trade restrictions and other foreign regulatory requirements which could increase costs or reduce the supply of material available to us, or delay the procurement or supply of such material. The processes for cell and genetic therapies can be more complex than those required for small molecule drugs and require additional investments in different systems, equipment, facilities and expertise. We are focused on ensuring the stability of the supply chains for our current products, as well as for our pipeline programs.
Sales of our products depend, to a large degree, on the extent to which our products are reimbursed by third-party payors, such as government health programs, commercial insurance and managed health care organizations. Reimbursement for our products, including our potential pipeline therapies, cannot be assured and may take significant periods of time to obtain. We dedicate substantial management and other resources to obtain and maintain appropriate levels of reimbursement for our products from third-party payors, including governmental organizations in the U.S. and ex-U.S. markets.
In the U.S., we have worked successfully with third-party payors to promptly obtain appropriate levels of reimbursement for our CF medicines. In addition, we are working with U.S. government and commercial payors with respect to CASGEVY. We anticipate broad access with government and commercial payors for CASGEVY in the U.S., and we have recently entered into multiple agreements with government and commercial health insurance providers to provide access to CASGEVY. We plan to continue to engage in discussions with numerous commercial insurers and managed health care organizations, along with government health programs that are typically managed by authorities in the individual states, to ensure that payors recognize the significant benefits that all of our therapies provide and provide patients with appropriate levels of access to our medicines and therapies now and in the future. We cannot, however, predict how recent changes in the law, including through the Inflation Reduction Act of 2022 and passage of state laws (e.g., transparency laws and prescription drug affordability boards), will affect our ability to negotiate successfully with third-party payors and distribute our products. Similarly, in ex-U.S. markets, we seek government reimbursement for our medicines on a country-by-country or region-by-region basis, as required. This is necessary for each new medicine, as well as for label expansions for our current medicines. We are working with ex-U.S. payors with respect to CASGEVY, and we are pursuing long-term reimbursement agreements. We have secured reimbursed access for people with SCD or TDT in Saudi Arabia and Bahrain and for people with TDT in France through an expanded access program. We expect to continue to focus significant resources to expand and maintain reimbursement for our CF medicines, CASGEVY and, ultimately, pipeline therapies, in U.S. and ex-U.S. markets.
Strategic Transactions
Acquisitions
As part of our business strategy, we seek to acquire technologies, products, product candidates and other businesses that are aligned with our corporate and research and development strategies and complement and advance our ongoing research and development efforts. We have engaged in a number of acquisitions of privately held biotechnology companies over the last several years. In 2019, we acquired Semma Therapeutics, Inc., pursuant to which we established our T1D program, and Exonics Therapeutics, Inc., which enhanced our gene-editing capabilities to repair mutations that cause severe neuromuscular diseases, such as DM1 and Duchenne muscular dystrophy. In 2022, we acquired ViaCyte, Inc. (“ViaCyte”), which had intellectual property, tools, technologies and assets with the potential to accelerate development of our T1D programs. Our

24
acquisition of ViaCyte, for $315.0 million, was accounted for as a business combination. As of the acquisition date, the cash payment was allocated primarily to goodwill and the fair value of an in-process research and development asset.
In 2023 and 2022, we also acquired programs that were accounted for as asset acquisitions resulting in $47.5 million and $60.0 million of AIPR&D, respectively.
In April 2024, we entered into the Alpine Merger Agreement to acquire Alpine as described above. Alpine is a publicly traded biotechnology company focused on discovering and developing innovative, protein-based immunotherapies. Alpine’s lead molecule, povetacicept, has shown potential best-in-class efficacy in IgAN through Phase 2 development. We will pay approximately $4.9 billion in cash when the transaction closes and intend to fund the acquisition with our cash and cash equivalents. We will account for the acquisition in the period that it closes.
Collaboration and In-Licensing Arrangements
We enter into arrangements with third parties, including collaboration and licensing arrangements, for the development, manufacture and commercialization of products, product candidates and other technologies that have the potential to complement our ongoing research and development efforts. Over the last several years, we entered into collaboration agreements with a number of companies, including CRISPR Therapeutics AG (“CRISPR”), Entrada, and Moderna. Generally, when we in-license a technology or product candidate, we make upfront payments to the collaborator, assume the costs of the program and/or agree to make contingent payments, which could consist of milestone, royalty and option payments. Most of these collaboration payments are expensed as AIPR&D, including a $75.0 million milestone due to Entrada in the first quarter of 2024, and our upfront payments of $225.1 million to Entrada and $100.0 million to CRISPR related to T1D in the first quarter of 2023. These payments were expensed to AIPR&D because they were primarily attributable to acquired in-process research and development for which there was no alternative future use. However, depending on many factors, including the structure of the collaboration, the stage of development of the acquired technology, the significance of the in-licensed product candidate to the collaborator’s operations and the other activities in which our collaborators are engaged, the accounting for these transactions can vary significantly. We expect to continue to identify and evaluate collaboration and licensing opportunities that may be similar to or different from the collaborations and licenses that we have engaged in previously.
Acquired In-Process Research and Development Expenses
In the first quarter of 2024 and 2023, our AIPR&D included $76.8 million and $347.1 million, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including the collaborations, licenses of third-party technologies, and asset acquisitions described above. Please refer to Note C, “Collaboration, License and Other Arrangements,” for further information regarding our collaboration, in-license agreements and asset acquisitions.

RESULTS OF OPERATIONS
Three Months Ended March 31,
20242023Change
(in millions, except percentages and per share amounts)
Product revenues, net
$2,690.6 $2,374.8 13%
Operating costs and expenses1,551.1 1,595.8 (3)%
Income from operations
1,139.5 779.0 46%
Other non-operating income, net139.6 112.5 24%
Provision for income taxes
179.5 191.7 (6)%
Net income
$1,099.6 $699.8 57%
Net income per diluted common share$4.21 $2.69 
Diluted shares used in per share calculations
261.1 260.3 

25
Product Revenues, net
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
TRIKAFTA/KAFTRIO$2,483.6 $2,096.7 18%
Other CF products207.0 278.1 (26)%
Product revenues, net$2,690.6 $2,374.8 13%
In the first quarter of 2024, our net product revenues increased by $315.8 million, or 13%, as compared to the first quarter of 2023. The increase was primarily due to the continued strong uptake of TRIKAFTA/KAFTRIO in ex-U.S. markets and label extensions in younger age groups and performance of TRIKAFTA in the U.S., following the launch of TRIKAFTA in children with CF 2 to 5 years of age. Decreases in revenues for our CF products other than TRIKAFTA/KAFTRIO were primarily the result of patients switching from these medicines to TRIKAFTA/KAFTRIO.
Our net product revenues from the U.S. and from ex-U.S. markets were as follows:
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
United States$1,519.9 $1,403.8 8%
ex-U.S.1,170.7 971.0 21%
Product revenues, net$2,690.6 $2,374.8 13%
Operating Costs and Expenses

Three Months Ended March 31,
20242023Change
(in millions, except percentages)
Cost of sales$342.6 $266.9 28%
Research and development expenses789.1 742.6 6%
Acquired in-process research and development expenses76.8 347.1 (78)%
Selling, general and administrative expenses342.7 241.1 42%
Change in fair value of contingent consideration(0.1)(1.9)**
Total costs and expenses$1,551.1 $1,595.8 (3)%
** Not meaningful
Cost of Sales
Our cost of sales primarily consists of third-party royalties payable on net sales of our CF products as well as the cost of producing inventories. Pursuant to our agreement with the Cystic Fibrosis Foundation, our tiered third-party royalties on sales of TRIKAFTA/KAFTRIO, SYMDEKO/SYMKEVI, KALYDECO, and ORKAMBI, calculated as a percentage of net sales, range from the single digits to the sub-teens, with lower royalties on sales of TRIKAFTA/KAFTRIO than for our other products. Over the last several years, our cost of sales has been increasing due to increased net product revenues. Our cost of sales as a percentage of our net product revenues increased to 13% in the first quarter of 2024 as compared to 11% in the first quarter of 2023, primarily due to cost of sales associated with CASGEVY following its regulatory approval in the fourth quarter of 2023.

26
Research and Development Expenses
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
Research expenses$196.1 $166.8 18%
Development expenses
593.0 575.8 3%
Total research and development expenses
$789.1 $742.6 6%
Our research and development expenses include internal and external costs incurred for research and development of our products and product candidates. We do not assign our internal costs, such as salary and benefits, stock-based compensation expense, laboratory supplies and other direct expenses and infrastructure costs, to individual products or product candidates, because the employees within our research and development groups typically are deployed across multiple research and development programs. We assign external costs of services provided to us by clinical research organizations and other outsourced research by individual program. Our internal costs are greater than our external costs. All research and development costs for our products and product candidates are expensed as incurred.
Since January 2022, we have incurred approximately $7.2 billion in total research and development and AIPR&D expenses associated with product discovery and development. The successful development of our product candidates is highly uncertain and subject to a number of risks. In addition, the duration of clinical trials may vary substantially according to the type, complexity and novelty of the product candidate and the disease indication being targeted. The FDA and comparable agencies in foreign countries impose substantial requirements on the introduction of therapeutic pharmaceutical products, typically requiring lengthy and detailed laboratory and clinical testing procedures, sampling activities and other costly and time-consuming procedures. Data obtained from nonclinical and clinical activities at any step in the testing process may be adverse and lead to discontinuation or redirection of development activities. Data obtained from these activities also are susceptible to varying interpretations, which could delay, limit or prevent regulatory approval. The duration and cost of discovery, nonclinical studies and clinical trials may vary significantly over the life of a project and are difficult to predict. Therefore, accurate and meaningful estimates of the ultimate costs to bring our product candidates to market are not available.
Any estimates regarding development and regulatory timelines for our product candidates are highly subjective and subject to change. Until we have data from Phase 3 clinical trials, we cannot make a meaningful estimate regarding when, or if, a clinical development program will generate revenues and cash flows.
Research Expenses
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
Research Expenses:
Salary and benefits$53.0 $45.5 16%
Stock-based compensation expense29.9 20.2 48%
Outsourced services and other direct expenses64.4 53.6 20%
Infrastructure costs
48.8 47.5 3%
Total research expenses
$196.1 $166.8 18%
Our research expenses have been increasing over the last several years as we have invested in our pipeline and expanded our cell and genetic therapy capabilities, resulting in increased headcount, and outside services and other direct expenses. We expect to continue to invest in our research programs with a focus on creating transformative medicines for serious diseases.

27
Development Expenses
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
Development Expenses:
Salary and benefits$170.1 $144.2 18%
Stock-based compensation expense89.5 56.1 60%
Outsourced services and other direct expenses236.1 295.3 (20)%
Infrastructure costs
97.3 80.2 21%
Total development expenses
$593.0 $575.8 3%
Our development expenses increased by $17.2 million, or 3%, in the three months ended March 31, 2024 as compared to the three months ended March 31, 2023, primarily due to increased headcount costs, including stock-based compensation expense, and infrastructure costs to support our clinical trials, partially offset by decreased outsourced services and other direct expenses.
We are investing significantly in internal headcount and in infrastructure to support our advancing pipeline. Additional headcount over the last several years has resulted in increased stock-based compensation expense. Our stock-based compensation expense has historically fluctuated, and is expected to continue to fluctuate from one period to another based on the probability of achieving milestones associated with our performance-based awards. Our outsourced services and other direct expenses decreased as compared to the three months ended March 31, 2023 primarily due to lower clinical trial costs resulting from the commercialization of CASGEVY, as well as advancements in both our suzetrigine program in acute pain and the vanzacaftor triple for CF. These decreased clinical trial expenses were partially offset by increased costs to support our T1D program.
Acquired In-process Research and Development Expenses
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
Acquired in-process research and development expenses$76.8 $347.1 (78)%
AIPR&D in the first quarter of 2024 was primarily related to the $75.0 million milestone due to Entrada. AIPR&D in the first quarter of 2023 was primarily related to our upfront payments of $225.1 million to Entrada and $100.0 million to CRISPR. Our AIPR&D has historically fluctuated, and is expected to continue to fluctuate, from one period to another due to upfront, contingent milestone, and other payments pursuant to our existing and future business development transactions, including collaborations, licenses of third-party technologies, and asset acquisitions.
Selling, General and Administrative Expenses
Three Months Ended March 31,
20242023Change
(in millions, except percentages)
Selling, general and administrative expenses$342.7 $241.1 42%
Selling, general and administrative expenses increased by 42% in the first quarter of 2024 as compared to the first quarter of 2023, primarily due to increased investments to support the launches of our therapies globally and prepare for near-term launches of multiple potential new products.
Contingent Consideration
The fair value of our contingent consideration decreased by $0.1 million and $1.9 million in the first quarter of 2024 and 2023, respectively.

28
Other Non-Operating Income (Expense), Net
Interest Income
Interest income increased to $181.2 million in the first quarter of 2024, as compared to $122.6 million in the first quarter of 2023, primarily due to increased market interest rates, increased cash equivalents and available-for-sale debt securities and mix of available-for-sale debt securities earning higher yields. Our future interest income is dependent on the amount of, and prevailing market interest rates on, our outstanding cash equivalents and available-for-sale debt securities.
Interest Expense
Interest expense was $10.4 million and $11.4 million in the first quarter of 2024 and 2023, respectively. The majority of our interest expense in these periods was related to imputed interest expense associated with our leased corporate headquarters in Boston.
Other Income (Expense), Net
Other income (expense), net was expense of $31.2 million and income of $1.3 million in the first quarter of 2024 and 2023, respectively. These amounts related primarily to net unrealized gains or losses resulting from changes in the fair value of our strategic equity investments, which consist of investments in our collaborators that may be public or private companies. To the extent that we continue to hold strategic equity investments in publicly traded companies, we expect that due to the volatility of the stock price of biotechnology companies, our other income (expense), net will fluctuate in future periods based on increases or decreases in the fair value of our strategic equity investments. As of March 31, 2024, the fair value of our investments in publicly traded companies was $43.4 million.
Income Taxes
Our effective tax rate fluctuates from period to period due to the global nature of our operations. The factors that most significantly impact our effective tax rate include changes in tax laws, variability in the allocation of our taxable earnings among multiple jurisdictions, the amount and characterization of our research and development expenses, the levels of certain deductions and credits, adjustments to the value of our uncertain tax positions, acquisitions and third-party collaboration and licensing transactions.
We recorded provisions for income taxes of $179.5 million and $191.7 million in the first quarter of 2024 and 2023, respectively. Our effective tax rate of 14.0% in the first quarter of 2024 was lower than the U.S. statutory rate primarily due to changes in our unrecognized tax positions as well as excess tax benefits related to stock-based compensation. Our effective tax rate of 21.5% in the first quarter of 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax positions partially offset by excess tax benefits related to stock-based compensation.

LIQUIDITY AND CAPITAL RESOURCES
The following table summarizes the components of our financial condition as of March 31, 2024 and December 31, 2023:
As of March 31, 2024As of December 31, 2023Change
(in millions, except percentages)
Cash, cash equivalents and marketable securities:
Cash and cash equivalents$9,158.0 $10,369.1 
Marketable securities1,013.3 849.2 
Long-term marketable securities4,381.4 2,497.8 
Total cash, cash equivalents and marketable securities$14,552.7 $13,716.1 6%
Working Capital:
Total current assets$13,288.7 $14,144.2 (6)%
Total current liabilities(3,795.9)(3,547.4)7%
Total working capital$9,492.8 $10,596.8 (10)%

29
Working Capital
As of March 31, 2024, total working capital was $9.5 billion, which represented a decrease of $1.1 billion from $10.6 billion as of December 31, 2023. The decrease in total working capital during the first quarter of 2024 was primarily due to net purchases of long-term marketable securities of $2.1 billion.
Cash Flows
Three Months Ended March 31,
20242023
(in millions)
Net cash provided by (used in):
Operating activities$1,306.6 $899.9 
Investing activities$(2,136.4)$(1,833.6)
Financing activities$(357.5)$(294.7)
Operating Activities
Cash provided by operating activities was $1.3 billion in the first quarter of 2024 as compared to $899.9 million in the first quarter of 2023, primarily due to increased net income resulting from increased net product revenues.
Investing Activities
Cash used in investing activities were $2.1 billion and $1.8 billion in the first quarter of 2024 and 2023, respectively, which primarily relate to net purchases of available-for-sale debt securities.
Financing Activities
Cash used in financing activities were $357.5 million and $294.7 million in the first quarter of 2024 and 2023, respectively. The largest portions of our financing activities in each of these periods were payments related to our employee stock benefit plans and repurchases of our common stock pursuant to our share repurchase program.
Sources and Uses of Liquidity
We intend to rely on our existing cash, cash equivalents and current marketable securities together with cash flows from product sales as our primary source of liquidity. We expect that cash flows from our product sales together with our cash, cash equivalents and current marketable securities will be sufficient to fund our operations for at least the next twelve months. The adequacy of our available funds to meet our future operating and capital requirements will depend on many factors, including our future product sales, and the potential introduction of one or more of our other product candidates to the market, our business development activities, and the number, breadth, cost and prospects of our research and development programs.
Credit Facilities & Financing Strategy
We may borrow up to a total of $500.0 million pursuant to a revolving credit facility that we entered into in July 2022 and could repay and reborrow amounts under this revolving credit agreement without penalty. Subject to certain conditions, we could request that the borrowing capacity be increased by an additional $500.0 million, for a total of $1.0 billion. Negative covenants in our credit agreement could prohibit or limit our ability to access this source of liquidity. As of March 31, 2024, the facility was undrawn, and we were in compliance with these covenants.
We may also raise additional capital by borrowing under credit agreements, through public offerings or private placements of our securities or securing new collaborative agreements or other methods of financing. We will continue to manage our capital structure and will consider all financing opportunities, whenever they may occur, that could strengthen our long-term liquidity profile. There can be no assurance that any such financing opportunities will be available on acceptable terms, if at all.

30
Future Capital Requirements
We have significant future capital requirements, including:
•In April 2024, we entered into the Alpine Merger Agreement to acquire Alpine for approximately $4.9 billion in cash, as described above. The transaction is expected to close in the second quarter of 2024, subject to certain customary closing conditions. We intend to fund the acquisition with our cash and cash equivalents.
•Expected operating expenses to conduct research and development activities, manufacture and commercialize our existing and future products, and to operate our organization.
•Cash that we pay for income taxes.
•Royalties we pay related to sales of our CF products.
•Facility, operating and finance lease obligations.
•Firm purchase obligations related to our supply and manufacturing processes.
In addition, other potential significant future capital requirements may include:
•We have entered into certain business development-related and strategic agreements with third parties that include the funding of certain research, development, manufacturing and commercialization efforts. Certain of our transactions, including collaborations, licensing arrangements, and asset acquisitions, include the potential for future milestone and royalty payments by us upon the achievement of pre-established developmental and regulatory targets and/or commercial targets. Other transactions include the potential for future lease-related expenses and other costs. Our obligation to fund these research and development and commercialization efforts and to pay these potential milestones, expenses and royalties is contingent upon continued involvement in the programs and/or the lack of any adverse events that could cause their discontinuance. We may enter into additional business development transactions and strategic agreements, including acquisitions, collaborations, licensing arrangements and equity investments, which require additional capital.
•To the extent we borrow amounts under our existing credit agreement, we would be required to repay any outstanding principal amounts in 2027.
•As of March 31, 2024, we had $2.4 billion remaining authorization available under our Share Repurchase Program that our Board of Directors approved in February 2023. We expect to fund repurchases of our common stock through a combination of cash on hand and cash generated by operations. This program does not have an expiration date and can be discontinued at any time.
Other than our potential payment to acquire Alpine noted above, there have not been any material changes to our future capital requirements disclosed in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the Securities and Exchange Commission, or SEC, on February 15, 2024.

CRITICAL ACCOUNTING POLICIES AND ESTIMATES
Our discussion and analysis of our financial condition and results of operations are based upon our condensed consolidated financial statements prepared in accordance with generally accepted accounting principles in the U.S. The preparation of these financial statements requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reported periods. These items are monitored and analyzed by management for changes in facts and circumstances, and material changes in these estimates could occur in the future. Changes in estimates are reflected in reported results for the period in which the change occurs. We base our estimates on historical experience and various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from our estimates if past experience or other assumptions do not turn out to be substantially accurate. During the three months ended March 31, 2024, there were no material changes to our critical accounting policies as reported in our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 15, 2024.


31
RECENT ACCOUNTING PRONOUNCEMENTS
For a discussion of recent accounting pronouncements, please refer to Note A, “Basis of Presentation and Accounting Policies.”

Item 3.    Quantitative and Qualitative Disclosures About Market Risk
Information required by this item is incorporated by reference from the discussion in Part II, Item 7A, “Quantitative and Qualitative Disclosures About Market Risk,” of our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 15, 2024.

Item 4.    Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management (under the supervision and with the participation of our chief executive officer and chief financial officer), after evaluating the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended) as of the end of the period covered by this Quarterly Report on Form 10-Q, has concluded that, based on such evaluation, as of March 31, 2024 our disclosure controls and procedures were effective and designed to provide reasonable assurance that the information required to be disclosed is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. In designing and evaluating our disclosure controls and procedures, our management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
Changes in Internal Controls Over Financial Reporting
No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended) occurred during the three months ended March 31, 2024 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. Other Information
Item 1. Legal Proceedings
We are not currently subject to any material legal proceedings.

Item 1A. Risk Factors
The information presented below supplements the risk factors set forth in Part I, Item 1A. “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 15, 2024.
We may be unable to complete the pending strategic acquisition of Alpine or successfully integrate Alpine’s business which could adversely affect our business and financial condition.
Our inability to complete the pending acquisition of Alpine or to successfully integrate this new acquisition could have a material adverse effect on our business. Our ability to execute on our long-term strategy depends in part on our ability to engage in transactions and collaborations with other entities that add to our pipeline or provide us with new commercial opportunities. We may continue to seek attractive opportunities to acquire businesses, enter into collaborations and make other investments that are complementary to our existing strengths. There are no assurances, however, that any strategic acquisition opportunities will arise or, if they do, that they will be consummated. The pending Alpine acquisition may be difficult to complete for a number of reasons, including the need to satisfy customary closing conditions, the need for antitrust and/or other regulatory approvals, as well as potential disputes or litigation that may arise. Our realization of the value from the pending acquisition of Alpine relies on successful integration and continued operations. We may not be able to

32
integrate Alpine’s business successfully into our existing business, make Alpine’s business profitable, retain key employees or realize anticipated cost savings or synergies, if any, from this pending acquisition, which could adversely affect our business and financial condition. Further, our ongoing business may be disrupted, and our management's attention may be diverted by the pending Alpine acquisition, transition and/or integration activities.
SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q and, in particular, our Management’s Discussion and Analysis of Financial Condition and Results of Operations set forth in Part I, Item 2, contain a number of forward-looking statements. Forward-looking statements are not purely historical and may be accompanied by words such as “anticipates,” “may,” “forecasts,” “expects,” “intends,” “plans,” “potentially,” “believes,” “seeks,” “estimates,” and other words and terms of similar meaning. Such statements may relate to:
•our expectations regarding the amount of, timing of, and trends with respect to our financial performance, including revenues, costs and expenses, and other gains and losses;
•our expectations regarding our clinical trials and pipeline programs, including expectations for patient enrollment, development timelines, the expected timing of data from our ongoing and planned clinical trials, regulatory authority filings and other submissions for our therapies, communications with regulatory authorities and anticipated regulatory approvals;
•our ability to maintain and obtain adequate reimbursement for our products, our ability to launch, commercialize and market our products or any of our other therapies for which we obtain regulatory approval and our ability to obtain label expansions for existing therapies;
•our expectations regarding our ability to continue to grow our CF business by increasing the number of people with CF eligible and able to receive our medicines, providing improved treatment options for people who are already eligible for one of our medicines, and pursuing genetic therapies for people with CF who cannot currently benefit from our medicines;
•the data that will be generated by ongoing and planned clinical trials and the ability to use that data to advance compounds, continue development or support regulatory filings;
•our beliefs regarding the support provided by clinical trials and preclinical and nonclinical studies of our therapies for further investigation, clinical trials or potential use as a treatment;
•our plans to continue investing in our research and development programs, including anticipated timelines for our programs, and our strategy to develop our pipeline programs, alone or with third party-collaborators;
•our beliefs regarding the approximate patient populations for the disease areas on which we focus;
•our expectations, plans and anticipated timeline for the pending Alpine acquisition, including regarding Alpine’s business and operations, and the therapeutic scope of and the potential benefits of povetacicept, our beliefs regarding povetacicept’s target patient population and our beliefs regarding the clinical progress and availability of clinical data from the current Alpine pipeline;
•plans for and prospects of our business development activities, including the potential benefits and therapeutic scope of our collaborations, our ability to integrate and continue operations of acquired businesses, and our ability to successfully capitalize on these opportunities;
•the establishment, development and maintenance of collaborative relationships, including potential milestone payments or other obligations;
•potential business development activities, including the identification of potential collaborative partners or acquisition targets;
•our ability to expand and protect our intellectual property portfolio and otherwise maintain exclusive rights to products;
•potential fluctuations in foreign currency exchange rates and the effectiveness of our foreign currency management program;

33
•our expectations regarding cash generated by operations, our cash balance and expected generation and interest income;
•our expectations regarding our provision for or benefit from income taxes and the utilization of our deferred tax assets;
•our ability to use our research programs to identify and develop new product candidates to address serious diseases and significant unmet medical needs;
•our plans to expand, strengthen, and invest in our global supply chains and manufacturing infrastructure and capabilities, including for cell and gene therapies; and
•our liquidity and our expectations regarding the possibility of raising additional capital.
Forward-looking statements are subject to certain risks, uncertainties, or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any such statements. These risks, uncertainties, and other factors include, but are not limited to, those described in our “Risk Factors” in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, which was filed with the SEC on February 15, 2024, and those described from time to time in our future reports filed with the Securities and Exchange Commission.
Any such forward-looking statements are made on the basis of our views and assumptions as of the date of the filing and are not estimates of future performance. Except as required by law, we undertake no obligation to publicly update any forward-looking statements. The reader is cautioned not to place undue reliance on any such statements.

Item 2.     Unregistered Sales of Equity Securities and Use of Proceeds
Issuer Repurchases of Equity Securities
In February 2023, our Board of Directors approved a share repurchase program (our “Share Repurchase Program”), pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. Our Share Repurchase Program does not have an expiration date and can be discontinued at any time. The table set forth below shows repurchases of securities by us during the three months ended March 31, 2024 under our Share Repurchase Program.
PeriodTotal Number
of Shares Purchased		Average Price
Paid per Share		Total Number of Shares
Purchased as Part of
Publicly Announced
Plans or Programs (1)		Approximate Dollar Value
 of Shares that May Yet be
Purchased Under the
Plans or Programs (1)
January 1, 2024 to January 31, 2024
— $— — $2,572,394,027 
February 1, 2024 to February 29, 2024
94,000 $425.87 94,000 $2,532,362,623 
March 1, 2024 to March 31, 2024
241,773 $415.22 241,773 $2,431,973,750 
Total335,773 $418.20 335,773 $2,431,973,750 
(1) Under our Share Repurchase Program, we are authorized to purchase shares from time to time through open market or privately negotiated transactions. Such purchases may be pursuant to Rule 10b5-1 plans or other means as determined by our management and in accordance with the requirements of the Securities and Exchange Commission.

Item 5.     Other Information
Rule 10b5-1 Trading Plans
Our policy governing transactions in our securities by our directors, officers, and employees permits our officers, directors and employees to enter into trading plans complying with Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the first quarter of 2024, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).

34
Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
E. Morrow "Morrey" Atkinson, III
EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
2/22/20242/28/2025
25,290(2)
Jonathan Biller
EVP, Chief Legal Officer
2/13/20244/30/2025
9,825(2)
Carmen Bozic
EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer
2/27/20241/31/2025
13,680
Reshma Kewalramani
Chief Executive Officer and President
2/7/20245/20/2025
96,388(2)
Ourania "Nia" Tatsis
EVP, Chief Regulatory and Quality Officer
2/29/20245/1/2025
9,484(2)
Charles F. Wagner, Jr.
EVP, Chief Financial Officer
2/26/20241/31/2025
6,500
Bruce Sachs
Director
2/12/20242/28/2025
12,368
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.

Item 6.    Exhibits
Exhibit Number
Exhibit Description
2.1*
31.1
31.2
32.1
101.INSXBRL Instance - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
101.SCHXBRL Taxonomy Extension Schema
101.CALXBRL Taxonomy Extension Calculation
101.LABXBRL Taxonomy Extension Labels
101.PREXBRL Taxonomy Extension Presentation
101.DEFXBRL Taxonomy Extension Definition
104Cover Page Interactive Data File––the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
*Schedules and similar attachments have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule will be furnished supplementally to the SEC upon request.


35
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Vertex Pharmaceuticals Incorporated
May 7, 2024
By:
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President, Chief Financial Officer
(principal financial officer and
duly authorized officer)

36
 EX-31.1 2 a2024q110-qexhibit311.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION
I, Reshma Kewalramani, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 7, 2024/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President


 EX-31.2 3 a2024q110-qexhibit312.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION
I, Charles F. Wagner, Jr., certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Vertex Pharmaceuticals Incorporated;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: May 7, 2024/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer

 EX-32.1 4 a2024q110-qexhibit321.htm EX-32.1 Document

Exhibit 32.1
SECTION 906 CEO/CFO CERTIFICATION
Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code) each of the undersigned officers of Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (the “Company”), does hereby certify, to such officer’s knowledge, that the Quarterly Report on Form 10-Q for the quarter ended March 31, 2024 (the “Form 10-Q”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: May 7, 2024
/s/ Reshma Kewalramani
Reshma Kewalramani
Chief Executive Officer and President
Date: May 7, 2024
/s/ Charles F. Wagner, Jr.
Charles F. Wagner, Jr.
Executive Vice President and Chief Financial Officer



 EX-101.SCH 5 vrtx-20240331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - Condensed Consolidated Statements of Income link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Condensed Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Basis of Presentation and Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Collaboration, License and Other Arrangements link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Earnings Per Share link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Marketable Securities and Equity Investments link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Hedging link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Inventories link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Additional Cash Flow Information link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Subsequent Event link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - Basis of Presentation and Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - Earnings Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - Marketable Securities and Equity Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - Hedging (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - Inventories (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - Additional Cash Flow Information (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - Basis of Presentation and Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - Collaboration, License and Other Arrangements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - Earnings Per Share - Schedule of Computation (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - Fair Value Measurements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Our Contingent Consideration Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - Hedging - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - Hedging - Notional Amount (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - Hedging - Derivative Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - Hedging - Offsetting Derivatives (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - Inventories (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - Income Taxes (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - Additional Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 vrtx-20240331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 vrtx-20240331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 vrtx-20240331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Variable Rate [Domain] Variable Rate [Domain] Pay vs Performance Disclosure [Line Items] Accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Line of credit facility, maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Research and development expenses Research and Development Expense Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Debt covenant, consolidated leverage ratio Debt Covenant, Consolidated Leverage Ratio Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants. Award Type [Domain] Award Type [Domain] Fair Value as of Grant Date Award Grant Date Fair Value Acquired in-process research and development expenses Research and Development Asset Acquired Other than Through Business Combination, Writeoff Other current liabilities Other Current Liabilities [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Jonathan Biller [Member] Jonathan Biller Payments to acquire business in cash Payments to Acquire Businesses, Gross Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Revolving Credit Facility Revolving Credit Facility [Member] Schedule of Cash Equivalents and Marketable Debt and Equity Securities Cash, Cash Equivalents and Investments [Table Text Block] Effect of changes in exchange rates on cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] Accounts payable Accounts Payable, Current Prepaid expenses and other current assets Prepaid Expenses and Other Current Assets [Member] Restatement Determination Date: Restatement Determination Date [Axis] Corporate debt securities Corporate Debt Securities [Member] Collaborative arrangement, allocation of research and development expenses, percent Collaborative Arrangement, Allocation Of Research And Development Expenses, Percent Collaborative Arrangement, Allocation Of Research And Development Expenses, Percent Commitments and contingencies Commitments and Contingencies Insider Trading Policies and Procedures [Line Items] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Total cash equivalents and marketable securities, Gross Unrealized Gains Cash Equivalents, Debt and Equity Securities, Unrealized Gain Cash Equivalents, Debt and Equity Securities, Unrealized Gain Prepaid expenses and other current assets, foreign currency forward contracts Derivative Asset, Current Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Line of Credit Facility [Line Items] Line of Credit Facility [Line Items] Geographical [Axis] Geographical [Axis] Income Taxes Income Tax Disclosure [Text Block] Canadian dollar Canada, Dollars Total financial liabilities Financial Liabilities Fair Value Disclosure Current liabilities: Liabilities, Current [Abstract] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding Preferred Stock, Value, Issued Subsequent Event Type [Domain] Subsequent Event Type [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Derivative Instruments, Gain (Loss) [Line Items] Derivative Instruments, Gain (Loss) [Line Items] Diluted (in dollars per share) Diluted net income per common share (in dollars per share) Earnings Per Share, Diluted Total liabilities Gross Amounts Recognized Derivative Liability, Subject to Master Netting Arrangement, before Offset Net unrealized (losses) gains Unrealized Gain (Loss) on Investments PEO Total Compensation Amount PEO Total Compensation Amount Hedging Relationship [Axis] Hedging Relationship [Axis] Accounts receivable, net Accounts Receivable, after Allowance for Credit Loss, Current Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Collaborative Arrangements by Agreement [Domain] Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(12.3) and $7.4, respectively Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Level 3 Fair Value, Inputs, Level 3 [Member] Trading Symbol Trading Symbol U.S. government agency securities US Government Agencies Debt Securities [Member] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Interest income Investment Income, Interest and Dividend Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Unrealized holding (losses) gains on marketable securities, tax OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax Net income Net income Net income Net income Net Income (Loss) Total current liabilities Liabilities, Current Derivative Contract [Domain] Derivative Contract [Domain] Schedule of Cash Flow Hedging Instruments Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block] Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Company Selected Measure Name Company Selected Measure Name Schedule of Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] All Currencies [Domain] All Currencies [Domain] Property and equipment, net Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization Liabilities and Shareholders’ Equity Liabilities and Equity [Abstract] Total cash equivalents and marketable securities, Gross Unrealized Losses Cash Equivalents, Debt and Equity Securities, Unrealized Loss Cash Equivalents, Debt and Equity Securities, Unrealized Loss ESPP share issuances Employee Stock [Member] Repurchases of common stock Value of shares repurchased Stock Repurchased During Period, Value Derivative Instruments, Gain (Loss) [Table] Derivative Instruments, Gain (Loss) [Table] Amounts reclassified from accumulated other comprehensive income (loss) Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent Gross Unrealized Losses Unrealized loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Contract liabilities Contract with Customer, Liability Computation of Basic and Diluted Net Income Per Common Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Cost of sales Cost of Goods and Services Sold Executive Category: Executive Category [Axis] Level 1 Fair Value, Inputs, Level 1 [Member] Name Measure Name Marketable securities Marketable Securities, Current Name Forgone Recovery, Individual Name British pound sterling United Kingdom, Pounds Goodwill Goodwill Equity Components [Axis] Equity Components [Axis] Equity Components [Axis] Financial Instruments [Domain] Financial Instruments [Domain] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Hedging Relationship [Domain] Hedging Relationship [Domain] Certificates of deposit Certificates of Deposit [Member] Underlying Securities Award Underlying Securities Amount Entity Small Business Entity Small Business Accumulated Other Comprehensive Income (Loss) Comprehensive Income (Loss) Note [Text Block] Local Phone Number Local Phone Number Accounts receivable, net Increase (Decrease) in Accounts Receivable Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Letters of Credit Letter of Credit [Member] Selling, general and administrative expenses Selling, General and Administrative Expenses [Member] Notional amount of foreign currency forward contract Derivative, Notional Amount Fair Value by Measurement Frequency [Axis] Measurement Frequency [Axis] Long-term operating lease liabilities Operating Lease, Liability, Noncurrent Restricted stock units (including performance-based restricted stock units (“PSUs”)) Unvested restricted stock units (including PSUs) Restricted Stock Units (RSUs) [Member] Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Purchase of common stock Payment To Acquire Common Stock Payment To Acquire Common Stock Schedule of Foreign Exchange Contracts Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Reclassification out of Accumulated Other Comprehensive Income [Axis] Reclassification out of Accumulated Other Comprehensive Income [Axis] Line of Credit Facility [Table] Line of Credit Facility [Table] Income Statement Location [Axis] Income Statement Location [Axis] Research and development expenses Research and Development Expense (Excluding Acquired in Process Cost) Issuance of common stock under benefit plans (in shares) Stock Issued During Period, Shares, Employee Benefit Plan Total stock-based compensation expense, net of tax Share-Based Payment Arrangement, Expense, after Tax Common stock withheld for employee tax obligations Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Foreign currency forward contracts Foreign Exchange Forward [Member] Europe Europe [Member] Product and Service [Domain] Product and Service [Domain] Schedule of Potential Gross Common Equivalent Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Other Performance Measure, Amount Other Performance Measure, Amount Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Inventories Increase (Decrease) in Inventories Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $5.4 and $(0.8), respectively Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Research and development expenses Research and Development Expense [Member] Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Carmen Bozic [Member] Carmen Bozic Antidilutive securities excluded from computation of earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Award Type [Axis] Award Type [Axis] Derivative Instruments and Hedging Activities Disclosure [Abstract] Derivative Instruments and Hedging Activities Disclosure [Abstract] Unrealized gains (losses) on foreign currency forward contracts, tax Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent Document Quarterly Report Document Quarterly Report Fair Value, Measurements, Fair Value Hierarchy [Domain] Fair Value Hierarchy and NAV [Domain] Additional Cash Flow Information Additional Financial Information Disclosure [Text Block] Hedging Designation [Axis] Hedging Designation [Axis] Trading Arrangement: Trading Arrangement [Axis] Contingent consideration, measurement input (percent) Business Combination, Contingent Consideration, Liability, Measurement Input Use of Estimates Use of Estimates, Policy [Policy Text Block] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Corporate equity securities Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract] Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates Schedule of Components of Income Tax Expense (Benefit) [Table Text Block] Stock-based compensation expense: Share-based Compensation Allocation [Abstract] -- None. No documentation exists for this element. -- Total marketable available-for-sale debt securities Debt Securities, Available-for-Sale [Abstract] Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Amortized Cost Cash Equivalents And Debt Securities, Available for Sale Cash Equivalents And Debt Securities, Available for Sale Total liabilities Offsetting Derivative Liabilities [Abstract] Discount Rate Measurement Input, Discount Rate [Member] Derivative term Derivative, Term of Contract On Available-For-Sale Debt Securities AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member] Allowance for credit loss for available-for-sale debt securities Debt Securities, Available-for-Sale, Allowance for Credit Loss Sales and maturities of available-for-sale debt securities Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale Entity Shell Company Entity Shell Company Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Other comprehensive income (loss) before reclassifications OCI, before Reclassifications, Net of Tax, Attributable to Parent Recently Adopted and Recently Issued Accounting Standards New Accounting Pronouncements, Policy [Policy Text Block] Restatement Determination Date Restatement Determination Date Schedule of Offsetting Liabilities Offsetting Liabilities [Table Text Block] Other liabilities Increase (Decrease) in Other Operating Liabilities Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Cash, cash equivalents and restricted cash—beginning of period Cash, cash equivalents and restricted cash—end of period Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Fair value of available-for-sale debt securities in unrealized loss positions for greater than 12 months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer Common stock, shares issued (in shares) Common Stock, Shares, Issued Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities Unrealized Gain (Loss) on Investments [Table Text Block] Security Exchange Name Security Exchange Name Total financial assets Assets, Fair Value Disclosure Selling, general and administrative expenses Selling, General and Administrative Expense Accumulated other comprehensive income (loss) Accumulated Other Comprehensive Income (Loss), Net of Tax Swiss Franc Switzerland, Francs Collaboration, License and Other Arrangements Collaborative Arrangement Disclosure [Text Block] Foreign Currency Translation Adjustment Foreign Currency Forward Contract Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Stock options Stock options Employee Stock Option [Member] Hedging Derivative Instruments and Hedging Activities Disclosure [Text Block] CRISPR T1D CRISPR T1D [Member] CRISPR T1D Gross Amounts Not Offset Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Legal Offset Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Collaborative arrangement, development and regulatory potential milestone payments maximum Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized. Total costs and expenses Costs and Expenses Other financing activities Proceeds from (Payments for) Other Financing Activities Maximum Maximum [Member] Comprehensive income Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Reshma Kewalramani [Member] Reshma Kewalramani [Member] Tabular List, Table Tabular List [Table Text Block] Entity Address, Address Line One Entity Address, Address Line One Long-term marketable securities Marketable Securities, Noncurrent Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Other current liabilities, foreign currency forward contracts Derivative Liability, Current Stock-based Compensation Expense and Share Repurchase Programs Share-Based Payment Arrangement [Text Block] Up-front payment Collaborative Arrangement Up-front License Fee Collaborative Arrangement Up-front License Fee Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Other non-cash items, net Other Noncash Income (Expense) Purchases of available-for-sale debt securities Payments to Acquire Debt Securities, Available-for-Sale Business Acquisition [Axis] Business Acquisition [Axis] Gross Unrealized Losses Equity Securities, FV-NI, Unrealized Loss Subsequent Event Subsequent Event [Member] Derivative [Table] Derivative [Table] Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Income Statement [Abstract] Raw materials Inventory, Raw Materials, Net of Reserves Costs and expenses: Costs and Expenses [Abstract] Title of 12(b) Security Title of 12(b) Security Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Gross Amounts Presented Derivative Liability Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Net payments related to finite-lived intangible assets Proceeds From (Payments For) Finite-Lived Intangible Assets Proceeds From (Payments For) Finite-Lived Intangible Assets Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Amortized Cost Debt and Equity Securities, Cost Debt and Equity Securities, Cost Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Collaborative Arrangements by Agreement [Axis] Collaborative Arrangements by Agreement [Axis] Significant terms of collaboration arrangements, by individual agreement. Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Entity Tax Identification Number Entity Tax Identification Number Inventories Total Inventory, Net Stock-based compensation expense related to inventories Share-Based Payment Arrangement, Amount Capitalized Statistical Measurement [Axis] Statistical Measurement [Axis] Balance Sheet Location [Domain] Balance Sheet Location [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Adjustments to reconcile net income to net cash provided by operating activities: Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Total Shareholder Return Amount Total Shareholder Return Amount Repurchases of common stock Payments for Repurchase of Common Stock Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Other Assets Other Assets [Member] E. Morrow "Morrey" Atkinson III [Member] Morrey Atkinson [Member] Share-based Compensation Arrangement by Share-based Payment Award Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Other CF products Other Cystic Fibrosis Products [Member] Other Cystic Fibrosis Products Retained earnings Retained Earnings (Accumulated Deficit) Measure: Measure [Axis] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Name Outstanding Recovery, Individual Name Contract Liabilities Revenue from Contract with Customer [Policy Text Block] Gross Amounts Not Offset Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Current assets: Assets, Current [Abstract] Entity Address, State or Province Entity Address, State or Province Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding PEO PEO [Member] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Total assets Gross Amounts Recognized Derivative Asset, Subject to Master Netting Arrangement, before Offset Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Foreign currency translation adjustment Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent Remaining milestone payment Business Combination, Remaining Milestone Payment Business Combination, Remaining Milestone Payment Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Fair Value Equity Securities, FV-NI, Current Schedule of Inventories by Type Schedule of Inventory, Current [Table Text Block] Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations Reclassification out of Accumulated Other Comprehensive Income [Table Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Effective tax rate Effective Income Tax Rate Reconciliation, Percent Measurement Input Type [Domain] Measurement Input Type [Domain] Milestone payment Collaborative Arrangement, Milestone Payment Collaborative Arrangement, Milestone Payment Credit Facility [Axis] Credit Facility [Axis] Total liabilities Liabilities Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income (Loss) Total AOCI Attributable to Parent [Member] Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Debt securities fair value, unrealized loss position Debt Securities, Available-for-Sale, Unrealized Loss Position Measurement Frequency [Domain] Measurement Frequency [Domain] All Executive Categories All Executive Categories [Member] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Income tax effect Share-Based Payment Arrangement, Expense, Tax Benefit Net income per common share: Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively Common Stock, Value, Issued Matures after one year through five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Deferred income taxes Increase (Decrease) in Other Deferred Liability Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Total current assets Assets, Current Fair Value Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure Payments on finance leases Finance Lease, Principal Payments Beginning balance Ending balance Business Combination, Contingent Consideration, Liability Corporate equity securities Equity Securities [Member] Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] All Individuals All Individuals [Member] Supplemental disclosure of cash flow information: Supplemental Cash Flow Information [Abstract] Other (expense) income, net Other (expense) income, net Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Statement [Table] Statement [Table] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Number of shares authorized to be repurchased Stock Repurchase Program, Authorized Amount Repurchase of common stock (in shares) Shares repurchased (in shares) Stock Repurchased During Period, Shares Contingent liabilities Contingent Liabilities Contingent Liabilities Marketable Securities and Equity Investments Cash, Cash Equivalents, and Marketable Securities [Text Block] PEO Name PEO Name Entrada Therapeutics Entrada Therapeutics [Member] Entrada Therapeutics Schedule of Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Base Rate Base Rate [Member] Issuance of common stock under benefit plans Stock Issued During Period, Value, Employee Benefit Plan Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Charles F. Wagner, Jr. [Member] Charles F. Wager, Jr. [Member] Asset-backed securities Asset-Backed Securities [Member] Ourania "Nia" Tatsis [Member] Ourania "Nia" Tatsis Net cash provided by operating activities Net Cash Provided by (Used in) Operating Activities Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Depreciation and amortization expense Depreciation, Depletion and Amortization Euro Euro Member Countries, Euro Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Total shareholders’ equity Beginning balance Ending balance Equity, Attributable to Parent Indemnification claims Indemnification Claims Amount of indemnification claims currently outstanding Commercial paper Commercial Paper [Member] Net unrecognized tax benefits which would affect the tax rate if recognized Unrecognized Tax Benefits that Would Impact Effective Tax Rate Restricted stock units (including performance-based restricted stock units (“PSUs”)) Restricted Stock [Member] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Prepaid expenses and other current assets Restricted Cash and Cash Equivalents Debt covenant, increase in consolidated leverage ratio Debt Covenant, Increase In Consolidated Leverage Ratio Debt Covenant, Increase In Consolidated Leverage Ratio Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table] Schedule of the cash and cash equivalents and available-for-sale investments held by the entity. On Foreign Currency Forward Contracts Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member] Long-term marketable securities Marketable Securities, Noncurrent [Member] Marketable Securities, Noncurrent Subsequent Events [Abstract] Income before provision for income taxes Income before provision for income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Reduction in carrying value of equity investments without readily determinable fair value, based on an observable price decrease Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount Not Designated as Hedging Instrument Not designated as hedging instruments Not Designated as Hedging Instrument [Member] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Hedging Designation [Domain] Hedging Designation [Domain] Level 2 Fair Value, Inputs, Level 2 [Member] Entity Emerging Growth Company Entity Emerging Growth Company Investment in equity securities Payments to Acquire Equity Securities, FV-NI Other intangible assets, net Intangible Assets, Net (Excluding Goodwill) Increase (Decrease) in Stockholders' Equity Increase (Decrease) in Stockholders' Equity [Roll Forward] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Accrued expenses Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Title Trading Arrangement, Individual Title Stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Bruce Sachs [Member] Bruce Sachs Common Stock Common Stock [Member] Individual: Individual [Axis] Total cash equivalents and marketable securities, Amortized Cost Cash Equivalents, Debt and Equity Securities, Cost Cash Equivalents, Debt and Equity Securities, Cost City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] Earnings Per Share Earnings Per Share [Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Document Fiscal Year Focus Document Fiscal Year Focus Geographical [Domain] Geographical [Domain] Minimum Minimum [Member] Shares used in per share calculations: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Basis of Presentation and Accounting Policies Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] Exercise Price Award Exercise Price CRISPR CRISPR [Member] CRISPR Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Assets Assets [Abstract] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Payments in connection with common stock withheld for employee tax obligations Payment, Tax Withholding, Share-Based Payment Arrangement U.S. Treasury securities US Treasury Securities [Member] Cash paid for income taxes Income Taxes Paid, Net Net cash used in financing activities Net Cash Provided by (Used in) Financing Activities Deferred tax assets Deferred Income Tax Assets, Net Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Retained Earnings Retained Earnings [Member] Summary of cash, cash equivalents and marketable securities Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items] -- None. No documentation exists for this element. -- Schedule of Stock-based Compensation Expense by Line Item Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Total liabilities and shareholders’ equity Liabilities and Equity Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Other assets Other Assets, Noncurrent Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Operating lease assets Operating Lease, Right-of-Use Asset Basic (in dollars per share) Basic net income per common share (in dollars per share) Earnings Per Share, Basic Accounting Policies [Abstract] Accounting Policies [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Currency [Axis] Currency [Axis] Arrangement Duration Trading Arrangement Duration Entity Address, City or Town Entity Address, City or Town Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Schedule of Restricted Cash Restrictions on Cash and Cash Equivalents [Table Text Block] Total marketable available-for-sale debt securities Marketable Securities And Other Noncurrent Assets [Member] Marketable Securities And Other Noncurrent Assets Schedule of Fair Value of Our Contingent Consideration Liabilities Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block] Document Transition Report Document Transition Report Award Timing Predetermined Award Timing Predetermined [Flag] SOFR Loan Secured Overnight Financing Rate (SOFR) [Member] Secured Overnight Financing Rate (SOFR) Stock repurchase program, remaining amount Stock Repurchase Program, Remaining Authorized Repurchase Amount Termination Date Trading Arrangement Termination Date Total cash equivalents and marketable securities, Fair Value Cash Equivalents, Debt and Equity Securities, Fair Value Cash Equivalents, Debt and Equity Securities, Fair Value Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Fair Value Total Debt Securities, Available-for-Sale Gross Unrealized Gains Equity Securities, FV-NI, Unrealized Gain Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] CRISPR Therapeutics CRISPR Therapeutics AG [Member] CRISPR Therapeutics AG Derivative Instrument [Axis] Derivative Instrument [Axis] Allocation of net profits and net losses, percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent Gross Unrealized Gains Debt and Equity Securities, Unrealized Gain Debt and Equity Securities, Unrealized Gain All Trading Arrangements All Trading Arrangements [Member] Measurement Input Type [Axis] Measurement Input Type [Axis] All Adjustments to Compensation All Adjustments to Compensation [Member] Derivative [Line Items] Derivative [Line Items] Award Timing Disclosures [Line Items] Compensation Amount Outstanding Recovery Compensation Amount Marketable securities Marketable Securities [Member] Marketable Securities [Member] Matures after five years Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10 Gross Amounts Presented Derivative Asset Subsequent Event Type [Axis] Subsequent Event Type [Axis] Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract] Statement of Comprehensive Income [Abstract] Australian dollar Australia, Dollars TRIKAFTA/KAFTRIO TRIKAFTA/KAFTRIO [Member] TRIKAFTA/KAFTRIO [Member] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Alpine Alpine [Member] Alpine Insider Trading Arrangements [Line Items] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Entity Registrant Name Entity Registrant Name Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Award Timing Method Award Timing Method [Text Block] Share-based payment arrangements (in shares) Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Losses (gains) on equity securities Equity Securities, FV-NI, Unrealized Gain (Loss) Adjustment to Compensation, Amount Adjustment to Compensation Amount Cost of sales Cost of Sales [Member] Change in fair value of contingent consideration Decrease in fair value of contingent consideration Decrease in fair value of contingent payments Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability Document Period End Date Document Period End Date Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Adoption Date Trading Arrangement Adoption Date Schedule of Financial Assets Subject to Fair Value Measurements Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Long-term finance lease liabilities Finance Lease, Liability, Noncurrent Entity Central Index Key Entity Central Index Key Reclassification out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income [Member] Financial instruments carried at fair value (liability positions): Liabilities, Fair Value Disclosure [Abstract] Total stock-based compensation expense included in costs and expenses Share-Based Payment Arrangement, Expense Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Provision for income taxes Income Tax Expense (Benefit) Finished goods Inventory, Finished Goods, Net of Reserves Total product revenues outside of the United States Non-US [Member] Designated as Hedging Instruments Designated as hedging instruments Designated as Hedging Instrument [Member] Fair Value Measurements Fair Value Disclosures [Text Block] Number of operating segments Number of Operating Segments Name Trading Arrangement, Individual Name Cash equivalents Cash and Cash Equivalents [Abstract] Total other comprehensive income (loss) Other comprehensive (loss) income, net of tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Schedule of Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Unrealized loss position for greater than twelve months Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss Equity [Abstract] Equity [Abstract] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Inventories Inventory Disclosure [Text Block] Product revenues, net Revenue from Contract with Customer, Excluding Assessed Tax Entity [Domain] Entity [Domain] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Amendment Flag Amendment Flag Other Other, Non U.S. [Member] Other, Non U.S. [Member] Legal Entity [Axis] Legal Entity [Axis] Gross Amounts Offset Derivative Liability, Subject to Master Netting Arrangement, Asset Offset Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Common stock withheld for employee tax obligations (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Interest expense Interest Income (Expense), Net Matures within one year Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One Financial instruments carried at fair value (asset positions): Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Basis spread on variable rate (as a percent) Debt Instrument, Basis Spread on Variable Rate Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Fair Value Debt and Equity Securities, Fair Value Debt and Equity Securities, Fair Value Diluted (in shares) Diluted weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Realized gain (loss) amount Debt Securities, Available-for-Sale, Realized Gain (Loss) Revenue Recognition Revenue from Contract with Customer [Text Block] Total assets Offsetting Derivative Assets [Abstract] Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Company Selected Measure Amount Company Selected Measure Amount Additional paid-in capital Additional Paid in Capital, Common Stock Legal Offset Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election Fair value of equity securities Restricted Investments, at Fair Value Additional Paid-in Capital Additional Paid-in Capital [Member] Effect of potentially dilutive securities: Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Total assets Assets Name Awards Close in Time to MNPI Disclosures, Individual Name Employee stock purchase program (in shares) Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements Gross Unrealized Losses Debt and Equity Securities, Unrealized Loss Debt and Equity Securities, Unrealized Loss Cover [Abstract] Cover [Abstract] Commercial paper Commercial Paper, Not Included with Cash and Cash Equivalents [Member] Subsequent Event Subsequent Events [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition United States UNITED STATES Recurring Basis Fair Value, Recurring [Member] Other long-term liabilities Other Liabilities, Noncurrent Non-NEOs Non-NEOs [Member] Cash Flow Hedging Cash Flow Hedging [Member] Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Non-PEO NEO Non-PEO NEO [Member] Marketable securities: Marketable Securities Equity Component [Domain] Equity Component [Domain] Line of credit facility additional borrowing capacity Line Of Credit Facility Additional Borrowing Capacity Amount of increased borrowing capacity available in the future. Adjustment to Compensation: Adjustment to Compensation [Axis] Amortized Cost Equity Securities, FV-NI, Cost Schedule of Offsetting Assets Offsetting Assets [Table Text Block] Work-in-process Inventory, Work in Process, Net of Reserves Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Gross Amounts Offset Derivative Asset, Subject to Master Netting Arrangement, Liability Offset Basic (in shares) Basic weighted-average common shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Collaborative arrangement, right to exclusively license, number of targets Collaborative Arrangement, Right To License, Number Of Targets Collaborative Arrangement, Right To License, Number Of Targets Income from operations Operating Income (Loss) Cash and cash equivalents Cash and Cash Equivalents [Member] Issuances of common stock under benefit plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Statement Statement [Line Items] Other comprehensive income (loss): Other Comprehensive Income (Loss), Net of Tax [Abstract] Total stock-based compensation expense included in “Total costs and expenses” Share-Based Payment Arrangement, Expensed and Capitalized, Amount CRISPR JDCA CRISPR JDCA [Member] CRISPR joint development and commercialization agreement Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Shareholders’ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Reclassification out of Accumulated Other Comprehensive Income [Domain] Reclassification out of Accumulated Other Comprehensive Income [Domain] EX-101.PRE 9 vrtx-20240331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 10 vrtx-20240331_g1.jpg GRAPHIC begin 644 vrtx-20240331_g1.jpg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

%TBN&\X2SWCI:7,S&$6UP84MHH8I)I]TZ*TDL*.D: MQNI;B7R@#K];^(6A>'7>/4+DQM (FGV07$PMQ/Q";HPPR"U$G\!N#'N[4 >9 M?&WQMJ7AC3]+U;P_?>1#>W4<3E8[:6&:"6,RK)NFAD8?*HVLCJI5R2"=I4 ] M7T_Q?I6N7<^D6=RR7]NFYX7BEAF5& VS1I);U9HM)O7B$\L=O;K'#&K;F*:"01RC=%*(YXXG:*4.9_!-M8&*06<6 MH7T=M<7IB\[[+ 59I'2,@HTNT$IO5U 5SY;XP #5T:75QJ=J8;]=9T&YM;B3 M[28K?SA.K0^4'FM8XK=HG1I#'LAC; M=.((I?(AWL%\V;9'DXW4 1W?Q"T&QO;/3)KG%QJRQO9;8;AXKA9<;#'<)$UN M0<@G]Z-H92V RD@$6E?$G0-;COI;&>64:/C[8%\QOECW- MQ0!P7A_XI+;6.NZU?WHUBUTVZ8P06MC=036T+;_*MYQ-;0D-E=KN^]82K&6< M[E4 %6^^*4]YX'76H[HZ-J,_E 75QIU\]I$\DI?8C"SF22/RE:)9E2>/?M5F M\QU- 'J'R8)WDN?W2R220VL48 M5Q0!;NO&FCVEG;:BUP);?4"JVI@CEN'N"REL10VZ2S2$*K%PL9\L []N#0!L MZ9JEKK-N+NQD6>!FD19$SM+12/#(!D#.V1'7/0D9!(P: +] !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ')>-O&-EX M(TR34KZ1$(!2WC=@OG3D'RXE_P!XC+MTC0,[$*I( /EWXO>&[FW\*V&M'5=, MNCILHFLYK:W,$UU)<2!YY([AM1N([B1I0;IUB@4L4=P$ *D Z7XC?$;2_&?P MQFN4N8%O;M+-'M?,191^(M+?X/"T6\ MMCI.J:C?V M$*JPENIKI;2;).U;:6:2&U;@.%2*/HKJ/NF@#S7XK:CI=[\3]*$UXD-M;VL4 M%U/%=^0;:19[XLKW$4B-;RIO0D%T9=PW##8(!J>"-9/P>\4W>@^*'22VU8^? M::W/@R2I@!!<7398QL%56#.4@F72YTB=K.5I9T8,D=HT6TSK;RMLEDMF4RH\<,4R"#!0 Z_]HW5K+^UO#<(E MBCDLIY9+B'?'OMD=]/=/.1&;R@51BN?E8*Q4E1F@#7^+R#XOZAI7A[PTXO[> M&5Y[V]MR)+6W1MB#-PH:)I HE.Q7+9VKM)/R@'U-=N(X)'93(JHQ**,LX"DE M0.Y;H!W)Q0!^?T]XE_:^']1M8!INE0^()$CM$$C16B^=;.6GN9RTCSS'S"?G M6%$C"I&A!R >NZ]KNG6'Q>M;FYN8(8;;2W2:1Y45(G\FZ?9(Q8!&V,K;6()# M*-OEE3[T1^^%&* / MJ;Q3JCZ)I5UJ$47VE[:%Y%A +&4J,^6%')9_NJ!G)(X/2@#Y7\9^'M%TZXM] M<^'4SV'B1YXE_LJ .KN)6'F+?2;R,17LL*/)]DD^R_9-[H@9Q#\L3^9M(QYBD!MFX G\>>.-6N];TN MW\#:P]];:C-LO8K*+3[U+*)6MD$@<6LLD6]7FD;[3(^&4D;8P$ !F?$CQ3<> M%O%MG;>*HIM0\+-9"W#/&KI)/(FR6[E2*..)[E&!!1$7RXG+V\:%]K 'E4MN M/"2/H]ZEU>> M8O(I+>[DM)DEMRDD;,T22I'*DCQYMVDV 2H6GMT=U>$@'TW MXM\4Z+H^C6N@6D\&B?VN@M[9;E?LZVUFVX27$L1D@>)#"KB,/)!*TTB*Q20/ ML /%OBU]L^'?BG1_%T]U8SW*;89K:SMVM)#:IN0MY$E[=LZR0O- )08XT,<: MX)Z 'V!I&L6>O6D6HZ=*ES:W"[HY8R&5@"5(R.C*P*.IPR.K*P# @ 'Q?';.+^S+6_M[BRT.PA%W?>8H@0@QV]NOF@F)GF*N=J.QW>6B[F? /GSP)X MMT;P+XQEG$EO%H/B2.2XLI!,C"R+S,,3*#BT69H2)$8 QJ+=)F4V\JQ@'2Z' MKNG^'OB7XFN]5D2"W6S3<\@PG"6C%"Q&W-)(U^=%#NIBR&F &^+()K+XBI=ZW5[=O,3$R23 MZBJ-$<_.'::)5*YR9$ Y89 ,7^WM/2T^'X^U0*=/O)9+L>:@-M&=1M3NG^;] MTI6.0Y?:"JL>@)H ^[O$/_(,O/\ KUG_ /13T ?$=@?M7PS'A*-6;7;O4(S! M8%"MR4>9)EG$3 .+!_,7;,LKZG'$T9 MS\ZR27$"*5R"TT:CEUR />N]%2XNV8LNPW]POAGQMKVJ:Q*L5EJVB_\ $NN';]U/B*!?L\#_ '7FW(Q6 M%"7D&'53N!(!Y3XUT^Y\/_"O1M-U3]Q>3:H]S%;2$+,MN8[PD^6?F 4S1L_' M[LSHK[68"@#U70-=T^_^+UU<6MS!-#?V?!G$C @M;(_F[(Y 0ERK MR*!(S+,X!VNBQ/=?%C5+BW!$-II$$-RP VF64V\D2,1_$8U+ GG$9'2@#Z!H M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H XGQ_K-CHNE-+J%Q#:H\UN MJ&614WL)XW*IN(+,$5G(7)"JS$8!( /GCQ!X6N;?Q_!=^'61]+\96LJ7,T#; MH_)*JU\\(-)M_C"+L75JEE';^1YWG1B!9%LO M*\KS-VP,''E[XH SOB;=#59?%UIIEH;$VRV#7A59))M0>.ZB(F?> M6CM[:&,/*/(2-Y28Y))2C-'0!/\ &*^MV^&'AJ!9$,KC3F5-PWL(--EBG(7. M2(9'2.0@81W56P6 (![+\9I]+3P/J-]:-; :A!;)'/&8_P#20LL9A59%YFVQ M[S& 6VIO*X7=0!Y!X*^(#>$KC0'\136MQHMSIB0V$T+GV^OS)U MN&D>-)8A$EJZ,Y$B,'*A5 .I\36R>'?B1X9O[DRQV<>E/:"68;G,D=O?JL;- M&"LEPYFC7RXP6>1@$4[U% '+?$V[74M0\4V.F6ALY8+&V>]D59))]0*20%#A MRT,%M#$6=FB199?+5C)C*4 1^.XWO_A[X4%HCW)CEM6984:5@(;64RG;&&;] MV%8O@?+M.>E 'H4;1^*OB7;^(M'E2;2=)T@QW=Y&RFV,C_:\0^<,HSJL\&Z1;S>(?!WBJWT@_:9?[5BNVBB.Z22U$I8NJ#YF3Y?,R!R(S MC)&* /H[X7Z7I>JSVWBJTU"]U&]?3$LIED-H(K9$,;_9Y8[>VMV66.0$('+N M5#,Q8;6H [/Q[?:>HMM+UNT^W:9J)F2X_@4D@'CWP^T6+PUXR%GX*O7O_#5Q;2S7T:R?:+6UFPPA6.X4M&9V<)\F[SA$ M'$A< %0#B/AIX7AU"&^\+>);[4+34K+5_P"T%L(?LL;W,H6-$NHFFM7N)"7C M8NTX 7XKK%9^)/!^HA/LFF6]QLWNGD0VZ[[8QHX8*L "+\J.$VJI M&!M( !SOPQUFRAU3QX\TT<(EFGG02L(V,2SZBK/M?:P"--"KY VO*BMAF4$ M[']FT:?=>$XU?[/+/97L\[!O+:2W=P524@Y:)FBW*K_*2FX E=U 'F'@QDUS M1_'=O8L+B2XEEGA2+YVECWW3JT:KEG5N "H(RP]0" :7B;6;.7X.6MNDJ&7; M:0;)23*K1NUQ#<6Z;G=%=I(\A68@@Q,5 .QU_P#HNDZ)IVCZ?J-[IDMC+>7 MNF:I<,ACBPT7FF>:)8EBM9FF7RY65%)P=["1%F /4/A#J^I:WXN4 % !0 4 M% !0 4 %8FU>/7[.1K6\\L07("AH[NW!W".5"1B2,\PSJ0\>65A)&=E M'54 % !0 4 % !0 4 % !0 4 13J[QLL+".0J0C%=X5B#M8KE=P!P2NYVGR\C MS7_AH/Q!_P ^^G_]^KC_ .2J]W_5["_SUO\ P*'_ ,K-_81[O\/\@_X:#\0? M\^^G_P#?JX_^2J/]7L+_ #UO_ H?_*P]A'N_P_R.Q\ ?&/6/%6N6VDWD-FD% MQYVYHHYE<>7!+*-I>X=1ED .5/&<8."/,S#)L/@\-4Q-*55RARV4G%KWIQB[ MV@GLWUW,ITHPBY*^GIW]#Z3KX0XPH * "@ H * "@ H BGN(K6-IIW6*-!EG M=@JJ/4LQ ]R: $MKF*\B2XMW2:&9%DCDC8.CHX#(Z.I*LK*0RLI(((()!H MFH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@"AJNIVVBVDVH7KB& MVM8VEE<]%1 23ZD\8 '+' )(% 'EFJ^/]4M_#+>(8DTZRGO3$VEVVH726X> M%RK W$LLT$7GR0;IQ DB",84R2,"" =Q#XRTF(007]_I]O>SP1S&#[9!D[XP M^Z(,ZM)$1DI(%PZ#<.* -O3=6LM9A^TZ=<0WD&XKYMO*DL>Y?O+OC9ER.XSD M=Z /*?B?X^U7P3J6C6]BMI):ZO=K:S">*4RI^]B5GCD2XC0927 5HFVLNXE@ MVU0#TNU\2:5?0S75M>VDT%GN-Q+'<1/' $!9S,ZN5BVJ"S;RNT DX - 'A>J M_%3Q!8>#KCQ.HT9[NTO_ +.T=O,;^V>!FC2/][;78$C:5&U33E:V) M$RF\MP8B&V$2@R9C(?Y2&QAOE//% &MPQW-NRRPS(LD;J_P!UG_U^E_Z13/1H?"_7]$>$U]>=04 >G_!K_D;;#_MY_P#2 M.XKP,Y_W&M_W#_\ 3L#"K\#^7YH^W-3TNTUJV>QU"&.ZMI@!)%,BNC8(9$]7&R.24!UTVXF+*UM<;LYL M;DD[)'RL4A,Y"QVNH:@$>2WL4 M-Q.D$$20Q1(4"AE_>11J[ J:YXN\0ZGHCY7^S9X-7L+7[1)IU[;Q7MM<7," MK)%!>/#/"NYREQ&7D+*C(DJB42* >[-IXO[/['JRP7@DC"7"^3M@E./F_<2/ M/M0GD(\DA'=F/- 'QEX(+[7;[1K)=/6/35TV8R3"XR\5TT_GKA'XDV0 MDPM@JC#:XD#[HP#GKCXCZG#HB^-4CM7T(RC=;;)1>+:&X^SBZ%QYOE-)TE:U M^R@JI*>>6'(!/XMUW5-?LM>M])%I'9:3!/:SFYBEDDN9OL@GF2$I-$MNL4^&X;F(F&7SXI;>WL8\._P!H\N6- MC.6VK%$P "[_ .(@%W2/'NIW]C9P.MJ=7U'4K_3XW6.5+1%L'N3+<-$9GE;] MS;$K")U+R.H\Q%!8 %'QCJ7BJ#1BMTUK8W":Q96JSQ1,\5Y:37-NBR+#]K,E ML"\A2:)YG=TC=%>,2K(H!Z^VGB_L_L>K+!>"2,)<+Y.V"4X^;]Q(\^U">0CR M2$=V8\T ?%VGVVE?V FB:'9M'XLN-1O$TZZB@:U=%@OV);^T'2-)HHK=2CQ) M+.5X1HU(R #Z:\4>+KK1)[;2+?)O9[=[B6<:??:A&BQ-'&?]%L!YI,LCG#-+ M%'&JG)9F1& .4G\>^(TT_3=5FM[?38);];#4A>6=XK1!YO*AO(%EFM9%MYR4 M $T9:)I5W,P1Z .FUKQ??Z$;VZD$-Q9I9 \%[^]$L M14'*3LLB."-A5A0!T">)]<768-'N/L$0U33Y[JS=([B0P30&$%;@&:,7$;++ MO'E_9B-I3<>&(!DV/CO6;G2=!U9A9 ZKJ"V-[&(9L8DFEC62V;[3^Z*B$[EE M6?>7!!385< @U?XFZE'-<3:3:2WL%A>O:-:QZ7JL\UR()O(N9(;^&/[#"\;B M39$RS!Q'\TL;MY:@'2/XIU*77'TR-[*U6.>%([6ZBG6YO+5DA>:ZM;@S1PMY M?F2)Y"P3,K1$R2*6"4 >ET % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!X?^T5Y__"$WOD9V^9:^;C/^ MK^T1^G;?LSGC&: ,GXZ>3_PKIO*QY>W3_*^GF0[<9YSLS[XSGO0!P^N)'+XG M\"!PK*;" X(!'$2%3SZ$97WY'- '4?L_2?\ $Q\41*?W::LS*HZ#=)<@D >H M11]%'I0!#^T,8QJ'A@S;?*_M3Y]^-NWS+7=NSQMQG.>,9SQ0!HZ1 7^*VI36 M6T6<>E1+J!7_ %1E98C$LG\)DV $9R1&K]/FH ^?M!8#X/ZL"0"=:CP/^ Z< M?Y G\#Z4 >H:PZ_\)3X$ (S_ &? >O8PK@_0X./7!H H6S7:^(/'G]DY^U_8 MW\KROO[N=_E[>?-QNV[?F$F,?-0!2@+_ &#X?#1]OVS[1)GRL;O*\V'[7OV\ M^7M\SS\\8W9YH L:A'$WBSQVSA"5T&Z*D@9!-I /E)Z'..G?'>@#4\.:3+XE M^'/A^&UOTT_5H+V>?36FYBEN;:XOO+@?(91^ZR4W*V-H 1@2* .T\,Z\==\" MZ^VIV46G7%J-6M[Y(,^1+<);$W$T85F +,Q#B-F4RAG5B7H [+X'FX_X0G2O MM7^L\A\=?]5Y\OD]?^F/EX[>G% 'JU !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % 'RG\<_#NJ:OKD$UA9W5W$MC&A>""650PGN25+(C M, RDC.<$'&"*_1,BQ%&AAIPK5:<).K)VG.,7;DIJ]FT[73U\COHR48M-I:]7 MY(\8_P"$)\0?] S4/_ .X_\ C=?4_7L+_P!!%'_P;#_Y(Z.>/\R^]!_PA/B# M_H&:A_X!W'_QNCZ]A?\ H(H_^#8?_)!SQ_F7WH]%^$_A;6--\465S>6-Y;P) M]HW22VTT:+NM9U&YW0*,L0HR>20!R17B9MBL/5P56G2K4I2?):,:D9-VJ0;L MDV]DWZ&-647!I-=.J[H^QKM9GA=;5TBG*D1O)&TL:MC@O&LD+.H/51+&2. Z M]:_+3SCE]%\,20Z,VAZ[+!JL3*\3%;9K97@E:?>S6MWI%U<7=C?[%EEC:XFN)&25'.V=#'<-%*&*^=C>=I.T M&GJ?@F[UC2FLKV_,NH//;7 O/LZK&DEI-'-"BVJR "$,A+(9C(QD8?)"R%OE6/ ,"W^]DWAX7@;PZ\ M_G"R:VS.B>>+@VJW?G;/LIE'*&U,WEDH)QUH NWW@"Y-QJ3Z9?"TM=>C<7EO M);>?MF>#R#/;2">$Q,R!?,219T8CY1&<$ $K=[;A[RRO(+5K6ZM+MY9)FG5_M4X8B1Q ML""'";T9GW@H :<_@36KD6E\^L*FMZ>)(4OH[!5CGM91$7@NK1KETE)DB\P2 M1R0!6(V1JR[F .KN_"L>J:-<:+J4KW?VZ*1+B=U569Y!C>J+A$\O"^4J_<$: M9+,"Q *%]X%@O]!CT!YYE>#RI8[T$?:!=Q2"<7F3D&5[@&63/WB[@GG- &3J M7@?5]9T:ZTO4-66XN[Z VIN6L52..!O]9Y=M%<1CSI1C?*TS*"J[(E *D W%R03*!&[!F=X6B)#]D/VJ![=XY52"\^TXC1WC^<_9FDV/(B2(K# !Z)0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % %'5-,M]9M)M/O4$MO=1O%*AZ,CJ58>H.#P1R#@@@@4 MVMH8&9<@[6:)%)7(!P3C(!ZB@#1N]-M+\@W4$,Y570>;&CX20 2*-P.%D = M1PP # X% %2T\.Z786KZ=:V=K!9S!UDMXH(DAD60;7#Q*@1@ZDJX92&!P%='TFY:]L;"SM;J0 M,'GAMH8I6#D,X:1$5R&8!FR3N(!.30!+9>'-+TRX>]L[.UMKF;/F30V\4>: +MMX4T6SMS96]A90VS,[M#';0I$6=!&[&-4"%GC 1R1ED 4Y48H P_$G M@[^V-/C\/6'D:;I$N5NT@C$V1%6*(3_.LLIR43(2-FDWQ@':6MK% M8PQVUNJQ0PHL<:*,*B(H554=@J@ #L!0!/0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % 'G/B^^N+:\1(99(U,*DA'91G?(,X! S@ 9]A7H4(QE%MI/7JO)')5;3 MT;6G^9RG]K7O_/Q/_P!_7_\ BJZN2/\ *ON1CS2[O[V']K7O_/Q/_P!_7_\ MBJ.2/\J^Y!S2[O[V;OAO4;J?4(HY9I70[\JTCL#B-R,@D@X(!^M858Q4&TDG MIT7=&E.3ZBM2@E8(97$: M]6<@D*H[G"L?8 D\ F@">@# @\1V\^KRZ$$E6YM[:.[9F4")HI9'B4HV[%)((=4>>)[QUB@\NSO+A997)"0H]O;RH9G*G;#N\UA MR$((- %C1/%NF>(99;:QE8W%M@S6\T,]M<1AONL]O!))R\97<#''"KR2%A]U8T9VZ!2>* .,MOBKX=O(#=PRW;6R,R MO64L=Q;S+NCEB8.CKZJ MRD@\Y!]""#R* += !0 4 26,PF55/G1)%(Y3:[Y0 M"55!.TE@WR[<,P FI^+=-TFY^Q3R2-#@ NPZ_IUQ8G5H[F$V"AV-SO40[8V9'?S"0NP,K .#M;&5)!!(!A1_ M$+1'7S3--%"<;)YK.\@MY"3A5AN)K=()F=B%C6*1VD) 0,2!0!T6K:Q::%;F M\OY!#"K*N<,Q9W8(B(B!GDD=B%2-%9V8@*I- #-'UNTUV)I[)F98Y#%(LD4L M,L>.2\8) (K.\N!+(V<1(UM;RJ93M)$6 M?,*C<%VX- $VE>++#5[G[%!]JCN/*:8)=6-]9EHT9$=D-W;P!PK21A@A8KO7 M( - '24 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y?XV_X_4_ZX+_ .AR5Z6' M^%^OZ(XZOQ+T_5G'5UG.% '0^%O^0G#_ -M/_13UA6^!_+\T:T_B7S_(]=DC M652D@#*>H8 @]^0>.O->2=YY5)_R4B+_ +%N;_TY6] "W#'Q#XHN_#\\UQ9V MMA86]S!':7$MH\LES+.)KAI+=XI'$12-%0LT.]W:179@% /-HO/\4)X>_MB6 MXEGMM M:IIES?3_ -G:M90-.;F6WL[=&GL[>2P6S$DB7[@RLT]Q-#'@S?).SQ%& /1; M?_D?;G_L 6?_ *7W] &5\8FD2UT9K=4DF'B+2C$DCF-&D$K;5:14E9%)X9UC MD95)8(^-I ,7P+)+KOC'4=7UK98:S8VBZ*]9N]6F7QSHBR"QT*>YTZ[$)4W5S8^8@O)XE9'6+R)(P\0_UL MD>^0M#A,@'HO@0273-J5I?L_A^94ATBR\JW1!%'&H9R_D+=,=\9Y' M;R=_W-OR9W;>] &!\2=4OH!K.HZ3]!:-H\/' M_JD)V,N_ $F]?EH P?#'B&\\7Q^'M*O[F>&.]T>6^N9(9I()[N:!H(%C\^ Q MRHI$DEQ((G1W*J"^T,' .A^#MI]A37K8/),(O$=\H>5R\C 06>"[GEVQP6;Y MFZDDDF@#1U31=1@U:[UKPI!O(F:*)7A9)D'FVTX@E4*P$D#[ MEWH&5C0!YMXI\16VL:7HES+;/8:4/$/EZO;,0T<-Q'/*66=U^1[;[:2[-@1/ M\F54X0 'I?Q_T+P_-J&GBSE1&ACF@NX9I%E6YGAMUV/#W&G6UKO?7[>:*U,LNI*8U,,LDUMOC"11,DS0^4B MVXMH[<0LK^6 ;_CE1XFN3H3Z?=:M801.UXMJ]FFVXGC9+9&-W=VH)BB>2YPF M]DD-I+\A"D@$_P )M=N=1TEM*U0.FJZ')]ANTEV^:0@!MYGV/(A,T!0EUDD1 MY%D*NPP: *'Q>6=QH"VKI%.?$=D(WEC:6-6^SWF"\:R0LZ@]5$L9/0,.M '6 MV^FZC.T]OKUS;RI<1I%:RV,7*&49!0*[.S@&C? M7/B'QI?:A8V++:SV,%GY&-4O-/:"6YLX[C[0UM!8SB[3SI'B*7,K18@,8B1R M\C &K:)J&MZ];V%_?W"QS^'8;FX6PN)(8'N#.D;RP.%CEC5_O(Z>7*!A=RJS MHP!D>'+O5O$7A?2;MWN[X1&^6[A@OGM+^Y2VN9+:*=)XW@:5HMBF2)IHEE:1 M3([L%5P![:S=>(IM/T;2)Y+RUDTV6Y#W&HW>E74\L5R;9Q)<6UI/<-/:,I6: M$-$ID:.<"Q:ZDLTW MQ7,):%)I9 S!Y5$9 /4?"=[;W^D6<]I/)>PFWC5;B;(FE**$9Y@P#"8LK>:& M (DW C(H Z"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * M "@ H * "@ H * "@ H * "@#C?$7AVXU>X6:%HU58PA#E@7X_Y&IHOA>ZTV\CN96B*)NR%+D_,C*,9 M0#J1WZ5G4K1G%Q2=W;MW]2X4W%INQWE<)TG'MX$TA]7_ .$B*7']I@!?.%[> M@>6&W>3Y0N!#Y&[YC!Y?DELDH230!>UGPIINNS1W5Y&XN;=62.>">XM9U1^6 MC\ZUEAE:)CR8F$=*N[:VLGMPD&GR)+:K$\D!AD0, R/"\;@D, MP?YL2!F$@8,<@&;=?#O0+W[2);4E+^1)IT6>X2-IHRC),D23+'#,#&F985CD M8##,PR" 6K;P3I-GJG]N01S)?")8-XN[OR_)52JP_9S/]G\I0D9+M 6SSG- $.G_#G0-(EGGL+ M7[))=APY@GN(MGF<.UN$F46KL.#);"%\<;L4 4;7X5^'K*$VD,5VML[,SVYU M+4VMW9SES) UX8I-Y.7WHVX\MF@#NK&QM],@2TLXX[>WA4+'%$JHB*.@55 5 M1[ 4 &M.\.>=_9L( M@-W*T\QWR.9)6QND8R.YW-@9P1G ]!0!5O\ P=I>HS274D,JR6TM[?2VBE"&3;9RW+VJA64 M%0(@%QP!0!HZEX+TG5;X:K/$Z7JH(C/;W%S:R/&#D1RFVFB\Y/\ 8EWKCC&. M* *1^'/AW[=<&2ZNIP\F,;]L\TJ(VT!245245$/RH@ !1TWP)H^DZI-K MMK'.FH7>?/E:\O9!+QM DBDN'A94'$2F,K$ HB"!5P 2>(?!.E>*9H+C4TGD MDLV#P&.\O+<12*25E1;:XB42C) EQY@'RAL "@"L/A_I&7,@O9FEADMRT^IZ ME.RQ2[?,6-IKMVB+[0&>(HY7*[MK," %[X!T:\-C)-#.[Z*NVQ*WEXCQ !1P MRW*;V955"\S,64;78KD4 <+X*\%?:[K4KKQ!IES:/1O;S1NRM ) MK6TO9;>6:$IN/VB%U0E?+D?!P >@:YX#T/Q)=QZAJ5JLUU"GEB0/+&6BSGRI M?*=!-%DG]U,)(^3\O)R )<^!-(NM1;662X2^> VWFQ7U]#M@*;/*CCAN4CC0 M?? C1=LP$ZXF DH S[7X8Z!8V\5G:Q7,$5L\KP^7J.HH\1GVF81RK=B5$E*A MGC5PC/N\\$Z3>I;1M%)"-/22.V-K6A<.S;BN3DD MD@'0:?I]OI5O'9V<:P6\"A(XT&%51T _F2R(/[9L/ M^?F#_O['_P#%5?U>M_S[G_X!+_(?*^S^X/[9L/\ GY@_[^Q__%4?5ZW_ #[G M_P" 2_R#E?9_<2PZG:7#B.&>&1VSA5D1F.!DX ))P 2?89J94:D%S3A-)=7% MI?>T%FMTR[6!(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % ! M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Y+X\_X_P"/_K@O_HR6 MOKV;!0!TGA'_D*P?]M/_14E>;CO]WG_ -N_ M^EQ,Y_"_ZZGME?$G&<;K?C:ST'5[#1;@-YFINR"4?ZN%BKFW64XP&NGCDC@7 M(+-')_=- %;XA^+;OP1I;:O;6<>H10O&DR-=&V=?.EC@B,?^C3K)F20!PS1[ M5Y&[D Q]>\;ZUH>H:9I3:;9R3:SYB1M_:&P)=0LI+PHGV8P/<+/:W"VLGG;D4%4>& X)+E# ML5P"U;_$>[M9-*.M6$5I:^(#%':SVUX;H)-/&)(8KA)+2T=&D!VAH_.0-P2! MS0!UWBWQ.GA6UBG,9N)KNZM[*WBW>6K3W,@CC$DI5A%&#EGDV-M4<*Q(! +' MAS6IM9CG%U MK/9W+VTBQRF>%F1(W+03&*%I$ D$;%H8V29)8F7,9) .,@\: MZ_>:S?:%;Z78^=IL<,Q>35)D26.XW^44VZ5(0_[LAU?:%;@.X^:@#>\,^-$U MR]N=&N[>33M5L KRVTC*X>&3[D\$J?+-"Q^4MA&1OE=%.,@%7QKXNU#PM/81 M6EE!>QZI=Q6*/+>/;&.XE$C)O1;*YS%LB),BL6#<>5C#$ T(->U*RE8^(+:R MTZR2"28WD6H/-#&8WB7RYS/960BWB0NC;G!$;@[<#(!>@\8:',ILE9PC;ARNUCN'(S0 MWX@TS3[5=0NKNUM[.3&RXEG MB2%MWW=LK,$.[MAN>U !>^(-,TR".\O+NUMK:A23>R;]$9?_ FWA_\ Z">G_P#@ M9;__ !RNCZCBO^@>M_X*G_\ (CY)?RO[F'_";>'_ /H)Z?\ ^!EO_P#'*/J. M*_Z!ZW_@J?\ \B')+^5_'_P#H)Z?_ .!EO_\ '*/J.*_Z!ZW_ (*G_P#(AR2_E?W, M/^$V\/\ _03T_P#\#+?_ ..4?4<5_P! ];_P5/\ ^1#DE_*_N8?\)MX?_P"@ MGI__ (&6_P#\G_\ @9;_ /QRCZCBO^@>M_X*G_\ M(AR2_E?W,/\ A-O#_P#T$]/_ / RW_\ CE'U'%?] ];_ ,%3_P#D0Y)?RO[F M'_";>'_^@GI__@9;_P#QRCZCBO\ H'K?^"I__(AR2_E?W,V-.U6SU>,S:?/# M=QJVPO!*DJA@ 2I9&8!@&!P3G!!Z$5RU*52@^6M"4)-72G%Q=MKV:6FCU\B6 MG'1JWKH7ZQ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!X-\4_BCJG@?4XK'3X MK62.6U68F=)68,TLJ$ I-&-N(QP5)R3SC 'V&5971S"C*M6E44HU'%[_#_(/^&@_$'_ M #[Z?_WZN/\ Y*H_U>PO\];_ ,"A_P#*P]A'N_P_R#_AH/Q!_P ^^G_]^KC_ M .2J/]7L+_/6_P# H?\ RL/81[O\/\@_X:#\0?\ /OI__?JX_P#DJC_5["_S MUO\ P*'_ ,K#V$>[_#_(/^&@_$'_ #[Z?_WZN/\ Y*H_U>PO\];_ ,"A_P#* MP]A'N_P_R#_AH/Q!_P ^^G_]^KC_ .2J/]7L+_/6_P# H?\ RL/81[O\/\@_ MX:#\0?\ /OI__?JX_P#DJC_5["_SUO\ P*'_ ,K#V$>[_#_(/^&@_$'_ #[Z M?_WZN/\ Y*H_U>PO\];_ ,"A_P#*P]A'N_P_R#_AH/Q!_P ^^G_]^KC_ .2J M/]7L+_/6_P# H?\ RL/81[O\/\@_X:#\0?\ /OI__?JX_P#DJC_5["_SUO\ MP*'_ ,K#V$>[_#_(/^&@_$'_ #[Z?_WZN/\ Y*H_U>PO\];_ ,"A_P#*P]A' MN_P_R#_AH/Q!_P ^^G_]^KC_ .2J/]7L+_/6_P# H?\ RL/81[O\/\@_X:#\ M0?\ /OI__?JX_P#DJC_5["_SUO\ P*'_ ,K#V$>[_#_(/^&@_$'_ #[Z?_WZ MN/\ Y*H_U>PO\];_ ,"A_P#*P]A'N_P_R#_AH/Q!_P ^^G_]^KC_ .2J/]7L M+_/6_P# H?\ RL/81[O\/\@_X:#\0?\ /OI__?JX_P#DJC_5["_SUO\ P*'_ M ,K#V$>[_#_(Z_P%\9-8\4ZY;:5=PV:0W!EW-%',KC9#)(-I>X=1\R '*GC. M,'D>9C\FP^#PU3$4I57*'+92<6M9QB[V@GL^^YG.E&$7)7T]._H?2M?"'$% M!0 4 % 'DOCS_C_C_P"N"_\ HR6OK;CO]WG_V[_Z7$SG\+_KJ>P:AJ%MI5O)>WLB6]O I>220 MA411U))__63P,DU\2<9X!J.FW?C[P[>ZW#J6F6]EJ.+V)Y+:0RV8M<&U0WRZ MC%% \'EAILVV(9I+@,CY;< 8?C#XH:5XP^'1NGN;>._F:P6:U,BB83PWUJ\X M6+.\KMC>92%(\K![' !K_$SQ/H][K_AEX=5M[9%ENYFNH9[4F"*6VVQ3$S+- M J2,"J-+&R-R "1P =%XPT/2? 7AC7KJ>Y=[S6K2YCENKV6/S[NX:TFCMX%V MI#&2H+"*&&)0J;R%VJ< 'G6FW,.BMH?B;6;J37/#T-M;Q0SAHV31;_RD0M-% M:1QQRQY_W+L MS">*X) =K218Q';Q.ID?S/,#C:J@&+X4U'3+W4K&'QA9I;ZYHL(MM.A%I(!? M9='COK=3 BC&Q&BB(0VCM/*XBW?N@#HM)\;Z!:>-];GGU&QAA^QZ?"))+F%$ M:2(W!E1&9P':/< ZH258[2 >* -+P]#)XJ\<3^*[6.6/2K32UTR&:1&C%Y*U MPUP\D*N%9X(P=GF;0KN%,98 X *_QKU33(Y-"L+^ZCMB=;M)Y!]I-M+';+%= M1O/YLY:RU5;Z.:W$MQNU&34EMX;42 MEY9)IKBY>.-S,D0BW?-(R[(VW.5 .&\+:MI?@K6+6&ZD@CT?7HY9]"4S(XT\ M3.'FMR/NQQWA=)(W4E(I UIO<#>P!D73:'<:3XHT5D@DU>ZU34$L[543[5+. MVS[(;=2-[+'.=[-'E81O=RF6- &CK*06VKZAI7BS4+W3TU2TLXH##;VL\5[" MMHD5Q DLVFW4]JL7DRK$" K M"0#UWP7>_VAH=C65W*IR =/0 4 % !0 4 % !0 4 % !0 M4 % !0!\R_M&_=TOZWG\K6OON'-\1_W"_P#_P#D W/_ %_R?^D]M7YEQ#_O4/\ MKS'_ -+F>=7^)>GZL]XKX\Y0H * "@ H * "@ H * "@ H * "@ H * "@ H M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /CW]H M3_D/6W_7A'_Z47-?IO#W^ZS_ .OTO_2('H4/A?K^B/!Z^P.L* "@ H * "@ MH * "@ H * "@ H * "@ H * "@#TSX._P#(VV'UN/\ TEGKP6% !0 4 % '.ZOX9MM9F$\[2JRH$ 0J!@%F_B1CG+'O MZ<5Z-#&5,-%PIJ+3=]4[WLET:[&D9N*LC+_X0*P_YZ3_ /?4?_QJNK^TZW\L M/NE_\D5[1^7]?,/^$"L/^>D__?4?_P :H_M.M_+#[I?_ "0>T?E_7S+VG>$K M32[A+J%YB\>[ 9D*_,I4Y 13T8XY'-85<=4KP=*:@D[;)WT:?63[=A.;DK.Q MU%>69!0 4 % !0 4 % !0 4 % !0 4 (V2#MP#C@D9 /;(R,CVR,^HH X?P5 MX7O_ P;W[=>0WPU"[EO?W5HUL8Y9B/,4$W=R&CPJB-2 ZX.Z23/ !W- !0 M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'S+^T;]W2_K>?RM:^^X*^/.4* "@ H * M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * " M@ H * "@ H * "@ H * "@#X]_:$_P"0];?]>$?_ *47-?IO#W^ZS_Z_2_\ M2('H4/A?K^B/!Z^P.L* "@ H * "@ H * "@ H * "@ H * "@ H * "@#TS MX._\C;8?6X_])9Z\'./]QK?]N?\ IR!A5^!_+\T?=U?D!Y84 % !0 4 % !0 M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % M !0 4 % !0 4 % !0 4 % 'S+^T;]W2_K>?RM:^^X@_\ 02L/_ NW_P#CE'U+%?\ /BM_X+G_ /(AR2_E?W,/^$ST'_H)6'_@ M7;__ !RCZEBO^?%;_P %S_\ D0Y)?RO[F'_"9Z#_ -!*P_\ NW_ /CE'U+% M?\^*W_@N?_R(@_]!*P_P# NW_^.4?4L5_SXK?^"Y__ "(@_\ 02L/_ NW_P#CE'U+%?\ /BM_X+G_ /(AR2_E?W,/ M^$ST'_H)6'_@7;__ !RCZEBO^?%;_P %S_\ D0Y)?RO[F'_"9Z#_ -!*P_\ M NW_ /CE'U+%?\^*W_@N?_R(@_]!*P_P# NW_^.4?4L5_SXK?^"Y__ "(_M"?\AZV_Z\(__2BYK]-X>_W6?_7Z7_I$#T*'POU_1'@]?8'6% !0 4 % M !0 4 % !0 4 % !0 4 % !0 4 % !0!Z9\'?^1ML/K#G'^XUO^W/ M_3D#"K\#^7YH^[J_(#RPH * "@ H ^4OB9\3/$/AWQ#=:=IUT(;:$0;$\BW? M&^WB=OF>)F.68GDG&<#C K]%RS+,)B<)3KUZ?-.7/=\\UM.26BDELET.^G3C M**;6NO5]S@_^%S>+?^?T?^ UK_\ &*]C^QL#_P ^O_*E3_Y,U]E#M^+_ ,P_ MX7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X# M6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _ M\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#D MP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_ MX7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X# M6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _ M\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#D MP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_ MX7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X# M6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _ M\^O_ "I4_P#DP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#D MP]E#M^+_ ,P_X7-XM_Y_1_X#6O\ \8H_L; _\^O_ "I4_P#DP]E#M^+_ ,SZ MM^&>M7?B'P]:ZCJ+^=^U$SLN)47Y455&%4#@#.,GG)K\ZS.A3PN+J4* M"Y81Y+*[=KPBWJVWNWU."HE&32VT_([RO',@H * "@ H * "@ H * "@ H * M "@ H * "@ H * "@#YE_:-^[I?UO/Y6M??<.;XC_N%_[D.W#_:^7ZGR_7WY MW!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'V%^SW_R ;G_ *_Y/_2>VK\R MXA_WJ'_7F/\ Z7,\ZO\ $O3]6>\5\>

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end XML 12 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover - shares
 3 Months Ended
Mar. 31, 2024
Apr. 30, 2024
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2024  
Document Transition Report false  
Entity File Number 000-19319  
Entity Registrant Name VERTEX PHARMACEUTICALS INC / MA  
Entity Incorporation, State or Country Code MA  
Entity Tax Identification Number 04-3039129  
Entity Address, Address Line One 50 Northern Avenue  
Entity Address, City or Town Boston  
Entity Address, State or Province MA  
Entity Address, Postal Zip Code 02210  
City Area Code 617  
Local Phone Number 341-6100  
Title of 12(b) Security Common Stock, $0.01 Par Value Per Share  
Trading Symbol VRTX  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   258,053,387
Entity Central Index Key 0000875320  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2024  
Document Fiscal Period Focus Q1  
Amendment Flag false  
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Income - USD ($)
shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Income Statement [Abstract]    
Product revenues, net $ 2,690.6 $ 2,374.8
Costs and expenses:    
Cost of sales 342.6 266.9
Research and development expenses 789.1 742.6
Acquired in-process research and development expenses 76.8 347.1
Selling, general and administrative expenses 342.7 241.1
Change in fair value of contingent consideration (0.1) (1.9)
Total costs and expenses 1,551.1 1,595.8
Income from operations 1,139.5 779.0
Interest income 181.2 122.6
Interest expense (10.4) (11.4)
Other (expense) income, net (31.2) 1.3
Income before provision for income taxes 1,279.1 891.5
Provision for income taxes 179.5 191.7
Net income $ 1,099.6 $ 699.8
Net income per common share:    
Basic (in dollars per share) $ 4.26 $ 2.72
Diluted (in dollars per share) $ 4.21 $ 2.69
Shares used in per share calculations:    
Basic (in shares) 258.2 257.4
Diluted (in shares) 261.1 260.3
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Comprehensive Income - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Net income $ 1,099.6 $ 699.8
Other comprehensive income (loss):    
Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $5.4 and $(0.8), respectively (19.7) 2.9
Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(12.3) and $7.4, respectively 44.5 (26.8)
Foreign currency translation adjustment 6.8 10.0
Total other comprehensive income (loss) 31.6 (13.9)
Comprehensive income $ 1,131.2 $ 685.9
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Statement of Comprehensive Income [Abstract]    
Unrealized holding (losses) gains on marketable securities, tax $ 5.4 $ (0.8)
Unrealized gains (losses) on foreign currency forward contracts, tax $ (12.3) $ 7.4
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 9,158.0 $ 10,369.1
Marketable securities 1,013.3 849.2
Accounts receivable, net 1,793.2 1,563.4
Inventories 813.1 738.8
Prepaid expenses and other current assets 511.1 623.7
Total current assets 13,288.7 14,144.2
Property and equipment, net 1,172.8 1,159.3
Goodwill 1,088.0 1,088.0
Other intangible assets, net 834.9 839.9
Deferred tax assets 1,963.0 1,812.1
Operating lease assets 312.9 293.6
Long-term marketable securities 4,381.4 2,497.8
Other assets 875.7 895.3
Total assets 23,917.4 22,730.2
Current liabilities:    
Accounts payable 351.4 364.9
Accrued expenses 2,795.9 2,655.3
Other current liabilities 648.6 527.2
Total current liabilities 3,795.9 3,547.4
Long-term finance lease liabilities 361.5 376.1
Long-term operating lease liabilities 359.8 348.6
Other long-term liabilities 853.6 877.7
Total liabilities 5,370.8 5,149.8
Commitments and contingencies 0.0 0.0
Shareholders’ equity:    
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding 0.0 0.0
Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively 2.6 2.6
Additional paid-in capital 7,284.7 7,449.7
Accumulated other comprehensive income (loss) 17.3 (14.3)
Retained earnings 11,242.0 10,142.4
Total shareholders’ equity 18,546.6 17,580.4
Total liabilities and shareholders’ equity $ 23,917.4 $ 22,730.2
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares
Mar. 31, 2024
Dec. 31, 2023
Statement of Financial Position [Abstract]    
Preferred stock, par value (in dollars per share) $ 0.01 $ 0.01
Preferred stock, shares authorized (in shares) 1,000,000 1,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 0.01 $ 0.01
Common stock, shares authorized (in shares) 500,000,000 500,000,000
Common stock, shares issued (in shares) 258,296,249 257,695,221
Common stock, shares outstanding (in shares) 258,296,249 257,695,221
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Shareholders' Equity - USD ($)
$ in Millions
Total
Common Stock
Additional Paid-in Capital
Accumulated Other Comprehensive Income (Loss)
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2022   257,000,000.0      
Beginning balance at Dec. 31, 2022 $ 13,912.7 $ 2.6 $ 7,386.5 $ 0.8 $ 6,522.8
Increase (Decrease) in Stockholders' Equity          
Other comprehensive (loss) income, net of tax (13.9)     (13.9)  
Net income $ 699.8       699.8
Repurchase of common stock (in shares) (459,017) (500,000)      
Repurchases of common stock $ (135.6) $ (0.0) (135.6)    
Common stock withheld for employee tax obligations (in shares)   (600,000)      
Common stock withheld for employee tax obligations (166.6) $ (0.0) (166.6)    
Issuance of common stock under benefit plans (in shares)   1,600,000      
Issuance of common stock under benefit plans 13.1 $ 0.0 13.1    
Stock-based compensation expense 122.8   122.8    
Ending balance (in shares) at Mar. 31, 2023   257,500,000      
Ending balance at Mar. 31, 2023 $ 14,432.3 $ 2.6 7,220.2 (13.1) 7,222.6
Beginning balance (in shares) at Dec. 31, 2023 257,695,221 257,700,000      
Beginning balance at Dec. 31, 2023 $ 17,580.4 $ 2.6 7,449.7 (14.3) 10,142.4
Increase (Decrease) in Stockholders' Equity          
Other comprehensive (loss) income, net of tax 31.6     31.6  
Net income $ 1,099.6       1,099.6
Repurchase of common stock (in shares) (335,773) (300,000)      
Repurchases of common stock $ (140.4) $ (0.0) (140.4)    
Common stock withheld for employee tax obligations (in shares)   (600,000)      
Common stock withheld for employee tax obligations (233.5) $ (0.0) (233.5)    
Issuance of common stock under benefit plans (in shares)   1,500,000      
Issuance of common stock under benefit plans 15.9 $ 0.0 15.9    
Stock-based compensation expense $ 193.0   193.0    
Ending balance (in shares) at Mar. 31, 2024 258,296,249 258,300,000      
Ending balance at Mar. 31, 2024 $ 18,546.6 $ 2.6 $ 7,284.7 $ 17.3 $ 11,242.0
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Condensed Consolidated Statements of Cash Flows - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Cash flows from operating activities:    
Net income $ 1,099.6 $ 699.8
Adjustments to reconcile net income to net cash provided by operating activities:    
Stock-based compensation expense 191.9 122.4
Depreciation and amortization expense 53.5 38.8
Deferred income taxes (158.3) (113.4)
Losses (gains) on equity securities 27.0 (6.4)
Decrease in fair value of contingent consideration (0.1) (1.9)
Other non-cash items, net (36.3) 21.7
Changes in operating assets and liabilities:    
Accounts receivable, net (251.6) (90.5)
Inventories (80.1) (82.6)
Prepaid expenses and other assets 99.2 46.2
Accounts payable 0.1 35.7
Accrued expenses 194.1 140.7
Other liabilities 167.6 89.4
Net cash provided by operating activities 1,306.6 899.9
Cash flows from investing activities:    
Purchases of available-for-sale debt securities (2,598.5) (1,816.6)
Sales and maturities of available-for-sale debt securities 710.5 50.0
Purchases of property and equipment (68.4) (42.1)
Net payments related to finite-lived intangible assets (180.0) 0.0
Investment in equity securities 0.0 (24.9)
Net cash used in investing activities (2,136.4) (1,833.6)
Cash flows from financing activities:    
Issuances of common stock under benefit plans 16.9 14.2
Repurchases of common stock (131.2) (132.8)
Payments in connection with common stock withheld for employee tax obligations (233.5) (166.6)
Payments on finance leases (13.2) (10.6)
Other financing activities 3.5 1.1
Net cash used in financing activities (357.5) (294.7)
Effect of changes in exchange rates on cash (15.6) 12.0
Net decrease in cash, cash equivalents and restricted cash (1,202.9) (1,216.4)
Cash, cash equivalents and restricted cash—beginning of period 10,372.3 10,512.0
Cash, cash equivalents and restricted cash—end of period 9,169.4 9,295.6
Supplemental disclosure of cash flow information:    
Cash paid for income taxes 34.8 120.3
Cash paid for interest $ 10.0 $ 11.1
XML 20 R9.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Accounting Policies
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation and Accounting Policies Basis of Presentation and Accounting Policies
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2024 and 2023.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023, which are contained in our 2023 Annual Report on Form 10-K.
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted Accounting Standards
As noted in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K, we did not adopt any accounting standards that had a significant impact on our consolidated financial statements in the three years ended December 31, 2023.
Recently Issued Accounting Standards
Segment Reporting
In 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose significant segment expenses and other segment items. ASU 2023-07 also requires public entities to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for the interim periods starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-07 will have on our segment disclosures.
Income Tax Disclosures
In 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 becomes effective for the annual period starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-09 will have on our income tax disclosures.
Summary of Significant Accounting Policies
Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K.
XML 21 R10.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Revenue Recognition Revenue Recognition
Disaggregation of Revenue
Revenues by Product
“Product revenues, net” consisted of the following:
Three Months Ended March 31,
20242023
(in millions)
TRIKAFTA/KAFTRIO$2,483.6 $2,096.7 
Other CF products207.0 278.1 
Total product revenues, net$2,690.6 $2,374.8 
Product Revenues by Geographic Location
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20242023
(in millions)
United States$1,519.9 $1,403.8 
Outside of the United States
Europe967.4 807.2 
Other
203.3 163.8 
Total product revenues outside of the United States1,170.7 971.0 
Total product revenues, net
$2,690.6 $2,374.8 
Contract Liabilities
We had contract liabilities of $275.8 million and $170.3 million as of March 31, 2024 and December 31, 2023, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive for our cystic fibrosis (“CF”) products. Upon exceeding the annual reimbursement amount provided by the customer’s contract with us, our CF products are provided free of charge, which is a material right. These contracts include upfront payments and fees. If we estimate that we will exceed the annual reimbursement amount under a contract, we defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” Once the reimbursement limit has been reached, we recognize the deferred amount as revenue when we ship the free products. Our CF product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with CF annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 22 R11.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration, License and Other Arrangements
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Collaboration, License and Other Arrangements Collaboration, License and Other Arrangements
We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $76.8 million and $347.1 million for the three months ended March 31, 2024 and 2023, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including
collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.
Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2024 and 2023, or were new or materially revised during the three months ended March 31, 2024, are described below. Additional agreements were described in Note B, “Collaboration, License and Other Arrangements,” of our 2023 Annual Report on Form 10-K.
In-license Agreements
CRISPR Therapeutics AG
CRISPR-Cas9 Gene-editing Therapies Agreements
In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including CF, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales.
In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR were co-developing and preparing to co-commercialize CASGEVY for the treatment of hemoglobinopathies, including treatments for severe sickle cell disease (“SCD”) and transfusion-dependent beta thalassemia.
Pursuant to the CRISPR JDCA, we lead global development, manufacturing and commercialization of CASGEVY, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.
CASGEVY was approved by the U.S. Food and Drug Administration in December 2023 for the treatment of SCD. In connection with this approval, we made a $200.0 million milestone payment to CRISPR in January 2024, which we accrued to “Other current liabilities” and recorded within “Other intangible assets, net” on our consolidated balance sheet as of December 31, 2023. Subsequent to receiving marketing approval for CASGEVY, we continue to lead the research and development activities under the CRISPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40% share of these research and development activities, subject to certain adjustments, and we record this reimbursement from CRISPR as a credit within “Research and development expenses.” We also share with CRISPR 40% of the net commercial profits or losses incurred with respect to CASGEVY, subject to certain adjustments, which is recorded to “Cost of sales.” The net commercial profits or losses equal the sum of the product revenues, cost of sales and selling, general and administrative expenses that we have recognized related to the CRISPR JDCA.
In the three months ended March 31, 2024, we recognized net reimbursements from CRISPR pursuant to the CRISPR JDCA as credits to “Cost of sales” of $15.8 million, related to CRISPR’s share of the CRISPR JDCA’s net commercial loss, and to “Research and development expenses” of $11.7 million, related to CRISPR’s share of the CRISPR JDCA’s research and development activities.
Prior to receiving marketing approvals for CASGEVY in various markets beginning in December 2023, we accounted for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to CASGEVY allocated 60% to us and 40% to CRISPR, subject to certain adjustments. In the three months ended March 31, 2023, we recognized net reimbursements from CRISPR as credits to “Research and development expenses” of $17.9 million and to “Selling, general and administrative expenses” of $5.8 million, related to CRISPR’s share of the CRISPR JDCA’s operating expenses.
CRISPR-Cas9 Gene-editing Hypoimmune Cell Therapies Agreement
In March 2023, we entered into a non-exclusive license agreement (the “CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes (“T1D”). Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR, and we determined that substantially all the fair value of our upfront payment was attributable to in-process research and development, for which there is no alternative future use, and that no substantive processes were acquired that would
constitute a business. CRISPR is eligible to receive up to an additional $160.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales.
Entrada Therapeutics, Inc.
In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. We determined that substantially all the fair value of our upfront payment was attributable to in-process research and development, for which there is no alternative future use, and that no substantive processes were acquired that would constitute a business. We recorded the upfront payment to “Acquired in-process research and development expenses” in the three months ended March 31, 2023. We recorded the investment in Entrada’s common stock at fair value on our condensed consolidated balance sheet within “Marketable securities.” In the first quarter of 2024, Entrada earned a $75.0 million milestone, which we recorded to “Acquired in-process research and development expenses” in the three months ended March 31, 2024 and accrued to “Other current liabilities” as of March 31, 2024. Entrada is eligible to receive up to an additional $335.0 million in development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales.
Cystic Fibrosis Foundation
In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record expenses related to these royalty obligations to “Cost of sales.”
XML 23 R12.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Earnings Per Share Earnings Per Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20242023
(in millions, except per share amounts)
Net income$1,099.6 $699.8 
Basic weighted-average common shares outstanding258.2 257.4 
Effect of potentially dilutive securities:
Restricted stock units (including performance-based restricted stock units (“PSUs”))
1.7 1.6 
Stock options1.2 1.3 
Employee stock purchase program
0.0 0.0 
Diluted weighted-average common shares outstanding261.1 260.3 
Basic net income per common share$4.26 $2.72 
Diluted net income per common share$4.21 $2.69 
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20242023
(in millions)
Unvested restricted stock units (including PSUs)— 0.6 
XML 24 R13.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Fair Value Measurements Fair Value Measurements
The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used to determine the fair value of our financial assets and liabilities:
Level 1:
Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Level 2:
Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.
Level 3:
Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy:
As of March 31, 2024As of December 31, 2023
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents$5,865.3 $4,921.3 $944.0 $— $7,033.9 $5,397.3 $1,636.6 $— 
Marketable securities:
Corporate equity securities43.4 43.4 — — 46.0 46.0 — — 
U.S. Treasury securities1,389.4 1,389.4 — — 546.5 546.5 — — 
U.S. government agency securities
356.7 — 356.7 — 425.2 — 425.2 — 
Asset-backed securities792.6 — 792.6 — 306.0 — 306.0 — 
Certificates of deposit42.6 — 42.6 — 33.7 — 33.7 — 
Corporate debt securities2,632.2 — 2,632.2 — 1,802.8 — 1,802.8 — 
Commercial paper137.8 — 137.8 — 186.8 — 186.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts26.3 — 26.3 — 1.8 — 1.8 — 
Total financial assets
$11,286.3 $6,354.1 $4,932.2 $— $10,382.7 $5,989.8 $4,392.9 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(1.4)$— $(1.4)$— $(33.7)$— $(33.7)$— 
Other long-term liabilities:
Contingent consideration(77.3)— — (77.3)(77.4)— — (77.4)
Total financial liabilities
$(78.7)$— $(1.4)$(77.3)$(111.1)$— $(33.7)$(77.4)
Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment. Our cash equivalents primarily include money market funds and time deposits.
Fair Value of Corporate Equity Securities
We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based
on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.
As of March 31, 2024, one of our investments in publicly traded corporate equity securities was subject to a contractual sales restriction expiring partially in 2024 and partially in 2025 with a total fair value of $23.0 million. We purchased this investment directly from the publicly traded company in the first quarter of 2023, and do not anticipate any circumstances that would cause this restriction to lapse prior to the periods listed above.
Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.
Fair Value of Contingent Consideration
In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy (“DMD”) and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to gene therapies and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.1% and 5.3% as of March 31, 2024, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period.
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2024
(in millions)
Balance at December 31, 2023$77.4 
Decrease in fair value of contingent payments
(0.1)
Balance at March 31, 2024$77.3 
XML 25 R14.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Marketable Securities and Equity Investments Marketable Securities and Equity Investments
A summary of our cash equivalents and marketable debt and equity securities, which are recorded at fair value, is shown below:
As of March 31, 2024As of December 31, 2023
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents
$5,865.3 $— $— $5,865.3 $7,033.9 $— $— $7,033.9 
Marketable securities:
U.S. Treasury securities1,395.1 1.1 (6.8)1,389.4 544.5 3.0 (1.0)546.5 
U.S. government agency securities
357.7 0.1 (1.1)356.7 424.8 0.9 (0.5)425.2 
Asset-backed securities793.5 0.7 (1.6)792.6 304.9 1.4 (0.3)306.0 
Certificates of deposit42.6 0.0 (0.0)42.6 33.7 0.0 (0.0)33.7 
Corporate debt securities
2,637.4 4.3 (9.5)2,632.2 1,794.0 10.5 (1.7)1,802.8 
Commercial paper
137.9 0.0 (0.1)137.8 186.8 0.1 (0.1)186.8 
Total marketable available-for-sale debt securities
5,364.2 6.2 (19.1)5,351.3 3,288.7 15.9 (3.6)3,301.0 
Corporate equity securities
72.1 — (28.7)43.4 72.1 — (26.1)46.0 
Total marketable securities
5,436.3 6.2 (47.8)5,394.7 3,360.8 15.9 (29.7)3,347.0 
Total cash equivalents and marketable securities$11,301.6 $6.2 $(47.8)$11,260.0 $10,394.7 $15.9 $(29.7)$10,380.9 
Amounts in the table above at fair value were classified on our condensed consolidated balance sheets as follows:
As of March 31, 2024As of December 31, 2023
(in millions)
Cash and cash equivalents$5,865.3 $7,033.9 
Marketable securities
1,013.3 849.2 
Long-term marketable securities4,381.4 2,497.8 
Total
$11,260.0 $10,380.9 
Marketable available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2024As of December 31, 2023
(in millions)
Matures within one year$969.9 $803.2 
Matures after one year through five years
4,273.3 2,495.6 
Matures after five years108.1 2.2 
Total
$5,351.3 $3,301.0 
We did not record any allowances for credit losses to adjust the fair value of our marketable available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2024 and 2023. Additionally, we did not record any realized gains or losses that were material to our condensed consolidated statements of income during the three months ended March 31, 2024 and 2023. As of March 31, 2024, we held marketable available-for-sale debt securities with a total fair value of $4.0 billion that were in unrealized loss positions totaling $19.1 million. Included in this amount were marketable available-for sale debt securities with a total fair value of $53.8 million and total unrealized loss of $0.4 million that had been in unrealized loss positions for greater than twelve months. We intend to hold these investments until maturity and do not expect to incur realized losses on these investments when they mature.
We record changes in the fair value of our investments in corporate equity securities to “Other (expense) income, net” in our condensed consolidated statements of income. During the three months ended March 31, 2024 and 2023, our net unrealized (losses) gains on corporate equity securities with readily determinable fair values held at the conclusion of each period were as follows:
Three Months Ended March 31,
20242023
(in millions)
Net unrealized (losses) gains
$(2.7)$6.4 
        
As of March 31, 2024, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $74.3 million. During the three months ended March 31, 2024, we reduced the carrying value of one of our equity investments without a readily determinable fair value by $24.3 million based on an observable change in price.
XML 26 R15.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive Income (Loss)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Accumulated Other Comprehensive Income (Loss) Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2023$1.1 $9.6 $(25.0)$(14.3)
Other comprehensive income (loss) before reclassifications6.8 (20.5)47.2 33.5 
Amounts reclassified from accumulated other comprehensive income (loss)— 0.8 (2.7)(1.9)
Net current period other comprehensive income (loss)6.8 (19.7)44.5 31.6 
Balance at March 31, 2024$7.9 $(10.1)$19.5 $17.3 
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications10.0 2.9 (9.6)3.3 
Amounts reclassified from accumulated other comprehensive income (loss)— — (17.2)(17.2)
Net current period other comprehensive income (loss)10.0 2.9 (26.8)(13.9)
Balance at March 31, 2023$(15.0)$2.8 $(0.9)$(13.1)
XML 27 R16.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Hedging Hedging
Foreign currency forward contracts - Designated as hedging instruments
We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from one to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes.
We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2024, all hedges were determined to be highly effective.
We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2024 and December 31, 2023, credit risk did not change the fair value of our foreign currency forward contracts.
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2024As of December 31, 2023
Foreign Currency(in millions)
Euro$1,305.5 $1,720.6 
Canadian dollar
190.0 229.5 
British pound sterling
186.4 225.0 
Australian dollar
122.1 153.3 
Swiss Franc50.5 63.9 
Total foreign currency forward contracts
$1,854.5 $2,392.3 
Foreign currency forward contracts - Not designated as hedging instruments
We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other (expense) income, net” in our condensed consolidated statements of income each period. As of March 31, 2024, we did not have any outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP was not applied.
During the three months ended March 31, 2024 and 2023, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended March 31,
20242023
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$3.4 $22.0 
Not designated as hedging instruments
Other (expense) income, net$(2.4)$3.6 
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,690.6 $2,374.8 
Other (expense) income, net$(31.2)$1.3 
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2024
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$26.3 Other current liabilities$(1.4)
As of December 31, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$1.8 Other current liabilities$(33.7)
As of March 31, 2024, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.
We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of March 31, 2024
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$26.3 $— $26.3 $(1.4)$24.9 
Total liabilities(1.4)— (1.4)1.4 — 
As of December 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$1.8 $— $1.8 $(1.8)$— 
Total liabilities(33.7)— (33.7)1.8 (31.9)
XML 28 R17.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Inventories Inventories
Inventories consisted of the following:
As of March 31, 2024As of December 31, 2023
(in millions)
Raw materials$95.7 $78.7 
Work-in-process601.8 525.1 
Finished goods
115.6 135.0 
Total
$813.1 $738.8 
During the first quarter of 2024, following positive results we announced related to our two Phase 3 trials for suzetrigine (formerly VX-548) for acute pain and vanzacaftor/tezacaftor/deutivacaftor for CF, we began capitalizing inventories produced in preparation for our planned product launches. We made these determinations based on our evaluation, among other factors, the safety and efficacy results, and expected likelihood of regulatory approval and commercial success. Prior to the first quarter of 2024, we expensed inventoriable and related costs associated with these product candidates as “Research and development expenses.” As of March 31, 2024, these inventories were not material to our condensed consolidated financial statements.
XML 29 R18.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation Expense and Share Repurchase Programs
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Stock-based Compensation Expense and Share Repurchase Programs Stock-based Compensation Expense and Share Repurchase Programs
Stock-based compensation expense
During the three months ended March 31, 2024 and 2023, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20242023
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$187.2 $115.9 
ESPP share issuances5.8 5.5 
Stock options— 1.4 
Stock-based compensation expense related to inventories
(1.1)(0.4)
Total stock-based compensation expense included in “Total costs and expenses”
$191.9 $122.4 
Stock-based compensation expense by line item:
Cost of sales$1.8 $1.9 
Research and development expenses119.4 76.3 
Selling, general and administrative expenses70.7 44.2 
Total stock-based compensation expense included in costs and expenses
191.9 122.4 
Income tax effect(79.0)(40.6)
Total stock-based compensation expense, net of tax
$112.9 $81.8 
Share repurchase program
In February 2023, our Board of Directors approved a share repurchase program, pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. The program does not have an expiration date and can be discontinued at any time. During the three months ended March 31, 2024 and 2023, we repurchased 335,773 and 459,017 shares of our common stock under the program, respectively, for aggregate repurchases of $140.4 million and $135.6 million, respectively. As of March 31, 2024, we had $2.4 billion remaining authorization under this program.
XML 30 R19.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Income Taxes Income Taxes
We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2024 and 2023, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20242023
(in millions, except percentages)
Income before provision for income taxes$1,279.1 $891.5 
Provision for income taxes$179.5 $191.7 
Effective tax rate14.0 %21.5 %
Our effective tax rate for the three months ended March 31, 2024 was lower than the U.S. statutory rate primarily due to changes in our unrecognized tax positions as well as excess tax benefits related to stock-based compensation.
Our effective tax rate for the three months ended March 31, 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax positions partially offset by excess tax benefits related to stock-based compensation.
We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2024 and December 31, 2023, we had $301.6 million and $288.7 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.
We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2015 in jurisdictions that have a material impact on our consolidated financial statements. In 2023, we came to settlement with the United Kingdom’s HM Revenue & Customs (“HMRC”) with respect to our tax positions for 2015 through 2020 and subsequently received Closure Notices for those periods during the three months ended March 31, 2024. Due to the nature of the adjustments, we will be asserting our rights under the U.S./U.K. Income Tax Convention pursuant to the mutual agreement procedures for the relief of double taxation for these matters.
In December 2022, European Union member states reached an agreement to implement the minimum tax component (“Pillar Two”) of the Organization for Economic Co-operation and Development’s (the “OECD’s”), global international tax reform initiative with effective dates of January 1, 2024 and 2025. In July 2023, the OECD published Administrative Guidance proposing certain safe harbors that effectively extend certain effective dates to January 1, 2027. The assessment of our potential 2024 exposure for the global per-country minimum tax of 15%, based on our forecasted 2024 results, is immaterial to our condensed consolidated financial statements as the effective tax rates in most of the jurisdictions in which we operate are above 15%.
XML 31 R20.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2024
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
2022 Credit Facility
In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.
Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period).
Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions.
The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of March 31, 2024, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.
Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements.
Guaranties and Indemnifications
As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.
We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.
Other Contingencies
We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2024 or December 31, 2023.
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Additional Cash Flow Information
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Additional Cash Flow Information Additional Cash Flow Information
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20242023
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,369.1 $9,158.0 $10,504.0 $9,289.9 
Prepaid expenses and other current assets
3.2 11.4 8.0 5.7 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,372.3 $9,169.4 $10,512.0 $9,295.6 
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Event
 3 Months Ended
Mar. 31, 2024
Subsequent Events [Abstract]  
Subsequent Event Subsequent Event
In April 2024, we entered into an agreement and plan of merger (the “Alpine Merger Agreement”) to acquire all of the issued and outstanding shares of common stock of Alpine Immune Sciences, Inc. (“Alpine”), a publicly traded biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, for approximately $4.9 billion in cash. Alpine’s lead molecule, povetacicept, is a highly potent and effective dual antagonist of BAFF (“B cell activating factor”) and APRIL (“a proliferation inducing ligand”). Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA nephropathy (“IgAN”), a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. The transaction is expected to close in the second quarter of 2024, subject to certain customary closing conditions, including the completion of a tender offer, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other conditions. We will account for the acquisition in the period that it closes. We intend to fund the acquisition with our cash and cash equivalents.
XML 34 R23.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Pay vs Performance Disclosure    
Net income $ 1,099.6 $ 699.8
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Insider Trading Arrangements
 3 Months Ended
Mar. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the first quarter of 2024, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”).
Name and TitleDate of Adoption of Trading PlanScheduled Expiration Date of Trading Plan (1)Maximum Shares Subject to Trading Plan
E. Morrow "Morrey" Atkinson, III
EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
2/22/20242/28/2025
25,290(2)
Jonathan Biller
EVP, Chief Legal Officer
2/13/20244/30/2025
9,825(2)
Carmen Bozic
EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer
2/27/20241/31/2025
13,680
Reshma Kewalramani
Chief Executive Officer and President
2/7/20245/20/2025
96,388(2)
Ourania "Nia" Tatsis
EVP, Chief Regulatory and Quality Officer
2/29/20245/1/2025
9,484(2)
Charles F. Wagner, Jr.
EVP, Chief Financial Officer
2/26/20241/31/2025
6,500
Bruce Sachs
Director
2/12/20242/28/2025
12,368
(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.
(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable.
Non-Rule 10b5-1 Arrangement Adopted false
Rule 10b5-1 Arrangement Terminated false
Non-Rule 10b5-1 Arrangement Terminated false
E. Morrow "Morrey" Atkinson III [Member]  
Trading Arrangements, by Individual  
Name E. Morrow "Morrey" Atkinson, III
Title EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/22/2024
Arrangement Duration 372 days
Aggregate Available 25,290
Jonathan Biller [Member]  
Trading Arrangements, by Individual  
Name Jonathan Biller
Title EVP, Chief Legal Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/13/2024
Arrangement Duration 442 days
Aggregate Available 9,825
Carmen Bozic [Member]  
Trading Arrangements, by Individual  
Name Carmen Bozic
Title EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/27/2024
Arrangement Duration 339 days
Aggregate Available 13,680
Reshma Kewalramani [Member]  
Trading Arrangements, by Individual  
Name Reshma Kewalramani
Title Chief Executive Officer and President
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/7/2024
Arrangement Duration 468 days
Aggregate Available 96,388
Ourania "Nia" Tatsis [Member]  
Trading Arrangements, by Individual  
Name Ourania "Nia" Tatsis
Title EVP, Chief Regulatory and Quality Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/29/2024
Arrangement Duration 427 days
Aggregate Available 9,484
Charles F. Wagner, Jr. [Member]  
Trading Arrangements, by Individual  
Name Charles F. Wagner, Jr.
Title EVP, Chief Financial Officer
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/26/2024
Arrangement Duration 340 days
Aggregate Available 6,500
Bruce Sachs [Member]  
Trading Arrangements, by Individual  
Name Bruce Sachs
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 2/12/2024
Arrangement Duration 382 days
Aggregate Available 12,368
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2024
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation
The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”).
The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.
Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2024 and 2023.
The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023, which are contained in our 2023 Annual Report on Form 10-K.
Use of Estimates
Use of Estimates
The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.
Recently Adopted and Recently Issued Accounting Standards
Recently Adopted Accounting Standards
As noted in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K, we did not adopt any accounting standards that had a significant impact on our consolidated financial statements in the three years ended December 31, 2023.
Recently Issued Accounting Standards
Segment Reporting
In 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”), which requires public entities to disclose significant segment expenses and other segment items. ASU 2023-07 also requires public entities to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for the interim periods starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-07 will have on our segment disclosures.
Income Tax Disclosures
In 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 becomes effective for the annual period starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-09 will have on our income tax disclosures.
Contract Liabilities Upon exceeding the annual reimbursement amount provided by the customer’s contract with us, our CF products are provided free of charge, which is a material right. These contracts include upfront payments and fees. If we estimate that we will exceed the annual reimbursement amount under a contract, we defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” Once the reimbursement limit has been reached, we recognize the deferred amount as revenue when we ship the free products. Our CF product revenue contracts include performance obligations that are one year or less.
Our contract liabilities at the end of each fiscal year relate to contracts with CF annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2024
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
“Product revenues, net” consisted of the following:
Three Months Ended March 31,
20242023
(in millions)
TRIKAFTA/KAFTRIO$2,483.6 $2,096.7 
Other CF products207.0 278.1 
Total product revenues, net$2,690.6 $2,374.8 
“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:
Three Months Ended March 31,
20242023
(in millions)
United States$1,519.9 $1,403.8 
Outside of the United States
Europe967.4 807.2 
Other
203.3 163.8 
Total product revenues outside of the United States1,170.7 971.0 
Total product revenues, net
$2,690.6 $2,374.8 
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share (Tables)
 3 Months Ended
Mar. 31, 2024
Earnings Per Share [Abstract]  
Computation of Basic and Diluted Net Income Per Common Share
The following table sets forth the computation of basic and diluted net income per common share for the periods ended:
Three Months Ended March 31,
20242023
(in millions, except per share amounts)
Net income$1,099.6 $699.8 
Basic weighted-average common shares outstanding258.2 257.4 
Effect of potentially dilutive securities:
Restricted stock units (including performance-based restricted stock units (“PSUs”))
1.7 1.6 
Stock options1.2 1.3 
Employee stock purchase program
0.0 0.0 
Diluted weighted-average common shares outstanding261.1 260.3 
Basic net income per common share$4.26 $2.72 
Diluted net income per common share$4.21 $2.69 
Schedule of Potential Gross Common Equivalent Shares
We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:
Three Months Ended March 31,
20242023
(in millions)
Unvested restricted stock units (including PSUs)— 0.6 
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements (Tables)
 3 Months Ended
Mar. 31, 2024
Fair Value Disclosures [Abstract]  
Schedule of Financial Assets Subject to Fair Value Measurements
The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy:
As of March 31, 2024As of December 31, 2023
Total
Level 1
Level 2
Level 3
Total
Level 1
Level 2
Level 3
(in millions)
Financial instruments carried at fair value (asset positions):
Cash equivalents$5,865.3 $4,921.3 $944.0 $— $7,033.9 $5,397.3 $1,636.6 $— 
Marketable securities:
Corporate equity securities43.4 43.4 — — 46.0 46.0 — — 
U.S. Treasury securities1,389.4 1,389.4 — — 546.5 546.5 — — 
U.S. government agency securities
356.7 — 356.7 — 425.2 — 425.2 — 
Asset-backed securities792.6 — 792.6 — 306.0 — 306.0 — 
Certificates of deposit42.6 — 42.6 — 33.7 — 33.7 — 
Corporate debt securities2,632.2 — 2,632.2 — 1,802.8 — 1,802.8 — 
Commercial paper137.8 — 137.8 — 186.8 — 186.8 — 
Prepaid expenses and other current assets:
Foreign currency forward contracts26.3 — 26.3 — 1.8 — 1.8 — 
Total financial assets
$11,286.3 $6,354.1 $4,932.2 $— $10,382.7 $5,989.8 $4,392.9 $— 
Financial instruments carried at fair value (liability positions):
Other current liabilities:
Foreign currency forward contracts
$(1.4)$— $(1.4)$— $(33.7)$— $(33.7)$— 
Other long-term liabilities:
Contingent consideration(77.3)— — (77.3)(77.4)— — (77.4)
Total financial liabilities
$(78.7)$— $(1.4)$(77.3)$(111.1)$— $(33.7)$(77.4)
Schedule of Fair Value of Our Contingent Consideration Liabilities
The following table represents a rollforward of the fair value of our contingent consideration liabilities:
Three Months Ended March 31, 2024
(in millions)
Balance at December 31, 2023$77.4 
Decrease in fair value of contingent payments
(0.1)
Balance at March 31, 2024$77.3 
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments (Tables)
 3 Months Ended
Mar. 31, 2024
Investments, Debt and Equity Securities [Abstract]  
Schedule of Cash Equivalents and Marketable Debt and Equity Securities
A summary of our cash equivalents and marketable debt and equity securities, which are recorded at fair value, is shown below:
As of March 31, 2024As of December 31, 2023
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
Amortized Cost
Gross
Unrealized
Gains
Gross
Unrealized
Losses
Fair
Value
(in millions)
Cash equivalents
$5,865.3 $— $— $5,865.3 $7,033.9 $— $— $7,033.9 
Marketable securities:
U.S. Treasury securities1,395.1 1.1 (6.8)1,389.4 544.5 3.0 (1.0)546.5 
U.S. government agency securities
357.7 0.1 (1.1)356.7 424.8 0.9 (0.5)425.2 
Asset-backed securities793.5 0.7 (1.6)792.6 304.9 1.4 (0.3)306.0 
Certificates of deposit42.6 0.0 (0.0)42.6 33.7 0.0 (0.0)33.7 
Corporate debt securities
2,637.4 4.3 (9.5)2,632.2 1,794.0 10.5 (1.7)1,802.8 
Commercial paper
137.9 0.0 (0.1)137.8 186.8 0.1 (0.1)186.8 
Total marketable available-for-sale debt securities
5,364.2 6.2 (19.1)5,351.3 3,288.7 15.9 (3.6)3,301.0 
Corporate equity securities
72.1 — (28.7)43.4 72.1 — (26.1)46.0 
Total marketable securities
5,436.3 6.2 (47.8)5,394.7 3,360.8 15.9 (29.7)3,347.0 
Total cash equivalents and marketable securities$11,301.6 $6.2 $(47.8)$11,260.0 $10,394.7 $15.9 $(29.7)$10,380.9 
Amounts in the table above at fair value were classified on our condensed consolidated balance sheets as follows:
As of March 31, 2024As of December 31, 2023
(in millions)
Cash and cash equivalents$5,865.3 $7,033.9 
Marketable securities
1,013.3 849.2 
Long-term marketable securities4,381.4 2,497.8 
Total
$11,260.0 $10,380.9 
Marketable available-for-sale debt securities by contractual maturity were as follows:
As of March 31, 2024As of December 31, 2023
(in millions)
Matures within one year$969.9 $803.2 
Matures after one year through five years
4,273.3 2,495.6 
Matures after five years108.1 2.2 
Total
$5,351.3 $3,301.0 
Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities During the three months ended March 31, 2024 and 2023, our net unrealized (losses) gains on corporate equity securities with readily determinable fair values held at the conclusion of each period were as follows:
Three Months Ended March 31,
20242023
(in millions)
Net unrealized (losses) gains
$(2.7)$6.4 
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive Income (Loss) (Tables)
 3 Months Ended
Mar. 31, 2024
Equity [Abstract]  
Schedule of Accumulated Other Comprehensive Income (Loss)
The following table summarizes the changes in accumulated other comprehensive income (loss) by component:
Unrealized Holding Gains (Losses), Net of Tax
Foreign Currency Translation AdjustmentOn Available-For-Sale Debt SecuritiesOn Foreign Currency Forward ContractsTotal
(in millions)
Balance at December 31, 2023$1.1 $9.6 $(25.0)$(14.3)
Other comprehensive income (loss) before reclassifications6.8 (20.5)47.2 33.5 
Amounts reclassified from accumulated other comprehensive income (loss)— 0.8 (2.7)(1.9)
Net current period other comprehensive income (loss)6.8 (19.7)44.5 31.6 
Balance at March 31, 2024$7.9 $(10.1)$19.5 $17.3 
Balance at December 31, 2022$(25.0)$(0.1)$25.9 $0.8 
Other comprehensive income (loss) before reclassifications10.0 2.9 (9.6)3.3 
Amounts reclassified from accumulated other comprehensive income (loss)— — (17.2)(17.2)
Net current period other comprehensive income (loss)10.0 2.9 (26.8)(13.9)
Balance at March 31, 2023$(15.0)$2.8 $(0.9)$(13.1)
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging (Tables)
 3 Months Ended
Mar. 31, 2024
Derivative Instruments and Hedging Activities Disclosure [Abstract]  
Schedule of Cash Flow Hedging Instruments
The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:
As of March 31, 2024As of December 31, 2023
Foreign Currency(in millions)
Euro$1,305.5 $1,720.6 
Canadian dollar
190.0 229.5 
British pound sterling
186.4 225.0 
Australian dollar
122.1 153.3 
Swiss Franc50.5 63.9 
Total foreign currency forward contracts
$1,854.5 $2,392.3 
Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations
During the three months ended March 31, 2024 and 2023, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:
Three Months Ended March 31,
20242023
(in millions)
Designated as hedging instruments - Reclassified from AOCI
Product revenues, net$3.4 $22.0 
Not designated as hedging instruments
Other (expense) income, net$(2.4)$3.6 
Total reported in the Condensed Consolidated Statements of Income
Product revenues, net$2,690.6 $2,374.8 
Other (expense) income, net$(31.2)$1.3 
Schedule of Foreign Exchange Contracts
The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:
As of March 31, 2024
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$26.3 Other current liabilities$(1.4)
As of December 31, 2023
AssetsLiabilities
ClassificationFair ValueClassificationFair Value
(in millions)
Prepaid expenses and other current assets$1.8 Other current liabilities$(33.7)
Schedule of Offsetting Assets The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of March 31, 2024
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$26.3 $— $26.3 $(1.4)$24.9 
Total liabilities(1.4)— (1.4)1.4 — 
As of December 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$1.8 $— $1.8 $(1.8)$— 
Total liabilities(33.7)— (33.7)1.8 (31.9)
Schedule of Offsetting Liabilities The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:

As of March 31, 2024
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$26.3 $— $26.3 $(1.4)$24.9 
Total liabilities(1.4)— (1.4)1.4 — 
As of December 31, 2023
Gross Amounts RecognizedGross Amounts OffsetGross Amounts PresentedGross Amounts Not OffsetLegal Offset
Foreign currency forward contracts(in millions)
Total assets$1.8 $— $1.8 $(1.8)$— 
Total liabilities(33.7)— (33.7)1.8 (31.9)
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories (Tables)
 3 Months Ended
Mar. 31, 2024
Inventory Disclosure [Abstract]  
Schedule of Inventories by Type
Inventories consisted of the following:
As of March 31, 2024As of December 31, 2023
(in millions)
Raw materials$95.7 $78.7 
Work-in-process601.8 525.1 
Finished goods
115.6 135.0 
Total
$813.1 $738.8 
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation Expense and Share Repurchase Programs (Tables)
 3 Months Ended
Mar. 31, 2024
Share-Based Payment Arrangement [Abstract]  
Schedule of Stock-based Compensation Expense by Line Item
During the three months ended March 31, 2024 and 2023, we recognized the following stock-based compensation expense:
Three Months Ended March 31,
20242023
(in millions)
Stock-based compensation expense by type of award:
Restricted stock units (including PSUs)$187.2 $115.9 
ESPP share issuances5.8 5.5 
Stock options— 1.4 
Stock-based compensation expense related to inventories
(1.1)(0.4)
Total stock-based compensation expense included in “Total costs and expenses”
$191.9 $122.4 
Stock-based compensation expense by line item:
Cost of sales$1.8 $1.9 
Research and development expenses119.4 76.3 
Selling, general and administrative expenses70.7 44.2 
Total stock-based compensation expense included in costs and expenses
191.9 122.4 
Income tax effect(79.0)(40.6)
Total stock-based compensation expense, net of tax
$112.9 $81.8 
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Tables)
 3 Months Ended
Mar. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates During the three months ended March 31, 2024 and 2023, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:
Three Months Ended March 31,
20242023
(in millions, except percentages)
Income before provision for income taxes$1,279.1 $891.5 
Provision for income taxes$179.5 $191.7 
Effective tax rate14.0 %21.5 %
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Additional Cash Flow Information (Tables)
 3 Months Ended
Mar. 31, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of Cash Equivalents
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20242023
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,369.1 $9,158.0 $10,504.0 $9,289.9 
Prepaid expenses and other current assets
3.2 11.4 8.0 5.7 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,372.3 $9,169.4 $10,512.0 $9,295.6 
Schedule of Restricted Cash
The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:
Three Months Ended March 31,
20242023
Beginning of periodEnd of periodBeginning of periodEnd of period
(in millions)
Cash and cash equivalents$10,369.1 $9,158.0 $10,504.0 $9,289.9 
Prepaid expenses and other current assets
3.2 11.4 8.0 5.7 
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows$10,372.3 $9,169.4 $10,512.0 $9,295.6 
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Basis of Presentation and Accounting Policies (Details)
 3 Months Ended
Mar. 31, 2024
segment
Accounting Policies [Abstract]  
Number of operating segments 1
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition - Disaggregation of Revenue (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 2,690.6 $ 2,374.8
United States    
Disaggregation of Revenue [Line Items]    
Product revenues, net 1,519.9 1,403.8
Total product revenues outside of the United States    
Disaggregation of Revenue [Line Items]    
Product revenues, net 1,170.7 971.0
Europe    
Disaggregation of Revenue [Line Items]    
Product revenues, net 967.4 807.2
Other    
Disaggregation of Revenue [Line Items]    
Product revenues, net 203.3 163.8
TRIKAFTA/KAFTRIO    
Disaggregation of Revenue [Line Items]    
Product revenues, net 2,483.6 2,096.7
Other CF products    
Disaggregation of Revenue [Line Items]    
Product revenues, net $ 207.0 $ 278.1
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Revenue Recognition - Additional Information (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Revenue from Contract with Customer [Abstract]    
Contract liabilities $ 275.8 $ 170.3
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Collaboration, License and Other Arrangements - Additional Information (Details)
 1 Months Ended 3 Months Ended 12 Months Ended
Jan. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Feb. 28, 2023
USD ($)
Mar. 31, 2024
USD ($)
Mar. 31, 2023
USD ($)
Dec. 31, 2019
USD ($)
target
Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Acquired in-process research and development expenses       $ 76,800,000 $ 347,100,000    
Cost of sales       342,600,000 266,900,000    
Selling, general and administrative expenses       $ 342,700,000 241,100,000    
CRISPR              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, allocation of research and development expenses, percent       40.00%      
Allocation of net profits and net losses, percent       40.00%      
CRISPR Therapeutics              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, right to exclusively license, number of targets | target           3  
Collaborative arrangement, development and regulatory potential milestone payments maximum           $ 410,000,000  
CRISPR JDCA              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Milestone payment $ 200,000,000            
Allocation of net profits and net losses, percent             60.00%
Cost of sales       $ 15,800,000      
Research and development expenses       11,700,000 17,900,000    
Selling, general and administrative expenses         $ 5,800,000    
CRISPR JDCA | CRISPR              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Allocation of net profits and net losses, percent             40.00%
CRISPR T1D              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, development and regulatory potential milestone payments maximum   $ 160,000,000          
Up-front payment   $ 100,000,000          
Entrada Therapeutics              
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]              
Collaborative arrangement, development and regulatory potential milestone payments maximum     $ 335,000,000        
Milestone payment       $ 75,000,000      
Up-front payment     225,100,000        
Purchase of common stock     $ 24,900,000        
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share - Schedule of Computation (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Net income $ 1,099.6 $ 699.8
Basic weighted-average common shares outstanding (in shares) 258.2 257.4
Effect of potentially dilutive securities:    
Employee stock purchase program (in shares) 0.0 0.0
Diluted weighted-average common shares outstanding (in shares) 261.1 260.3
Basic net income per common share (in dollars per share) $ 4.26 $ 2.72
Diluted net income per common share (in dollars per share) $ 4.21 $ 2.69
Restricted stock units (including performance-based restricted stock units (“PSUs”))    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1.7 1.6
Stock options    
Effect of potentially dilutive securities:    
Share-based payment arrangements (in shares) 1.2 1.3
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Earnings Per Share - Anti-dilutive Securities (Details) - shares
shares in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Unvested restricted stock units (including PSUs)    
Antidilutive Securities Excluded from Computation of Earnings Per Share    
Antidilutive securities excluded from computation of earnings per share (in shares) 0.0 0.6
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Additional Information (Details)
$ in Millions
Mar. 31, 2024
USD ($)
Dec. 31, 2019
USD ($)
Level 3    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Remaining milestone payment   $ 678.3
Level 3 | Minimum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (percent) 0.051  
Level 3 | Maximum | Discount Rate    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Contingent consideration, measurement input (percent) 0.053  
Corporate equity securities    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Fair value of equity securities $ 23.0  
XML 54 R43.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) - Recurring Basis - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Financial instruments carried at fair value (asset positions):    
Cash equivalents $ 5,865.3 $ 7,033.9
Prepaid expenses and other current assets, foreign currency forward contracts 26.3 1.8
Total financial assets 11,286.3 10,382.7
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (1.4) (33.7)
Contingent consideration (77.3) (77.4)
Total financial liabilities (78.7) (111.1)
Level 1    
Financial instruments carried at fair value (asset positions):    
Cash equivalents 4,921.3 5,397.3
Prepaid expenses and other current assets, foreign currency forward contracts 0.0 0.0
Total financial assets 6,354.1 5,989.8
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Contingent consideration 0.0 0.0
Total financial liabilities 0.0 0.0
Level 2    
Financial instruments carried at fair value (asset positions):    
Cash equivalents 944.0 1,636.6
Prepaid expenses and other current assets, foreign currency forward contracts 26.3 1.8
Total financial assets 4,932.2 4,392.9
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts (1.4) (33.7)
Contingent consideration 0.0 0.0
Total financial liabilities (1.4) (33.7)
Level 3    
Financial instruments carried at fair value (asset positions):    
Cash equivalents 0.0 0.0
Prepaid expenses and other current assets, foreign currency forward contracts 0.0 0.0
Total financial assets 0.0 0.0
Financial instruments carried at fair value (liability positions):    
Other current liabilities, foreign currency forward contracts 0.0 0.0
Contingent consideration (77.3) (77.4)
Total financial liabilities (77.3) (77.4)
Corporate equity securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 43.4 46.0
Corporate equity securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 43.4 46.0
Corporate equity securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Corporate equity securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
U.S. Treasury securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 1,389.4 546.5
U.S. Treasury securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 1,389.4 546.5
U.S. Treasury securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
U.S. Treasury securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
U.S. government agency securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 356.7 425.2
U.S. government agency securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
U.S. government agency securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 356.7 425.2
U.S. government agency securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Asset-backed securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 792.6 306.0
Asset-backed securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Asset-backed securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 792.6 306.0
Asset-backed securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Certificates of deposit    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 42.6 33.7
Certificates of deposit | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Certificates of deposit | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 42.6 33.7
Certificates of deposit | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Corporate debt securities    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 2,632.2 1,802.8
Corporate debt securities | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Corporate debt securities | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 2,632.2 1,802.8
Corporate debt securities | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Commercial paper    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 137.8 186.8
Commercial paper | Level 1    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 0.0 0.0
Commercial paper | Level 2    
Financial instruments carried at fair value (asset positions):    
Marketable securities: 137.8 186.8
Commercial paper | Level 3    
Financial instruments carried at fair value (asset positions):    
Marketable securities: $ 0.0 $ 0.0
XML 55 R44.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Fair Value Measurements - Schedule of Fair Value of Our Contingent Consideration Liabilities (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]    
Beginning balance $ 77.4  
Decrease in fair value of contingent payments (0.1) $ (1.9)
Ending balance $ 77.3  
XML 56 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) - USD ($)
$ in Millions
 3 Months Ended 12 Months Ended
Mar. 31, 2024
Dec. 31, 2023
Cash equivalents    
Amortized Cost $ 5,865.3 $ 7,033.9
Fair Value 5,865.3 7,033.9
Total marketable available-for-sale debt securities    
Gross Unrealized Losses (19.1)  
Corporate equity securities    
Amortized Cost 72.1 72.1
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (28.7) (26.1)
Fair Value 43.4 46.0
Amortized Cost 5,436.3 3,360.8
Gross Unrealized Gains 6.2 15.9
Gross Unrealized Losses (47.8) (29.7)
Fair Value 5,394.7 3,347.0
Total cash equivalents and marketable securities, Amortized Cost 11,301.6 10,394.7
Total cash equivalents and marketable securities, Gross Unrealized Gains 6.2 15.9
Total cash equivalents and marketable securities, Gross Unrealized Losses (47.8) (29.7)
Total cash equivalents and marketable securities, Fair Value 11,260.0 10,380.9
U.S. Treasury securities    
Total marketable available-for-sale debt securities    
Amortized Cost 1,395.1 544.5
Gross Unrealized Gains 1.1 3.0
Gross Unrealized Losses (6.8) (1.0)
Fair Value 1,389.4 546.5
U.S. government agency securities    
Total marketable available-for-sale debt securities    
Amortized Cost 357.7 424.8
Gross Unrealized Gains 0.1 0.9
Gross Unrealized Losses (1.1) (0.5)
Fair Value 356.7 425.2
Asset-backed securities    
Total marketable available-for-sale debt securities    
Amortized Cost 793.5 304.9
Gross Unrealized Gains 0.7 1.4
Gross Unrealized Losses (1.6) (0.3)
Fair Value 792.6 306.0
Certificates of deposit    
Total marketable available-for-sale debt securities    
Amortized Cost 42.6 33.7
Gross Unrealized Gains 0.0 0.0
Gross Unrealized Losses (0.0) (0.0)
Fair Value 42.6 33.7
Corporate debt securities    
Total marketable available-for-sale debt securities    
Amortized Cost 2,637.4 1,794.0
Gross Unrealized Gains 4.3 10.5
Gross Unrealized Losses (9.5) (1.7)
Fair Value 2,632.2 1,802.8
Commercial paper    
Total marketable available-for-sale debt securities    
Amortized Cost 137.9 186.8
Gross Unrealized Gains 0.0 0.1
Gross Unrealized Losses (0.1) (0.1)
Fair Value 137.8 186.8
Total marketable available-for-sale debt securities    
Total marketable available-for-sale debt securities    
Amortized Cost 5,364.2 3,288.7
Gross Unrealized Gains 6.2 15.9
Gross Unrealized Losses (19.1) (3.6)
Fair Value $ 5,351.3 $ 3,301.0
XML 57 R46.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Total cash equivalents and marketable securities, Fair Value $ 11,260.0 $ 10,380.9
Cash and cash equivalents    
Debt Securities, Available-for-sale [Line Items]    
Total cash equivalents and marketable securities, Fair Value 5,865.3 7,033.9
Marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Total cash equivalents and marketable securities, Fair Value 1,013.3 849.2
Long-term marketable securities    
Debt Securities, Available-for-sale [Line Items]    
Total cash equivalents and marketable securities, Fair Value $ 4,381.4 $ 2,497.8
XML 58 R47.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) - Total marketable available-for-sale debt securities - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Debt Securities, Available-for-sale [Line Items]    
Matures within one year $ 969.9 $ 803.2
Matures after one year through five years 4,273.3 2,495.6
Matures after five years 108.1 2.2
Total $ 5,351.3 $ 3,301.0
XML 59 R48.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Summary of cash, cash equivalents and marketable securities    
Allowance for credit loss for available-for-sale debt securities $ 0 $ 0
Realized gain (loss) amount 0 $ 0
Debt securities fair value, unrealized loss position 4,000,000,000  
Unrealized loss 19,100,000  
Fair value of available-for-sale debt securities in unrealized loss positions for greater than 12 months 53,800,000  
Unrealized loss position for greater than twelve months 400,000  
Reduction in carrying value of equity investments without readily determinable fair value, based on an observable price decrease 24,300,000  
Other Assets    
Summary of cash, cash equivalents and marketable securities    
Equity securities without readily determinable fair value, amount $ 74,300,000  
XML 60 R49.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]    
Net unrealized (losses) gains $ (2.7) $ 6.4
XML 61 R50.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance $ 17,580.4 $ 13,912.7
Other comprehensive income (loss) before reclassifications 33.5 3.3
Amounts reclassified from accumulated other comprehensive income (loss) (1.9) (17.2)
Total other comprehensive income (loss) 31.6 (13.9)
Ending balance 18,546.6 14,432.3
Total    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (14.3) 0.8
Total other comprehensive income (loss) 31.6 (13.9)
Ending balance 17.3 (13.1)
Foreign Currency Translation Adjustment    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 1.1 (25.0)
Other comprehensive income (loss) before reclassifications 6.8 10.0
Amounts reclassified from accumulated other comprehensive income (loss) 0.0 0.0
Total other comprehensive income (loss) 6.8 10.0
Ending balance 7.9 (15.0)
On Available-For-Sale Debt Securities    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance 9.6 (0.1)
Other comprehensive income (loss) before reclassifications (20.5) 2.9
Amounts reclassified from accumulated other comprehensive income (loss) 0.8 0.0
Total other comprehensive income (loss) (19.7) 2.9
Ending balance (10.1) 2.8
On Foreign Currency Forward Contracts    
AOCI Attributable to Parent, Net of Tax [Roll Forward]    
Beginning balance (25.0) 25.9
Other comprehensive income (loss) before reclassifications 47.2 (9.6)
Amounts reclassified from accumulated other comprehensive income (loss) (2.7) (17.2)
Total other comprehensive income (loss) 44.5 (26.8)
Ending balance $ 19.5 $ (0.9)
XML 62 R51.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging - Additional Information (Details) - Foreign currency forward contracts
 3 Months Ended
Mar. 31, 2024
USD ($)
Not Designated as Hedging Instrument  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Not Designated as Hedging Instrument  
Derivative [Line Items]  
Notional amount of foreign currency forward contract $ 0
Cash Flow Hedging | Minimum  
Derivative [Line Items]  
Derivative term 1 month
Cash Flow Hedging | Maximum  
Derivative [Line Items]  
Derivative term 18 months
XML 63 R52.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging - Notional Amount (Details) - Foreign currency forward contracts - Designated as Hedging Instruments - Cash Flow Hedging - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 1,854.5 $ 2,392.3
Euro    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 1,305.5 1,720.6
Canadian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 190.0 229.5
British pound sterling    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 186.4 225.0
Australian dollar    
Derivative [Line Items]    
Notional amount of foreign currency forward contract 122.1 153.3
Swiss Franc    
Derivative [Line Items]    
Notional amount of foreign currency forward contract $ 50.5 $ 63.9
XML 64 R53.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging - Cash Flow Hedging Instruments (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net $ 2,690.6 $ 2,374.8
Other (expense) income, net (31.2) 1.3
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Product revenues, net 3.4 22.0
Foreign Currency Forward Contract | Reclassification out of Accumulated Other Comprehensive Income | Foreign currency forward contracts | Not designated as hedging instruments    
Derivative Instruments, Gain (Loss) [Line Items]    
Other (expense) income, net $ (2.4) $ 3.6
XML 65 R54.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging - Derivative Fair Value (Details) - Designated as Hedging Instruments - Foreign currency forward contracts - Cash Flow Hedging - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Derivative [Line Items]    
Total assets $ 26.3 $ 1.8
Total liabilities (1.4) (33.7)
Prepaid expenses and other current assets    
Derivative [Line Items]    
Total assets 26.3 1.8
Other current liabilities    
Derivative [Line Items]    
Total liabilities $ (1.4) $ (33.7)
XML 66 R55.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Hedging - Offsetting Derivatives (Details) - Cash Flow Hedging - Designated as Hedging Instruments - Foreign currency forward contracts - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Total assets    
Gross Amounts Recognized $ 26.3 $ 1.8
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented 26.3 1.8
Gross Amounts Not Offset (1.4) (1.8)
Legal Offset 24.9 0.0
Total liabilities    
Gross Amounts Recognized (1.4) (33.7)
Gross Amounts Offset 0.0 0.0
Gross Amounts Presented (1.4) (33.7)
Gross Amounts Not Offset 1.4 1.8
Legal Offset $ 0.0 $ (31.9)
XML 67 R56.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Inventories (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Inventory Disclosure [Abstract]    
Raw materials $ 95.7 $ 78.7
Work-in-process 601.8 525.1
Finished goods 115.6 135.0
Total $ 813.1 $ 738.8
XML 68 R57.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 191.9 $ 122.4
Stock-based compensation expense related to inventories (1.1) (0.4)
Total stock-based compensation expense included in “Total costs and expenses” 191.9 122.4
Income tax effect (79.0) (40.6)
Total stock-based compensation expense, net of tax 112.9 81.8
Cost of sales    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 1.8 1.9
Research and development expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 119.4 76.3
Selling, general and administrative expenses    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 70.7 44.2
Restricted stock units (including performance-based restricted stock units (“PSUs”))    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 187.2 115.9
ESPP share issuances    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses 5.8 5.5
Stock options    
Stock-based compensation expense:    
Total stock-based compensation expense included in costs and expenses $ 0.0 $ 1.4
XML 69 R58.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) - USD ($)
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Feb. 28, 2023
Share-Based Payment Arrangement [Abstract]      
Number of shares authorized to be repurchased     $ 3,000,000,000
Shares repurchased (in shares) 335,773 459,017  
Value of shares repurchased $ 140,400,000 $ 135,600,000  
Stock repurchase program, remaining amount $ 2,400,000,000    
XML 70 R59.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Income Taxes (Details) - USD ($)
$ in Millions
 3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Dec. 31, 2023
Income Tax Disclosure [Abstract]      
Income before provision for income taxes $ 1,279.1 $ 891.5  
Provision for income taxes $ 179.5 $ 191.7  
Effective tax rate 14.00% 21.50%  
Net unrecognized tax benefits which would affect the tax rate if recognized $ 301.6   $ 288.7
XML 71 R60.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Commitments and Contingencies (Details) - USD ($)
 1 Months Ended
Jul. 31, 2022
Mar. 31, 2024
Dec. 31, 2023
Line of Credit Facility [Line Items]      
Indemnification claims   $ 0  
Contingent liabilities   $ 0 $ 0
Revolving Credit Facility      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 500,000,000    
Line of credit facility additional borrowing capacity $ 500,000,000    
Debt covenant, consolidated leverage ratio 3.50    
Debt covenant, increase in consolidated leverage ratio 4.00    
Revolving Credit Facility | Base Rate | Minimum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 0.00%    
Revolving Credit Facility | Base Rate | Maximum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 0.50%    
Revolving Credit Facility | SOFR Loan | Minimum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 1.00%    
Revolving Credit Facility | SOFR Loan | Maximum      
Line of Credit Facility [Line Items]      
Basis spread on variable rate (as a percent) 1.50%    
Letters of Credit      
Line of Credit Facility [Line Items]      
Line of credit facility, maximum borrowing capacity $ 100,000,000    
XML 72 R61.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Additional Cash Flow Information (Details) - USD ($)
$ in Millions
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]        
Cash and cash equivalents $ 9,158.0 $ 10,369.1 $ 9,289.9 $ 10,504.0
Prepaid expenses and other current assets 11.4 3.2 5.7 8.0
Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows $ 9,169.4 $ 10,372.3 $ 9,295.6 $ 10,512.0
XML 73 R62.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Subsequent Events (Details)
$ in Billions
 1 Months Ended
Apr. 30, 2024
USD ($)
Subsequent Event | Alpine  
Subsequent Event [Line Items]  
Payments to acquire business in cash $ 4.9
EXCEL 74 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 75 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 76 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 78 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 224 262 1 false 71 0 false 6 false false R1.htm 0000001 - Document - Cover Sheet http://www.vrtx.com/role/Cover Cover Cover 1 false false R2.htm 0000002 - Statement - Condensed Consolidated Statements of Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome Condensed Consolidated Statements of Income Statements 2 false false R3.htm 0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome Condensed Consolidated Statements of Comprehensive Income Statements 3 false false R4.htm 0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical Condensed Consolidated Statements of Comprehensive Income (Parenthetical) Statements 4 false false R5.htm 0000005 - Statement - Condensed Consolidated Balance Sheets Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets Condensed Consolidated Balance Sheets Statements 5 false false R6.htm 0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 6 false false R7.htm 0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity Condensed Consolidated Statements of Shareholders' Equity Statements 7 false false R8.htm 0000008 - Statement - Condensed Consolidated Statements of Cash Flows Sheet http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows Condensed Consolidated Statements of Cash Flows Statements 8 false false R9.htm 0000009 - Disclosure - Basis of Presentation and Accounting Policies Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies Basis of Presentation and Accounting Policies Notes 9 false false R10.htm 0000010 - Disclosure - Revenue Recognition Sheet http://www.vrtx.com/role/RevenueRecognition Revenue Recognition Notes 10 false false R11.htm 0000011 - Disclosure - Collaboration, License and Other Arrangements Sheet http://www.vrtx.com/role/CollaborationLicenseandOtherArrangements Collaboration, License and Other Arrangements Notes 11 false false R12.htm 0000012 - Disclosure - Earnings Per Share Sheet http://www.vrtx.com/role/EarningsPerShare Earnings Per Share Notes 12 false false R13.htm 0000013 - Disclosure - Fair Value Measurements Sheet http://www.vrtx.com/role/FairValueMeasurements Fair Value Measurements Notes 13 false false R14.htm 0000014 - Disclosure - Marketable Securities and Equity Investments Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments Marketable Securities and Equity Investments Notes 14 false false R15.htm 0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) Notes 15 false false R16.htm 0000016 - Disclosure - Hedging Sheet http://www.vrtx.com/role/Hedging Hedging Notes 16 false false R17.htm 0000017 - Disclosure - Inventories Sheet http://www.vrtx.com/role/Inventories Inventories Notes 17 false false R18.htm 0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms Stock-based Compensation Expense and Share Repurchase Programs Notes 18 false false R19.htm 0000019 - Disclosure - Income Taxes Sheet http://www.vrtx.com/role/IncomeTaxes Income Taxes Notes 19 false false R20.htm 0000020 - Disclosure - Commitments and Contingencies Sheet http://www.vrtx.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 20 false false R21.htm 0000021 - Disclosure - Additional Cash Flow Information Sheet http://www.vrtx.com/role/AdditionalCashFlowInformation Additional Cash Flow Information Notes 21 false false R22.htm 0000022 - Disclosure - Subsequent Event Sheet http://www.vrtx.com/role/SubsequentEvent Subsequent Event Notes 22 false false R23.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 23 false false R24.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 24 false false R25.htm 9954471 - Disclosure - Basis of Presentation and Accounting Policies (Policies) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies Basis of Presentation and Accounting Policies (Policies) Policies http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies 25 false false R26.htm 9954472 - Disclosure - Revenue Recognition (Tables) Sheet http://www.vrtx.com/role/RevenueRecognitionTables Revenue Recognition (Tables) Tables http://www.vrtx.com/role/RevenueRecognition 26 false false R27.htm 9954473 - Disclosure - Earnings Per Share (Tables) Sheet http://www.vrtx.com/role/EarningsPerShareTables Earnings Per Share (Tables) Tables http://www.vrtx.com/role/EarningsPerShare 27 false false R28.htm 9954474 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.vrtx.com/role/FairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://www.vrtx.com/role/FairValueMeasurements 28 false false R29.htm 9954475 - Disclosure - Marketable Securities and Equity Investments (Tables) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables Marketable Securities and Equity Investments (Tables) Tables http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments 29 false false R30.htm 9954476 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables Accumulated Other Comprehensive Income (Loss) (Tables) Tables http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss 30 false false R31.htm 9954477 - Disclosure - Hedging (Tables) Sheet http://www.vrtx.com/role/HedgingTables Hedging (Tables) Tables http://www.vrtx.com/role/Hedging 31 false false R32.htm 9954478 - Disclosure - Inventories (Tables) Sheet http://www.vrtx.com/role/InventoriesTables Inventories (Tables) Tables http://www.vrtx.com/role/Inventories 32 false false R33.htm 9954479 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables Stock-based Compensation Expense and Share Repurchase Programs (Tables) Tables http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms 33 false false R34.htm 9954480 - Disclosure - Income Taxes (Tables) Sheet http://www.vrtx.com/role/IncomeTaxesTables Income Taxes (Tables) Tables http://www.vrtx.com/role/IncomeTaxes 34 false false R35.htm 9954481 - Disclosure - Additional Cash Flow Information (Tables) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationTables Additional Cash Flow Information (Tables) Tables http://www.vrtx.com/role/AdditionalCashFlowInformation 35 false false R36.htm 9954482 - Disclosure - Basis of Presentation and Accounting Policies (Details) Sheet http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails Basis of Presentation and Accounting Policies (Details) Details http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies 36 false false R37.htm 9954483 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails Revenue Recognition - Disaggregation of Revenue (Details) Details 37 false false R38.htm 9954484 - Disclosure - Revenue Recognition - Additional Information (Details) Sheet http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails Revenue Recognition - Additional Information (Details) Details 38 false false R39.htm 9954485 - Disclosure - Collaboration, License and Other Arrangements - Additional Information (Details) Sheet http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails Collaboration, License and Other Arrangements - Additional Information (Details) Details 39 false false R40.htm 9954486 - Disclosure - Earnings Per Share - Schedule of Computation (Details) Sheet http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails Earnings Per Share - Schedule of Computation (Details) Details 40 false false R41.htm 9954487 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details) Sheet http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails Earnings Per Share - Anti-dilutive Securities (Details) Details 41 false false R42.htm 9954488 - Disclosure - Fair Value Measurements - Additional Information (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails Fair Value Measurements - Additional Information (Details) Details 42 false false R43.htm 9954489 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details) Details 43 false false R44.htm 9954490 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Our Contingent Consideration Liabilities (Details) Sheet http://www.vrtx.com/role/FairValueMeasurementsScheduleofFairValueofOurContingentConsiderationLiabilitiesDetails Fair Value Measurements - Schedule of Fair Value of Our Contingent Consideration Liabilities (Details) Details 44 false false R45.htm 9954491 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details) Details 45 false false R46.htm 9954492 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details) Details 46 false false R47.htm 9954493 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details) Details 47 false false R48.htm 9954494 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails Marketable Securities and Equity Investments - Additional Information (Details) Details 48 false false R49.htm 9954495 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) Sheet http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details) Details 49 false false R50.htm 9954496 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details) Sheet http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails Accumulated Other Comprehensive Income (Loss) (Details) Details http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables 50 false false R51.htm 9954497 - Disclosure - Hedging - Additional Information (Details) Sheet http://www.vrtx.com/role/HedgingAdditionalInformationDetails Hedging - Additional Information (Details) Details 51 false false R52.htm 9954498 - Disclosure - Hedging - Notional Amount (Details) Sheet http://www.vrtx.com/role/HedgingNotionalAmountDetails Hedging - Notional Amount (Details) Details 52 false false R53.htm 9954499 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details) Sheet http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails Hedging - Cash Flow Hedging Instruments (Details) Details 53 false false R54.htm 9954500 - Disclosure - Hedging - Derivative Fair Value (Details) Sheet http://www.vrtx.com/role/HedgingDerivativeFairValueDetails Hedging - Derivative Fair Value (Details) Details 54 false false R55.htm 9954501 - Disclosure - Hedging - Offsetting Derivatives (Details) Sheet http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails Hedging - Offsetting Derivatives (Details) Details 55 false false R56.htm 9954502 - Disclosure - Inventories (Details) Sheet http://www.vrtx.com/role/InventoriesDetails Inventories (Details) Details http://www.vrtx.com/role/InventoriesTables 56 false false R57.htm 9954503 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details) Details 57 false false R58.htm 9954504 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Sheet http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details) Details 58 false false R59.htm 9954505 - Disclosure - Income Taxes (Details) Sheet http://www.vrtx.com/role/IncomeTaxesDetails Income Taxes (Details) Details http://www.vrtx.com/role/IncomeTaxesTables 59 false false R60.htm 9954506 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.vrtx.com/role/CommitmentsandContingenciesDetails Commitments and Contingencies (Details) Details http://www.vrtx.com/role/CommitmentsandContingencies 60 false false R61.htm 9954507 - Disclosure - Additional Cash Flow Information (Details) Sheet http://www.vrtx.com/role/AdditionalCashFlowInformationDetails Additional Cash Flow Information (Details) Details http://www.vrtx.com/role/AdditionalCashFlowInformationTables 61 false false R62.htm 9954508 - Disclosure - Subsequent Events (Details) Sheet http://www.vrtx.com/role/SubsequentEventsDetails Subsequent Events (Details) Details http://www.vrtx.com/role/SubsequentEvent 62 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 9 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, ecd:TrdArrDuration, us-gaap:DerivativeTermOfContract - vrtx-20240331.htm 4 vrtx-20240331.htm vrtx-20240331.xsd vrtx-20240331_cal.xml vrtx-20240331_def.xml vrtx-20240331_lab.xml vrtx-20240331_pre.xml vrtx-20240331_g1.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 http://xbrl.sec.gov/ecd/2023 true true JSON 81 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vrtx-20240331.htm": { "nsprefix": "vrtx", "nsuri": "http://www.vrtx.com/20240331", "dts": { "inline": { "local": [ "vrtx-20240331.htm" ] }, "schema": { "local": [ "vrtx-20240331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/ecd/2023/ecd-2023.xsd" ] }, "calculationLink": { "local": [ "vrtx-20240331_cal.xml" ] }, "definitionLink": { "local": [ "vrtx-20240331_def.xml" ] }, "labelLink": { "local": [ "vrtx-20240331_lab.xml" ] }, "presentationLink": { "local": [ "vrtx-20240331_pre.xml" ] } }, "keyStandard": 238, "keyCustom": 24, "axisStandard": 23, "axisCustom": 1, "memberStandard": 50, "memberCustom": 20, "hidden": { "total": 14, "http://fasb.org/us-gaap/2023": 1, "http://xbrl.sec.gov/dei/2023": 6, "http://xbrl.sec.gov/ecd/2023": 7 }, "contextCount": 224, "entityCount": 1, "segmentCount": 71, "elementCount": 528, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 674, "http://xbrl.sec.gov/ecd/2023": 46, "http://xbrl.sec.gov/dei/2023": 29 }, "report": { "R1": { "role": "http://www.vrtx.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "longName": "0000002 - Statement - Condensed Consolidated Statements of Income", "shortName": "Condensed Consolidated Statements of Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R3": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "longName": "0000003 - Statement - Condensed Consolidated Statements of Comprehensive Income", "shortName": "Condensed Consolidated Statements of Comprehensive Income", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R4": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical", "longName": "0000004 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "longName": "0000005 - Statement - Condensed Consolidated Balance Sheets", "shortName": "Condensed Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R6": { "role": "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "longName": "0000006 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPerShare", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "us-gaap:PreferredStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R7": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "longName": "0000007 - Statement - Condensed Consolidated Statements of Shareholders' Equity", "shortName": "Condensed Consolidated Statements of Shareholders' Equity", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-6", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "longName": "0000008 - Statement - Condensed Consolidated Statements of Cash Flows", "shortName": "Condensed Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R9": { "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies", "longName": "0000009 - Disclosure - Basis of Presentation and Accounting Policies", "shortName": "Basis of Presentation and Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.vrtx.com/role/RevenueRecognition", "longName": "0000010 - Disclosure - Revenue Recognition", "shortName": "Revenue Recognition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangements", "longName": "0000011 - Disclosure - Collaboration, License and Other Arrangements", "shortName": "Collaboration, License and Other Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.vrtx.com/role/EarningsPerShare", "longName": "0000012 - Disclosure - Earnings Per Share", "shortName": "Earnings Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.vrtx.com/role/FairValueMeasurements", "longName": "0000013 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments", "longName": "0000014 - Disclosure - Marketable Securities and Equity Investments", "shortName": "Marketable Securities and Equity Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss", "longName": "0000015 - Disclosure - Accumulated Other Comprehensive Income (Loss)", "shortName": "Accumulated Other Comprehensive Income (Loss)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.vrtx.com/role/Hedging", "longName": "0000016 - Disclosure - Hedging", "shortName": "Hedging", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.vrtx.com/role/Inventories", "longName": "0000017 - Disclosure - Inventories", "shortName": "Inventories", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InventoryDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms", "longName": "0000018 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.vrtx.com/role/IncomeTaxes", "longName": "0000019 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.vrtx.com/role/CommitmentsandContingencies", "longName": "0000020 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.vrtx.com/role/AdditionalCashFlowInformation", "longName": "0000021 - Disclosure - Additional Cash Flow Information", "shortName": "Additional Cash Flow Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AdditionalFinancialInformationDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.vrtx.com/role/SubsequentEvent", "longName": "0000022 - Disclosure - Subsequent Event", "shortName": "Subsequent Event", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R23": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": null }, "R24": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies", "longName": "9954471 - Disclosure - Basis of Presentation and Accounting Policies (Policies)", "shortName": "Basis of Presentation and Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.vrtx.com/role/RevenueRecognitionTables", "longName": "9954472 - Disclosure - Revenue Recognition (Tables)", "shortName": "Revenue Recognition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.vrtx.com/role/EarningsPerShareTables", "longName": "9954473 - Disclosure - Earnings Per Share (Tables)", "shortName": "Earnings Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.vrtx.com/role/FairValueMeasurementsTables", "longName": "9954474 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables", "longName": "9954475 - Disclosure - Marketable Securities and Equity Investments (Tables)", "shortName": "Marketable Securities and Equity Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables", "longName": "9954476 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.vrtx.com/role/HedgingTables", "longName": "9954477 - Disclosure - Hedging (Tables)", "shortName": "Hedging (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.vrtx.com/role/InventoriesTables", "longName": "9954478 - Disclosure - Inventories (Tables)", "shortName": "Inventories (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables", "longName": "9954479 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.vrtx.com/role/IncomeTaxesTables", "longName": "9954480 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationTables", "longName": "9954481 - Disclosure - Additional Cash Flow Information (Tables)", "shortName": "Additional Cash Flow Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails", "longName": "9954482 - Disclosure - Basis of Presentation and Accounting Policies (Details)", "shortName": "Basis of Presentation and Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "segment", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails", "longName": "9954483 - Disclosure - Revenue Recognition - Disaggregation of Revenue (Details)", "shortName": "Revenue Recognition - Disaggregation of Revenue (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-36", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R38": { "role": "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails", "longName": "9954484 - Disclosure - Revenue Recognition - Additional Information (Details)", "shortName": "Revenue Recognition - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:ContractWithCustomerLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails", "longName": "9954485 - Disclosure - Collaboration, License and Other Arrangements - Additional Information (Details)", "shortName": "Collaboration, License and Other Arrangements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-46", "name": "vrtx:CollaborativeArrangementAllocationOfResearchAndDevelopmentExpensesPercent", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "2", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R40": { "role": "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "longName": "9954486 - Disclosure - Earnings Per Share - Schedule of Computation (Details)", "shortName": "Earnings Per Share - Schedule of Computation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R41": { "role": "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "longName": "9954487 - Disclosure - Earnings Per Share - Anti-dilutive Securities (Details)", "shortName": "Earnings Per Share - Anti-dilutive Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-58", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-58", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "longName": "9954488 - Disclosure - Fair Value Measurements - Additional Information (Details)", "shortName": "Fair Value Measurements - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-125", "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-125", "name": "vrtx:BusinessCombinationRemainingMilestonePayment", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "longName": "9954489 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "shortName": "Fair Value Measurements - Financial Assets and Liabilities Subject to Fair Value Measurements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-60", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.vrtx.com/role/FairValueMeasurementsScheduleofFairValueofOurContingentConsiderationLiabilitiesDetails", "longName": "9954490 - Disclosure - Fair Value Measurements - Schedule of Fair Value of Our Contingent Consideration Liabilities (Details)", "shortName": "Fair Value Measurements - Schedule of Fair Value of Our Contingent Consideration Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R45": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails", "longName": "9954491 - Disclosure - Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "shortName": "Marketable Securities and Equity Investments - Summary of Cash Equivalents and Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-4", "name": "vrtx:CashEquivalentsAndDebtSecuritiesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "vrtx:CashEquivalentsAndDebtSecuritiesAvailableForSale", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "longName": "9954492 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities at Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-4", "name": "vrtx:CashEquivalentsDebtAndEquitySecuritiesFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-143", "name": "vrtx:CashEquivalentsDebtAndEquitySecuritiesFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R47": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "longName": "9954493 - Disclosure - Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "shortName": "Marketable Securities and Equity Investments - Available-for-Sale Debt Securities by Contractual Maturity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-140", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-140", "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "longName": "9954494 - Disclosure - Marketable Securities and Equity Investments - Additional Information (Details)", "shortName": "Marketable Securities and Equity Investments - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails", "longName": "9954495 - Disclosure - Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details)", "shortName": "Marketable Securities and Equity Investments - Net Unrealized Gains (Losses) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrealizedGainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:UnrealizedGainLossOnInvestments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "longName": "9954496 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)", "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R51": { "role": "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "longName": "9954497 - Disclosure - Hedging - Additional Information (Details)", "shortName": "Hedging - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-182", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-182", "name": "us-gaap:DerivativeTermOfContract", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "longName": "9954498 - Disclosure - Hedging - Notional Amount (Details)", "shortName": "Hedging - Notional Amount (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-180", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "us-gaap:DerivativeNotionalAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R53": { "role": "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "longName": "9954499 - Disclosure - Hedging - Cash Flow Hedging Instruments (Details)", "shortName": "Hedging - Cash Flow Hedging Instruments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-184", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R54": { "role": "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "longName": "9954500 - Disclosure - Hedging - Derivative Fair Value (Details)", "shortName": "Hedging - Derivative Fair Value (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-180", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-188", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R55": { "role": "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails", "longName": "9954501 - Disclosure - Hedging - Offsetting Derivatives (Details)", "shortName": "Hedging - Offsetting Derivatives (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-180", "name": "us-gaap:DerivativeFairValueOfDerivativeAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-180", "name": "us-gaap:DerivativeAssetFairValueGrossLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R56": { "role": "http://www.vrtx.com/role/InventoriesDetails", "longName": "9954502 - Disclosure - Inventories (Details)", "shortName": "Inventories (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:InventoryRawMaterialsNetOfReserves", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfInventoryCurrentTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "longName": "9954503 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Stock-based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails", "longName": "9954504 - Disclosure - Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "shortName": "Stock-based Compensation Expense and Share Repurchase Programs - Additional Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-202", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.vrtx.com/role/IncomeTaxesDetails", "longName": "9954505 - Disclosure - Income Taxes (Details)", "shortName": "Income Taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R60": { "role": "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "longName": "9954506 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "vrtx:IndemnificationClaims", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "vrtx:IndemnificationClaims", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } }, "R61": { "role": "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "longName": "9954507 - Disclosure - Additional Cash Flow Information (Details)", "shortName": "Additional Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-19", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "unique": true } }, "R62": { "role": "http://www.vrtx.com/role/SubsequentEventsDetails", "longName": "9954508 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-210", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-210", "name": "us-gaap:PaymentsToAcquireBusinessesGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "vrtx-20240331.htm", "first": true, "unique": true } } }, "tag": { "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "currency_AUD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AUD", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australian dollar", "label": "Australia, Dollars" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Accounting Policies [Abstract]", "label": "Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r25", "r650" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r224", "r225" ] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "On Foreign Currency Forward Contracts", "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r155", "r162", "r163", "r396", "r625", "r755" ] }, "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "On Available-For-Sale Debt Securities", "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]", "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r150", "r151", "r152", "r155", "r162", "r163", "r755" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r161", "r162", "r423", "r424", "r425", "r426", "r427", "r428" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income (loss)", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r33", "r34", "r90", "r143", "r485", "r507", "r508" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r161", "r162", "r423", "r424", "r425", "r426", "r427", "r428" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "verboseLabel": "Total", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r12", "r34", "r402", "r405", "r434", "r503", "r504", "r755", "r756", "r757", "r762", "r763", "r764" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign Currency Translation Adjustment", "verboseLabel": "Foreign Currency Forward Contract", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r5", "r12", "r34", "r162", "r163", "r424", "r425", "r426", "r427", "r428", "r755" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r704" ] }, "us-gaap_AdditionalFinancialInformationDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalFinancialInformationDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Cash Flow Information", "label": "Additional Financial Information Disclosure [Text Block]", "documentation": "The entire disclosures of supplemental information, including descriptions and amounts, related to the balance sheet, income statement, and/or cash flow statement." } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r79" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r368", "r369", "r370", "r513", "r762", "r763", "r764", "r794", "r816" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r710" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r710" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r710" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r710" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:", "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock withheld for employee tax obligations", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r50", "r51", "r332" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r675", "r686", "r696", "r721" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r678", "r689", "r699", "r724" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r710" ] }, "currency_AllCurrenciesDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "AllCurrenciesDomain", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "All Currencies [Domain]", "label": "All Currencies [Domain]" } } }, "auth_ref": [] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r717" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r682", "r690", "r700", "r717", "r725", "r729", "r737" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r735" ] }, "us-gaap_AllocatedShareBasedCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense included in costs and expenses", "label": "Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } }, "auth_ref": [ "r363", "r371" ] }, "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllocatedShareBasedCompensationExpenseNetOfTax", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total stock-based compensation expense, net of tax", "label": "Share-Based Payment Arrangement, Expense, after Tax", "documentation": "Amount, after tax, of expense for award under share-based payment arrangement." } } }, "auth_ref": [] }, "vrtx_AlpineMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "AlpineMember", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Alpine", "label": "Alpine [Member]", "documentation": "Alpine" } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive securities excluded from computation of earnings per share (in shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r202" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r41" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r41" ] }, "us-gaap_AssetBackedSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetBackedSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Asset-backed securities", "label": "Asset-Backed Securities [Member]", "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans." } } }, "auth_ref": [ "r643", "r770", "r771", "r772" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r115", "r141", "r176", "r207", "r214", "r218", "r260", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r394", "r397", "r421", "r480", "r546", "r650", "r666", "r786", "r787", "r801" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Assets", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r136", "r145", "r176", "r260", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r394", "r397", "r421", "r650", "r786", "r787", "r801" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r73" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments carried at fair value (asset positions):", "label": "Assets, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r231" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "verboseLabel": "Unrealized loss", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r232" ] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r228", "r268", "r479" ] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matures after five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r237", "r478" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matures after one year through five years", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r236", "r477" ] }, "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Matures within one year", "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One", "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r235", "r476" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "totalLabel": "Total", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r229", "r268", "r471", "r768" ] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r732" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r733" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r728" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r728" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": [ "r728" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": [ "r728" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": [ "r728" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": [ "r728" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AwardTypeAxis", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": [ "r731" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": [ "r730" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": [ "r729" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": [ "r729" ] }, "us-gaap_BalanceSheetLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationAxis", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Axis]", "label": "Balance Sheet Location [Axis]", "documentation": "Information by location on balance sheet (statement of financial position)." } } }, "auth_ref": [] }, "us-gaap_BalanceSheetLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BalanceSheetLocationDomain", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Balance Sheet Location [Domain]", "label": "Balance Sheet Location [Domain]", "documentation": "Location in the balance sheet (statement of financial position)." } } }, "auth_ref": [ "r61", "r66" ] }, "us-gaap_BaseRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BaseRateMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Base Rate", "label": "Base Rate [Member]", "documentation": "Minimum rate investor will accept." } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "vrtx_BruceSachsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "BruceSachsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Bruce Sachs [Member]", "documentation": "Bruce Sachs" } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": [ "r389", "r646", "r647" ] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessAcquisitionAxis", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": [ "r52", "r53", "r389", "r646", "r647" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/FairValueMeasurementsScheduleofFairValueofOurContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Change in fair value of contingent consideration", "netLabel": "Decrease in fair value of contingent consideration", "terseLabel": "Decrease in fair value of contingent payments", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability", "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement." } } }, "auth_ref": [ "r392", "r759" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsScheduleofFairValueofOurContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": [ "r1", "r54", "r391" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration, measurement input (percent)", "label": "Business Combination, Contingent Consideration, Liability, Measurement Input", "documentation": "Value of input used to measure contingent consideration liability from business combination." } } }, "auth_ref": [ "r416" ] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r2", "r54" ] }, "vrtx_BusinessCombinationRemainingMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "BusinessCombinationRemainingMilestonePayment", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining milestone payment", "label": "Business Combination, Remaining Milestone Payment", "documentation": "Business Combination, Remaining Milestone Payment" } } }, "auth_ref": [] }, "currency_CAD": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CAD", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Canadian dollar", "label": "Canada, Dollars" } } }, "auth_ref": [] }, "currency_CHF": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "CHF", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Swiss Franc", "label": "Switzerland, Francs" } } }, "auth_ref": [] }, "vrtx_CRISPRJDCAMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CRISPRJDCAMember", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR JDCA", "label": "CRISPR JDCA [Member]", "documentation": "CRISPR joint development and commercialization agreement" } } }, "auth_ref": [] }, "vrtx_CRISPRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CRISPRMember", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR", "label": "CRISPR [Member]", "documentation": "CRISPR" } } }, "auth_ref": [] }, "vrtx_CRISPRT1DMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CRISPRT1DMember", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR T1D", "label": "CRISPR T1D [Member]", "documentation": "CRISPR T1D" } } }, "auth_ref": [] }, "vrtx_CRISPRTherapeuticsAGMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CRISPRTherapeuticsAGMember", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "CRISPR Therapeutics", "label": "CRISPR Therapeutics AG [Member]", "documentation": "CRISPR Therapeutics AG" } } }, "auth_ref": [] }, "vrtx_CarmenBozicMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CarmenBozicMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Carmen Bozic [Member]", "documentation": "Carmen Bozic" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r39", "r138", "r617" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [] }, "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable Securities and Equity Investments", "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]", "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)." } } }, "auth_ref": [ "r767" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents and restricted cash\u2014beginning of period", "periodEndLabel": "Cash, cash equivalents and restricted cash\u2014end of period", "totalLabel": "Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r99", "r175" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r99" ] }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSale", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_CashEquivalentsDebtAndEquitySecuritiesCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Cash Equivalents And Debt Securities, Available for Sale", "documentation": "Cash Equivalents And Debt Securities, Available for Sale" } } }, "auth_ref": [] }, "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CashEquivalentsAndDebtSecuritiesAvailableForSaleFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_CashEquivalentsAndDebtSecuritiesAvailableForSale", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure", "documentation": "Cash Equivalents And Debt Securities, Available for Sale, Fair Value Disclosure" } } }, "auth_ref": [] }, "vrtx_CashEquivalentsDebtAndEquitySecuritiesCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CashEquivalentsDebtAndEquitySecuritiesCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Total cash equivalents and marketable securities, Amortized Cost", "label": "Cash Equivalents, Debt and Equity Securities, Cost", "documentation": "Cash Equivalents, Debt and Equity Securities, Cost" } } }, "auth_ref": [] }, "vrtx_CashEquivalentsDebtAndEquitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CashEquivalentsDebtAndEquitySecuritiesFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_CashEquivalentsDebtAndEquitySecuritiesCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash equivalents and marketable securities, Fair Value", "label": "Cash Equivalents, Debt and Equity Securities, Fair Value", "documentation": "Cash Equivalents, Debt and Equity Securities, Fair Value" } } }, "auth_ref": [] }, "vrtx_CashEquivalentsDebtAndEquitySecuritiesUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CashEquivalentsDebtAndEquitySecuritiesUnrealizedGain", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_CashEquivalentsDebtAndEquitySecuritiesCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash equivalents and marketable securities, Gross Unrealized Gains", "label": "Cash Equivalents, Debt and Equity Securities, Unrealized Gain", "documentation": "Cash Equivalents, Debt and Equity Securities, Unrealized Gain" } } }, "auth_ref": [] }, "vrtx_CashEquivalentsDebtAndEquitySecuritiesUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CashEquivalentsDebtAndEquitySecuritiesUnrealizedLoss", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_CashEquivalentsDebtAndEquitySecuritiesCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total cash equivalents and marketable securities, Gross Unrealized Losses", "label": "Cash Equivalents, Debt and Equity Securities, Unrealized Loss", "documentation": "Cash Equivalents, Debt and Equity Securities, Unrealized Loss" } } }, "auth_ref": [] }, "us-gaap_CashFlowHedgingMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowHedgingMember", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Cash Flow Hedging", "label": "Cash Flow Hedging [Member]", "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk." } } }, "auth_ref": [ "r59" ] }, "us-gaap_CertificatesOfDepositMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CertificatesOfDepositMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Certificates of deposit", "label": "Certificates of Deposit [Member]", "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured." } } }, "auth_ref": [ "r10", "r657", "r658", "r659", "r660" ] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": [ "r708" ] }, "vrtx_CharlesFWagnerJrMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CharlesFWagnerJrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Charles F. Wagner, Jr. [Member]", "documentation": "Charles F. Wager, Jr. [Member]" } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": [ "r709" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": [ "r709" ] }, "vrtx_CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementAllocationOfNetProfitsAndLossesPercent", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allocation of net profits and net losses, percent", "label": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent", "documentation": "Collaborative Arrangement, Allocation Of Net Profits And Losses, Percent" } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementAllocationOfResearchAndDevelopmentExpensesPercent": { "xbrltype": "percentItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementAllocationOfResearchAndDevelopmentExpensesPercent", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, allocation of research and development expenses, percent", "label": "Collaborative Arrangement, Allocation Of Research And Development Expenses, Percent", "documentation": "Collaborative Arrangement, Allocation Of Research And Development Expenses, Percent" } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementDevelopmentAndRegulatoryPotentialMilestonePaymentsMaximum", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, development and regulatory potential milestone payments maximum", "label": "Collaborative Arrangement Development And Regulatory Potential Milestone Payments Maximum", "documentation": "Represents the potential milestone amount to be paid by the entity under the collaboration agreement if drug candidates are approved and commercialized." } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration, License and Other Arrangements", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r124", "r126", "r133" ] }, "vrtx_CollaborativeArrangementMilestonePayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementMilestonePayment", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "label": "Collaborative Arrangement, Milestone Payment", "documentation": "Collaborative Arrangement, Milestone Payment" } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementRightToLicenseNumberOfTargets": { "xbrltype": "integerItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementRightToLicenseNumberOfTargets", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative arrangement, right to exclusively license, number of targets", "label": "Collaborative Arrangement, Right To License, Number Of Targets", "documentation": "Collaborative Arrangement, Right To License, Number Of Targets" } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementUpFrontLicenseFee": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementUpFrontLicenseFee", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Up-front payment", "label": "Collaborative Arrangement Up-front License Fee", "documentation": "Collaborative Arrangement Up-front License Fee" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r393" ] }, "vrtx_CollaborativeArrangementsByAgreementAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementsByAgreementAxis", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements by Agreement [Axis]", "label": "Collaborative Arrangements by Agreement [Axis]", "documentation": "Significant terms of collaboration arrangements, by individual agreement." } } }, "auth_ref": [] }, "vrtx_CollaborativeArrangementsByAgreementDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "CollaborativeArrangementsByAgreementDomain", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangements by Agreement [Domain]", "label": "Collaborative Arrangements by Agreement [Domain]", "documentation": "Collaborative Arrangements by Agreement [Domain]" } } }, "auth_ref": [] }, "us-gaap_CommercialPaperMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds." } } }, "auth_ref": [ "r108", "r657", "r658", "r659", "r660" ] }, "us-gaap_CommercialPaperNotIncludedWithCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommercialPaperNotIncludedWithCashAndCashEquivalentsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Commercial paper", "label": "Commercial Paper, Not Included with Cash and Cash Equivalents [Member]", "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds that is excluded from cash and cash equivalents." } } }, "auth_ref": [ "r790", "r795" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r31", "r74", "r481", "r533" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r107", "r280", "r281", "r602", "r783" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r653", "r654", "r655", "r657", "r658", "r659", "r660", "r762", "r763", "r794", "r814", "r816" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r78" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r78", "r534" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r78" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r13", "r78", "r534", "r552", "r816", "r817" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Common stock, $0.01 par value; 500,000,000 shares authorized, 258,296,249 and 257,695,221 shares issued and outstanding, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r78", "r484", "r650" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r714" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r713" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r715" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r712" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive income", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r35", "r158", "r160", "r165", "r473", "r492" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLoss" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r89", "r164", "r472", "r490" ] }, "vrtx_ContingentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "ContingentLiabilities", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent liabilities", "label": "Contingent Liabilities", "documentation": "Contingent Liabilities" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r300", "r301", "r320" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CorporateDebtSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate debt securities", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r643", "r645", "r813" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r94", "r469" ] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfSalesMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of sales", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": [ "r93" ] }, "us-gaap_CostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostsAndExpensesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityAxis", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditFacilityDomain", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": [] }, "srt_CurrencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CurrencyAxis", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Currency [Axis]", "label": "Currency [Axis]" } } }, "auth_ref": [ "r800" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "vrtx_DebtCovenantConsolidatedLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "DebtCovenantConsolidatedLeverageRatio", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, consolidated leverage ratio", "label": "Debt Covenant, Consolidated Leverage Ratio", "documentation": "Consolidated leverage ratio that must be maintained in order to be in compliance with debt covenants." } } }, "auth_ref": [] }, "vrtx_DebtCovenantIncreaseInConsolidatedLeverageRatio": { "xbrltype": "pureItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "DebtCovenantIncreaseInConsolidatedLeverageRatio", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt covenant, increase in consolidated leverage ratio", "label": "Debt Covenant, Increase In Consolidated Leverage Ratio", "documentation": "Debt Covenant, Increase In Consolidated Leverage Ratio" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on variable rate (as a percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for credit loss for available-for-sale debt securities", "label": "Debt Securities, Available-for-Sale, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r230", "r268", "r274", "r275" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of available-for-sale debt securities in unrealized loss positions for greater than 12 months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r121", "r271", "r631" ] }, "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized loss position for greater than twelve months", "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss", "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for 12 months or longer, without allowance for credit loss. Includes beneficial interest in securitized financial asset." } } }, "auth_ref": [ "r121", "r271" ] }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Realized gain (loss) amount", "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r773" ] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238" ] }, "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt securities fair value, unrealized loss position", "label": "Debt Securities, Available-for-Sale, Unrealized Loss Position", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss." } } }, "auth_ref": [ "r120", "r270", "r631" ] }, "vrtx_DebtandEquitySecuritiesCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "DebtandEquitySecuritiesCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_CashEquivalentsDebtAndEquitySecuritiesCost", "weight": 1.0, "order": 2.0 }, "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized Cost", "label": "Debt and Equity Securities, Cost", "documentation": "Debt and Equity Securities, Cost" } } }, "auth_ref": [] }, "vrtx_DebtandEquitySecuritiesFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "DebtandEquitySecuritiesFairValue", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Debt and Equity Securities, Fair Value", "documentation": "Debt and Equity Securities, Fair Value" } } }, "auth_ref": [] }, "vrtx_DebtandEquitySecuritiesUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "DebtandEquitySecuritiesUnrealizedGain", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Debt and Equity Securities, Unrealized Gain", "documentation": "Debt and Equity Securities, Unrealized Gain" } } }, "auth_ref": [] }, "vrtx_DebtandEquitySecuritiesUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "DebtandEquitySecuritiesUnrealizedLoss", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Unrealized Losses", "label": "Debt and Equity Securities, Unrealized Loss", "documentation": "Debt and Equity Securities, Unrealized Loss" } } }, "auth_ref": [] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax assets", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r374", "r375" ] }, "us-gaap_DepreciationDepletionAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization expense", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets." } } }, "auth_ref": [ "r9", "r210" ] }, "us-gaap_DerivativeAssetFairValueGrossLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueGrossLiability", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Offset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset", "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r16", "r23", "r64", "r591", "r592" ] }, "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Legal Offset", "label": "Derivative Asset, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "documentation": "Fair value, after effects of master netting arrangements, deduction of assets not subject to a master netting arrangement and elected not to be offset, of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against an obligation to return collateral." } } }, "auth_ref": [ "r18", "r21" ] }, "us-gaap_DerivativeAssetNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetNotOffsetPolicyElectionDeduction", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross Amounts Not Offset", "label": "Derivative Asset, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative asset." } } }, "auth_ref": [ "r17", "r21", "r130" ] }, "us-gaap_DerivativeAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssets", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssetFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Gross Amounts Presented", "label": "Derivative Asset", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r147", "r149", "r420", "r515", "r516", "r517", "r518", "r519", "r521", "r522", "r523", "r524", "r525", "r540", "r541", "r584", "r587", "r590", "r591", "r593", "r594", "r624", "r655", "r815" ] }, "us-gaap_DerivativeAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeAssetsCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets, foreign currency forward contracts", "label": "Derivative Asset, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r147" ] }, "us-gaap_DerivativeContractTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeContractTypeDomain", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Contract [Domain]", "label": "Derivative Contract [Domain]", "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r523", "r525", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r560", "r561", "r562", "r563", "r566", "r567", "r568", "r569", "r584", "r585", "r590", "r593", "r653", "r655" ] }, "us-gaap_DerivativeFairValueOfDerivativeAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeAsset", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeAssets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Total assets", "terseLabel": "Gross Amounts Recognized", "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r64", "r88", "r146", "r624" ] }, "us-gaap_DerivativeFairValueOfDerivativeLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFairValueOfDerivativeLiability", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Total liabilities", "negatedTerseLabel": "Gross Amounts Recognized", "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset", "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement." } } }, "auth_ref": [ "r19", "r64", "r88", "r146", "r624" ] }, "us-gaap_DerivativeInstrumentRiskAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentRiskAxis", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instrument [Axis]", "label": "Derivative Instrument [Axis]", "documentation": "Information by type of derivative contract." } } }, "auth_ref": [ "r62", "r65", "r67", "r68", "r523", "r525", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r560", "r561", "r562", "r563", "r566", "r567", "r568", "r569", "r584", "r585", "r590", "r593", "r624", "r653", "r655" ] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]", "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/Hedging" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging", "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]", "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts." } } }, "auth_ref": [ "r113", "r400", "r407" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Axis]", "label": "Hedging Relationship [Axis]", "documentation": "Information by type of hedging relationship." } } }, "auth_ref": [ "r14", "r62", "r67" ] }, "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Table]", "label": "Derivative Instruments, Gain (Loss) [Table]", "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments." } } }, "auth_ref": [ "r14", "r62", "r67", "r68", "r71", "r72", "r399" ] }, "us-gaap_DerivativeInstrumentsGainLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeInstrumentsGainLossLineItems", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]", "label": "Derivative Instruments, Gain (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r399" ] }, "us-gaap_DerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilities", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Gross Amounts Presented", "label": "Derivative Liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r147", "r149", "r420", "r515", "r516", "r517", "r518", "r521", "r522", "r523", "r524", "r525", "r547", "r549", "r550", "r585", "r586", "r587", "r590", "r591", "r593", "r594", "r624", "r815" ] }, "us-gaap_DerivativeLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_FinancialLiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other current liabilities, foreign currency forward contracts", "label": "Derivative Liability, Current", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r147" ] }, "us-gaap_DerivativeLiabilityFairValueGrossAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueGrossAsset", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Offset", "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset", "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset." } } }, "auth_ref": [ "r16", "r23", "r64", "r591", "r592", "r623" ] }, "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Legal Offset", "label": "Derivative Liability, Fair Value, Offset Against Collateral, Net of Not Subject to Master Netting Arrangement, Policy Election", "documentation": "Fair value, after effects of master netting arrangements, deduction of liabilities not subject to a master netting arrangement and elected not to be offset, of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, offset against the right to receive collateral." } } }, "auth_ref": [ "r18", "r21" ] }, "us-gaap_DerivativeLiabilityNotOffsetPolicyElectionDeduction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLiabilityNotOffsetPolicyElectionDeduction", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails": { "parentTag": "us-gaap_DerivativeLiabilityFairValueOffsetAgainstCollateralNetOfNotSubjectToMasterNettingArrangementPolicyElection", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Amounts Not Offset", "label": "Derivative Liability, Subject to Master Netting Arrangement, Deduction of Financial Instrument Not Offset", "documentation": "Fair value of financial liability or contract with one or more underlyings, notional amount or payment provision or both, and contract can be net settled by means outside contract or delivery of asset, subject to master netting arrangement or similar agreement and not elected or qualified to offset, deducted from derivative liability." } } }, "auth_ref": [ "r17", "r21", "r130" ] }, "us-gaap_DerivativeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeLineItems", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Line Items]", "label": "Derivative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r407" ] }, "us-gaap_DerivativeNotionalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeNotionalAmount", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Notional amount of foreign currency forward contract", "label": "Derivative, Notional Amount", "documentation": "Nominal or face amount used to calculate payment on derivative." } } }, "auth_ref": [ "r792", "r793" ] }, "us-gaap_DerivativeTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTable", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative [Table]", "label": "Derivative [Table]", "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item." } } }, "auth_ref": [ "r14", "r55", "r56", "r58", "r60", "r63", "r67", "r69", "r70", "r72", "r407" ] }, "us-gaap_DerivativeTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeTermOfContract", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Derivative term", "label": "Derivative, Term of Contract", "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DesignatedAsHedgingInstrumentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DesignatedAsHedgingInstrumentMember", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Designated as Hedging Instruments", "terseLabel": "Designated as hedging instruments", "label": "Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueLineItems", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r319", "r636", "r637", "r638", "r639", "r640", "r641", "r642" ] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTable", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r319", "r636", "r637", "r638", "r639", "r640", "r641", "r642" ] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Disaggregation of Revenue", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": [ "r789" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchasePrograms" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation Expense and Share Repurchase Programs", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r330", "r335", "r365", "r366", "r367", "r649" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r670" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r703" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "vrtx_EMorrowMorreyAtkinsonIIIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "EMorrowMorreyAtkinsonIIIMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "E. Morrow \"Morrey\" Atkinson III [Member]", "documentation": "Morrey Atkinson [Member]" } } }, "auth_ref": [] }, "currency_EUR": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "EUR", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro", "label": "Euro Member Countries, Euro" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Net income per common share:", "label": "Earnings Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in dollars per share)", "terseLabel": "Basic net income per common share (in dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r166", "r183", "r184", "r185", "r186", "r187", "r192", "r194", "r199", "r200", "r201", "r205", "r409", "r410", "r474", "r493", "r627" ] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Diluted (in dollars per share)", "terseLabel": "Diluted net income per common share (in dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r166", "r183", "r184", "r185", "r186", "r187", "r194", "r199", "r200", "r201", "r205", "r409", "r410", "r474", "r493", "r627" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.vrtx.com/role/EarningsPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "Earnings Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r191", "r202", "r203", "r204" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of changes in exchange rates on cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r422" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r377" ] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Stock-based compensation expense related to inventories", "label": "Share-Based Payment Arrangement, Amount Capitalized", "documentation": "Amount of cost capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r364" ] }, "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails": { "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Income tax effect", "label": "Share-Based Payment Arrangement, Expense, Tax Benefit", "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement." } } }, "auth_ref": [ "r363" ] }, "us-gaap_EmployeeStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "ESPP share issuances", "label": "Employee Stock [Member]", "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock." } } }, "auth_ref": [] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeStockOptionMember", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Stock options", "terseLabel": "Stock options", "label": "Employee Stock Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r668" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityDomain", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entity [Domain]", "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r668" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r668" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r742" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r668" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r668" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r668" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r668" ] }, "vrtx_EntradaTherapeuticsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "EntradaTherapeuticsMember", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Entrada Therapeutics", "label": "Entrada Therapeutics [Member]", "documentation": "Entrada Therapeutics" } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity [Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r13", "r134", "r161", "r162", "r163", "r178", "r179", "r180", "r182", "r188", "r190", "r206", "r261", "r262", "r299", "r368", "r369", "r370", "r382", "r383", "r401", "r402", "r403", "r404", "r405", "r406", "r408", "r423", "r424", "r425", "r426", "r427", "r428", "r434", "r503", "r504", "r505", "r513", "r572" ] }, "us-gaap_EquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNi", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value", "label": "Equity Securities, FV-NI, Current", "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current." } } }, "auth_ref": [ "r142", "r419", "r619" ] }, "us-gaap_EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiAndWithoutReadilyDeterminableFairValueAbstract", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate equity securities", "label": "Equity Securities, FV-NI and without Readily Determinable Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails_1": { "parentTag": "vrtx_DebtandEquitySecuritiesCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortized Cost", "label": "Equity Securities, FV-NI, Cost", "documentation": "Cost of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI). Excludes equity method investment and investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r479" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGain": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGain", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Unrealized Gains", "label": "Equity Securities, FV-NI, Unrealized Gain", "documentation": "Amount of unrealized gain on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r259" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedGainLoss", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Losses (gains) on equity securities", "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)", "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r494", "r777" ] }, "us-gaap_EquitySecuritiesFvNiUnrealizedLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiUnrealizedLoss", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Gross Unrealized Losses", "label": "Equity Securities, FV-NI, Unrealized Loss", "documentation": "Amount of unrealized loss on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r259" ] }, "us-gaap_EquitySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate equity securities", "label": "Equity Securities [Member]", "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants." } } }, "auth_ref": [ "r45", "r661", "r662", "r663", "r819" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Equity securities without readily determinable fair value, amount", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "documentation": "Amount of investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r257" ] }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueDownwardPriceAdjustmentCumulativeAmount", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reduction in carrying value of equity investments without readily determinable fair value, based on an observable price decrease", "label": "Equity Securities without Readily Determinable Fair Value, Downward Price Adjustment, Cumulative Amount", "documentation": "Amount of cumulative loss from downward price adjustment on investment in equity security without readily determinable fair value." } } }, "auth_ref": [ "r258" ] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } }, "auth_ref": [ "r711" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": [ "r675", "r686", "r696", "r721" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "srt_EuropeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EuropeMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Europe", "label": "Europe [Member]" } } }, "auth_ref": [ "r818", "r820", "r821", "r822" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r717" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r412", "r413", "r417" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r412", "r413", "r417" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r295", "r323", "r324", "r325", "r326", "r327", "r328", "r413", "r441", "r442", "r443", "r633", "r634", "r643", "r644", "r645" ] }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value by Measurement Frequency [Axis]", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, "auth_ref": [ "r412", "r413", "r415", "r416", "r418" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurements" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r411" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a01", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r295", "r323", "r328", "r413", "r441", "r643", "r644", "r645" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a02", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r295", "r323", "r328", "r413", "r442", "r633", "r634", "r643", "r644", "r645" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level\u00a03", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r295", "r323", "r324", "r325", "r326", "r327", "r328", "r413", "r443", "r633", "r634", "r643", "r644", "r645" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsScheduleofFairValueofOurContingentConsiderationLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementFrequencyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementFrequencyDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Frequency [Domain]", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r295", "r323", "r324", "r325", "r326", "r327", "r328", "r441", "r442", "r443", "r633", "r634", "r643", "r644", "r645" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementsRecurringMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Recurring Basis", "label": "Fair Value, Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": [ "r411", "r418" ] }, "us-gaap_FinanceLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term finance lease liabilities", "label": "Finance Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent." } } }, "auth_ref": [ "r431" ] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments on finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r432", "r433" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r263", "r264", "r265", "r266", "r267", "r269", "r272", "r273", "r296", "r298", "r407", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r491", "r631", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r773", "r774", "r775", "r776" ] }, "us-gaap_FinancialLiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FinancialLiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "negatedTotalLabel": "Total financial liabilities", "label": "Financial Liabilities Fair Value Disclosure", "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities." } } }, "auth_ref": [] }, "us-gaap_ForeignExchangeForwardMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignExchangeForwardMember", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency forward contracts", "label": "Foreign Exchange Forward [Member]", "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate." } } }, "auth_ref": [ "r540", "r544", "r549", "r562", "r568", "r588", "r589", "r590", "r655" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r679", "r690", "r700", "r725" ] }, "currency_GBP": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/currency/2023", "localname": "GBP", "presentation": [ "http://www.vrtx.com/role/HedgingNotionalAmountDetails" ], "lang": { "en-us": { "role": { "terseLabel": "British pound sterling", "label": "United Kingdom, Pounds" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill", "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r139", "r277", "r470", "r632", "r650", "r779", "r780" ] }, "us-gaap_HedgingDesignationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationAxis", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Axis]", "label": "Hedging Designation [Axis]", "documentation": "Information by designation of purpose of derivative instrument." } } }, "auth_ref": [ "r14", "r399" ] }, "us-gaap_HedgingDesignationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingDesignationDomain", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Designation [Domain]", "label": "Hedging Designation [Domain]", "documentation": "Designation of purpose of derivative instrument." } } }, "auth_ref": [ "r14" ] }, "us-gaap_HedgingRelationshipDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HedgingRelationshipDomain", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails", "http://www.vrtx.com/role/HedgingNotionalAmountDetails", "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hedging Relationship [Domain]", "label": "Hedging Relationship [Domain]", "documentation": "Nature or intent of a hedge." } } }, "auth_ref": [ "r14" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Income before provision for income taxes", "terseLabel": "Income before provision for income taxes", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r0", "r91", "r117", "r207", "r213", "r217", "r219", "r475", "r488", "r629" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Statement Location [Axis]", "label": "Income Statement Location [Axis]", "documentation": "Information by location in the income statement." } } }, "auth_ref": [ "r278", "r279", "r557" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Income Statement Location [Domain]", "label": "Income Statement Location [Domain]", "documentation": "Location in the income statement." } } }, "auth_ref": [ "r279", "r557" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r177", "r373", "r378", "r380", "r381", "r384", "r386", "r387", "r388", "r512" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Provision for income taxes", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r123", "r131", "r189", "r190", "r211", "r376", "r385", "r495" ] }, "us-gaap_IncomeTaxesPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid, Net", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes." } } }, "auth_ref": [ "r40" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Accounts receivable, net", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities", "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other." } } }, "auth_ref": [ "r759" ] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 9.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Inventories", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOtherDeferredLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherDeferredLiability", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred income taxes", "label": "Increase (Decrease) in Other Deferred Liability", "documentation": "Amount of increase (decrease) in deferred obligations classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOtherOperatingLiabilities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Increase (Decrease) in Other Operating Liabilities", "documentation": "Amount of increase (decrease) in operating liabilities classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 10.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (Decrease) in Stockholders' Equity", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToEquityUnitPurchaseAgreements", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock purchase program (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Equity Unit Purchase Agreements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of equity unit purchase agreements using the treasury stock method." } } }, "auth_ref": [ "r195", "r196", "r201" ] }, "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based payment arrangements (in shares)", "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements", "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method." } } }, "auth_ref": [ "r195", "r196", "r197", "r201", "r334" ] }, "vrtx_IndemnificationClaims": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "IndemnificationClaims", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Indemnification claims", "label": "Indemnification Claims", "documentation": "Amount of indemnification claims currently outstanding" } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r682", "r690", "r700", "r717", "r725", "r729", "r737" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r735" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r671", "r741" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r671", "r741" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r671", "r741" ] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other intangible assets, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r46", "r48" ] }, "us-gaap_InterestIncomeExpenseNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestIncomeExpenseNet", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense", "label": "Interest Income (Expense), Net", "documentation": "The net amount of operating interest income (expense)." } } }, "auth_ref": [ "r119" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r170", "r173", "r174" ] }, "us-gaap_InventoryDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Inventory Disclosure [Abstract]", "label": "Inventory Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InventoryDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryDisclosureTextBlock", "presentation": [ "http://www.vrtx.com/role/Inventories" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "label": "Inventory Disclosure [Text Block]", "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory." } } }, "auth_ref": [ "r276" ] }, "us-gaap_InventoryFinishedGoodsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryFinishedGoodsNetOfReserves", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finished goods", "label": "Inventory, Finished Goods, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale." } } }, "auth_ref": [ "r106", "r620" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 }, "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inventories", "totalLabel": "Total", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r144", "r618", "r650" ] }, "us-gaap_InventoryRawMaterialsNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryRawMaterialsNetOfReserves", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Raw materials", "label": "Inventory, Raw Materials, Net of Reserves", "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process." } } }, "auth_ref": [ "r106", "r622" ] }, "us-gaap_InventoryWorkInProcessNetOfReserves": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryWorkInProcessNetOfReserves", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/InventoriesDetails": { "parentTag": "us-gaap_InventoryNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/InventoriesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Work-in-process", "label": "Inventory, Work in Process, Net of Reserves", "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing." } } }, "auth_ref": [ "r106", "r621" ] }, "us-gaap_InvestmentIncomeInterestAndDividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [ "r96" ] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "vrtx_JonathanBillerMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "JonathanBillerMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Jonathan Biller [Member]", "documentation": "Jonathan Biller" } } }, "auth_ref": [] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LegalEntityAxis", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal Entity [Axis]", "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "us-gaap_LetterOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LetterOfCreditMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Letters of Credit", "label": "Letter of Credit [Member]", "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)." } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r27", "r176", "r260", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r395", "r397", "r398", "r421", "r532", "r628", "r666", "r786", "r801", "r802" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and shareholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r83", "r116", "r487", "r650", "r761", "r778", "r797" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Liabilities and Shareholders\u2019 Equity", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r29", "r137", "r176", "r260", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r395", "r397", "r398", "r421", "r650", "r786", "r801", "r802" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial instruments carried at fair value (liability positions):", "label": "Liabilities, Fair Value Disclosure [Abstract]" } } }, "auth_ref": [] }, "vrtx_LineOfCreditFacilityAdditionalBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "LineOfCreditFacilityAdditionalBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility additional borrowing capacity", "label": "Line Of Credit Facility Additional Borrowing Capacity", "documentation": "Amount of increased borrowing capacity available in the future." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityLineItems", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Line Items]", "label": "Line of Credit Facility [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r760" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, maximum borrowing capacity", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LineOfCreditFacilityTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityTable", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit Facility [Table]", "label": "Line of Credit Facility [Table]", "documentation": "A table or schedule providing information pertaining to short-term or long-term contractual arrangements with lenders, including letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line." } } }, "auth_ref": [ "r26", "r760" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_MarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecurities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities:", "label": "Marketable Securities", "documentation": "Amount of investment in marketable security." } } }, "auth_ref": [ "r75", "r753" ] }, "vrtx_MarketableSecuritiesAndOtherNoncurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "MarketableSecuritiesAndOtherNoncurrentAssetsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total marketable available-for-sale debt securities", "label": "Marketable Securities And Other Noncurrent Assets [Member]", "documentation": "Marketable Securities And Other Noncurrent Assets" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r753" ] }, "vrtx_MarketableSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "MarketableSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Marketable securities", "label": "Marketable Securities [Member]", "documentation": "Marketable Securities [Member]" } } }, "auth_ref": [] }, "us-gaap_MarketableSecuritiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MarketableSecuritiesNoncurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Marketable Securities, Noncurrent", "documentation": "Amount of investment in marketable security, classified as noncurrent." } } }, "auth_ref": [ "r753" ] }, "vrtx_MarketableSecuritiesNoncurrentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "MarketableSecuritiesNoncurrentMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term marketable securities", "label": "Marketable Securities, Noncurrent [Member]", "documentation": "Marketable Securities, Noncurrent" } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r329", "r468", "r502", "r524", "r525", "r575", "r578", "r580", "r581", "r595", "r612", "r613", "r630", "r635", "r648", "r652", "r788", "r803", "r804", "r805", "r806", "r807", "r808" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r709" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r709" ] }, "us-gaap_MeasurementInputDiscountRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputDiscountRateMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Discount Rate", "label": "Measurement Input, Discount Rate [Member]", "documentation": "Measurement input using interest rate to determine present value of future cash flows." } } }, "auth_ref": [ "r796" ] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Axis]", "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r414" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Measurement Input Type [Domain]", "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r329", "r468", "r502", "r524", "r525", "r575", "r578", "r580", "r581", "r595", "r612", "r613", "r630", "r635", "r648", "r652", "r788", "r803", "r804", "r805", "r806", "r807", "r808" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r728" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r736" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r710" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r172" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r172" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r99", "r100", "r101" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net income", "terseLabel": "Net income", "verboseLabel": "Net income", "netLabel": "Net income", "label": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r92", "r101", "r118", "r135", "r156", "r159", "r163", "r176", "r181", "r183", "r184", "r185", "r186", "r189", "r190", "r198", "r207", "r213", "r217", "r219", "r260", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r410", "r421", "r489", "r554", "r570", "r571", "r629", "r664", "r786" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recently Adopted and Recently Issued Accounting Standards", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r709" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r679", "r690", "r700", "r717", "r725" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r707" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r706" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r717" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r736" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r736" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonUsMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total product revenues outside of the United States", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r818", "r820", "r821", "r822" ] }, "us-gaap_NondesignatedMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NondesignatedMember", "presentation": [ "http://www.vrtx.com/role/HedgingAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Not Designated as Hedging Instrument", "terseLabel": "Not designated as hedging instruments", "label": "Not Designated as Hedging Instrument [Member]", "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP)." } } }, "auth_ref": [ "r14" ] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of operating segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r766" ] }, "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss) before reclassifications", "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent", "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent." } } }, "auth_ref": [ "r22", "r34" ] }, "us-gaap_OffsettingAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingAssetsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Offsetting Assets", "label": "Offsetting Assets [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial assets that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r87", "r148" ] }, "us-gaap_OffsettingDerivativeAssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeAssetsAbstract", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total assets", "label": "Offsetting Derivative Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OffsettingDerivativeLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingDerivativeLiabilitiesAbstract", "presentation": [ "http://www.vrtx.com/role/HedgingOffsettingDerivativesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total liabilities", "label": "Offsetting Derivative Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OffsettingLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OffsettingLiabilitiesTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Offsetting Liabilities", "label": "Offsetting Liabilities [Table Text Block]", "documentation": "Tabular disclosure of derivative and other financial liabilities that are subject to offsetting, including master netting arrangements." } } }, "auth_ref": [ "r87", "r148" ] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "totalLabel": "Income from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r207", "r213", "r217", "r219", "r629" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r431" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r430" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation and Accounting Policies", "label": "Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block]", "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles." } } }, "auth_ref": [ "r102", "r103", "r104", "r111" ] }, "us-gaap_OtherAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsMember", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Other Assets", "label": "Other Assets [Member]", "documentation": "Primary financial statement caption encompassing other assets." } } }, "auth_ref": [ "r61", "r71" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r140" ] }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding (losses) gains on available-for-sale debt securities, net of tax of $5.4 and $(0.8), respectively", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent." } } }, "auth_ref": [ "r7", "r11", "r112" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity." } } }, "auth_ref": [ "r7", "r11", "r112" ] }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized holding (losses) gains on marketable securities, tax", "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment, Tax", "documentation": "Amount, after adjustment, of tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r150", "r151", "r154" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTaxParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, net of tax of $(12.3) and $7.4, respectively", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent", "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r153" ] }, "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTaxParent", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Unrealized gains (losses) on foreign currency forward contracts, tax", "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax, Parent", "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent." } } }, "auth_ref": [ "r154" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss):", "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 }, "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofComprehensiveIncome", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total other comprehensive income (loss)", "verboseLabel": "Other comprehensive (loss) income, net of tax", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r7", "r11", "r112", "r157", "r160" ] }, "us-gaap_OtherCurrentLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherCurrentLiabilitiesMember", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Current Liabilities [Member]", "documentation": "Primary financial statement caption encompassing other current liabilities." } } }, "auth_ref": [] }, "vrtx_OtherCysticFibrosisProductsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "OtherCysticFibrosisProductsMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other CF products", "label": "Other Cystic Fibrosis Products [Member]", "documentation": "Other Cystic Fibrosis Products" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other current liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r28", "r650" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "vrtx_OtherNonU.S.Member": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "OtherNonU.S.Member", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other, Non U.S. [Member]", "documentation": "Other, Non U.S. [Member]" } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash items, net", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r101" ] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other (expense) income, net", "verboseLabel": "Other (expense) income, net", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r97" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r709" ] }, "vrtx_OuraniaNiaTatsisMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "OuraniaNiaTatsisMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Ourania \"Nia\" Tatsis [Member]", "documentation": "Ourania \"Nia\" Tatsis" } } }, "auth_ref": [] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r677", "r688", "r698", "r723" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r680", "r691", "r701", "r726" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r680", "r691", "r701", "r726" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r705" ] }, "vrtx_PaymentToAcquireCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "PaymentToAcquireCommonStock", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of common stock", "label": "Payment To Acquire Common Stock", "documentation": "Payment To Acquire Common Stock" } } }, "auth_ref": [] }, "us-gaap_PaymentsForRepurchaseOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForRepurchaseOfCommonStock", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of common stock", "label": "Payments for Repurchase of Common Stock", "documentation": "The cash outflow to reacquire common stock during the period." } } }, "auth_ref": [ "r38" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payments in connection with common stock withheld for employee tax obligations", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r169" ] }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of available-for-sale debt securities", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r36", "r167", "r226" ] }, "us-gaap_PaymentsToAcquireBusinessesGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireBusinessesGross", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Payments to acquire business in cash", "label": "Payments to Acquire Businesses, Gross", "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price." } } }, "auth_ref": [ "r37", "r390" ] }, "us-gaap_PaymentsToAcquireEquitySecuritiesFvNi": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquireEquitySecuritiesFvNi", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Investment in equity securities", "label": "Payments to Acquire Equity Securities, FV-NI", "documentation": "Amount of cash outflow to acquire investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as investing activity." } } }, "auth_ref": [ "r122", "r171" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r98" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": [ "r708" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r708" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r707" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": [ "r717" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": [ "r710" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r706" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r77", "r297" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r77", "r534" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r77", "r297" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r77", "r534", "r552", "r816", "r817" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "verboseLabel": "Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r77", "r483", "r650" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r754" ] }, "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpensesAndOtherCurrentAssetsMember", "presentation": [ "http://www.vrtx.com/role/HedgingDerivativeFairValueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expenses and Other Current Assets [Member]", "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Issuances of common stock under benefit plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": [ "r6", "r15" ] }, "vrtx_ProceedsFromPaymentsForFiniteLivedIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "ProceedsFromPaymentsForFiniteLivedIntangibleAssets", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Net payments related to finite-lived intangible assets", "label": "Proceeds From (Payments For) Finite-Lived Intangible Assets", "documentation": "Proceeds From (Payments For) Finite-Lived Intangible Assets" } } }, "auth_ref": [] }, "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromPaymentsForOtherFinancingActivities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Other financing activities", "label": "Proceeds from (Payments for) Other Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities classified as other." } } }, "auth_ref": [ "r743", "r758" ] }, "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Sales and maturities of available-for-sale debt securities", "label": "Proceeds from Sale and Maturity of Debt Securities, Available-for-Sale", "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": [ "r167", "r168", "r769" ] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductOrServiceAxis", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Axis]", "label": "Product and Service [Axis]" } } }, "auth_ref": [ "r220", "r469", "r496", "r497", "r498", "r499", "r500", "r501", "r615", "r636", "r651", "r745", "r784", "r785", "r789", "r812" ] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ProductsAndServicesDomain", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product and Service [Domain]", "label": "Product and Service [Domain]" } } }, "auth_ref": [ "r220", "r469", "r496", "r497", "r498", "r499", "r500", "r501", "r615", "r636", "r651", "r745", "r784", "r785", "r789", "r812" ] }, "us-gaap_PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, net", "label": "Property, Plant, and Equipment and Finance Lease Right-of-Use Asset, after Accumulated Depreciation and Amortization", "documentation": "Amount, after accumulated depreciation and amortization, of property, plant, and equipment and finance lease right-of-use asset." } } }, "auth_ref": [ "r744", "r781" ] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": [ "r705" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": [ "r705" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r322", "r329", "r358", "r359", "r360", "r444", "r468", "r502", "r524", "r525", "r575", "r578", "r580", "r581", "r595", "r612", "r613", "r630", "r635", "r648", "r652", "r655", "r782", "r788", "r804", "r805", "r806", "r807", "r808" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails", "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/HedgingAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r282", "r283", "r284", "r285", "r322", "r329", "r358", "r359", "r360", "r444", "r468", "r502", "r524", "r525", "r575", "r578", "r580", "r581", "r595", "r612", "r613", "r630", "r635", "r648", "r652", "r655", "r782", "r788", "r804", "r805", "r806", "r807", "r808" ] }, "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails": { "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive income (loss)", "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent", "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent." } } }, "auth_ref": [ "r22", "r34" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeAxis", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Axis]", "documentation": "Information by item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeDomain", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "label": "Reclassification out of Accumulated Other Comprehensive Income [Domain]", "documentation": "Item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income", "label": "Reclassification out of Accumulated Other Comprehensive Income [Member]", "documentation": "Identifies item reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r163" ] }, "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Exchange Contracts, Condensed Consolidated Statements of Operations", "label": "Reclassification out of Accumulated Other Comprehensive Income [Table Text Block]", "documentation": "Tabular disclosure of information about items reclassified out of accumulated other comprehensive income (loss)." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": [ "r672", "r683", "r693", "r718" ] }, "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Acquired in-process research and development expenses", "label": "Research and Development Asset Acquired Other than Through Business Combination, Writeoff", "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination." } } }, "auth_ref": [ "r47", "r791" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r76", "r372", "r809" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "verboseLabel": "Research and development expenses", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r791" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "vrtx_ReshmaKewalramaniMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "ReshmaKewalramaniMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Reshma Kewalramani [Member]", "documentation": "Reshma Kewalramani [Member]" } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": [ "r673", "r684", "r694", "r719" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": [ "r674", "r685", "r695", "r720" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": [ "r681", "r692", "r702", "r727" ] }, "us-gaap_RestrictedCashAndCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCashAndCashEquivalents", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Restricted Cash and Cash Equivalents", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r39", "r114", "r138", "r175", "r482" ] }, "us-gaap_RestrictedInvestmentsAtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedInvestmentsAtFairValue", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of equity securities", "label": "Restricted Investments, at Fair Value", "documentation": "The aggregate value of all restricted investments." } } }, "auth_ref": [ "r577", "r582", "r596", "r600", "r601" ] }, "us-gaap_RestrictedStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "verboseLabel": "Restricted stock units (including performance-based restricted stock units (\u201cPSUs\u201d))", "label": "Restricted Stock [Member]", "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met." } } }, "auth_ref": [ "r41" ] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedStockUnitsRSUMember", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted stock units (including performance-based restricted stock units (\u201cPSUs\u201d))", "verboseLabel": "Unvested restricted stock units (including PSUs)", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Retained earnings", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r80", "r109", "r486", "r506", "r508", "r511", "r535", "r650" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Retained Earnings", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r134", "r178", "r179", "r180", "r182", "r188", "r190", "r261", "r262", "r368", "r369", "r370", "r382", "r383", "r401", "r403", "r404", "r406", "r408", "r503", "r505", "r513", "r816" ] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails", "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Product revenues, net", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r208", "r209", "r212", "r215", "r216", "r220", "r221", "r223", "r318", "r319", "r469" ] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Contract Liabilities", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": [ "r132", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r614" ] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": [ "http://www.vrtx.com/role/RevenueRecognition" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": [ "r132", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r321" ] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevolvingCreditFacilityMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r736" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r736" ] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r34", "r798", "r799" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareAntidilutiveSecuritiesDetails", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Gross Common Equivalent Shares", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r41" ] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesatFairValueDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAvailableforSaleDebtSecuritiesbyContractualMaturityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-sale [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238" ] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Fair Value of Our Contingent Consideration Liabilities", "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]", "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesLineItems", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Summary of cash, cash equivalents and marketable securities", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Line Items]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": [] }, "vrtx_ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "ScheduleOfCashCashEquivalentsAndAvailableForSaleSecuritiesTable", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsAdditionalInformationDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "label": "Schedule of Cash, Cash Equivalents and Available-for-sale Securities [Table]", "documentation": "Schedule of the cash and cash equivalents and available-for-sale investments held by the entity." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Equivalents and Marketable Debt and Equity Securities", "label": "Cash, Cash Equivalents and Investments [Table Text Block]", "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r393" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Provision for (Benefits from) Income Taxes and Effective Tax rates", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r110" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Computation of Basic and Diluted Net Income Per Common Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r765" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-based Compensation Expense by Line Item", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r49" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Financial Assets Subject to Fair Value Measurements", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r412", "r413" ] }, "us-gaap_ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfForeignExchangeContractsStatementOfFinancialPositionTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Foreign Exchange Contracts", "label": "Schedule of Foreign Exchange Contracts, Statement of Financial Position [Table Text Block]", "documentation": "Tabular disclosure of the presentation of foreign exchange contracts on the statement of financial position, including the fair value amounts and location of such amounts." } } }, "auth_ref": [ "r65" ] }, "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfInventoryCurrentTableTextBlock", "presentation": [ "http://www.vrtx.com/role/InventoriesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Inventories by Type", "label": "Schedule of Inventory, Current [Table Text Block]", "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process." } } }, "auth_ref": [ "r24", "r84", "r85", "r86" ] }, "us-gaap_ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfNotionalAmountsOfOutstandingDerivativePositionsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/HedgingTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash Flow Hedging Instruments", "label": "Schedule of Notional Amounts of Outstanding Derivative Positions [Table Text Block]", "documentation": "Tabular disclosure of the notional amounts of outstanding derivative positions." } } }, "auth_ref": [ "r57" ] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": [ "http://www.vrtx.com/role/AdditionalCashFlowInformationTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restricted Cash", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": [ "r20", "r114", "r811" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r331", "r333", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "vrtx_SecuredOvernightFinancingRateSOFRMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "SecuredOvernightFinancingRateSOFRMember", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "SOFR Loan", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Secured Overnight Financing Rate (SOFR)" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r667" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r669" ] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]" } } }, "auth_ref": [ "r221", "r222", "r517", "r520", "r522", "r576", "r579", "r583", "r597", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r616", "r637", "r655", "r789", "r812" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CollaborationLicenseandOtherArrangementsAdditionalInformationDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r95" ] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "vrtx_ShareBasedCompensationAllocationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "ShareBasedCompensationAllocationAbstract", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense:", "label": "Share-based Compensation Allocation [Abstract]", "documentation": "-- None. No documentation exists for this element. --" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r331", "r333", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360", "r361" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsStockbasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total stock-based compensation expense included in \u201cTotal costs and expenses\u201d", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation": "Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r362" ] }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Common stock withheld for employee tax obligations (in shares)", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/HedgingCashFlowHedgingInstrumentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "verboseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r13", "r32", "r134", "r161", "r162", "r163", "r178", "r179", "r180", "r182", "r188", "r190", "r206", "r261", "r262", "r299", "r368", "r369", "r370", "r382", "r383", "r401", "r402", "r403", "r404", "r405", "r406", "r408", "r423", "r424", "r425", "r426", "r427", "r428", "r434", "r503", "r504", "r505", "r513", "r572" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r221", "r222", "r517", "r520", "r522", "r576", "r579", "r583", "r597", "r599", "r603", "r604", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r616", "r637", "r655", "r789", "r812" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "verboseLabel": "Statement", "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r178", "r179", "r180", "r206", "r469", "r509", "r514", "r526", "r527", "r528", "r529", "r530", "r531", "r534", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r551", "r553", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r656" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r178", "r179", "r180", "r206", "r469", "r509", "r514", "r526", "r527", "r528", "r529", "r530", "r531", "r534", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r547", "r548", "r549", "r550", "r551", "r553", "r555", "r556", "r558", "r559", "r560", "r561", "r562", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r572", "r656" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r676", "r687", "r697", "r722" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeBenefitPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeBenefitPlan", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under benefit plans (in shares)", "label": "Stock Issued During Period, Shares, Employee Benefit Plan", "documentation": "Number of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeBenefitPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeBenefitPlan", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock under benefit plans", "label": "Stock Issued During Period, Value, Employee Benefit Plan", "documentation": "Value of shares issued during the period to an employee benefit plan, such as a defined contribution or defined benefit plan." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramAuthorizedAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramAuthorizedAmount1", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized to be repurchased", "label": "Stock Repurchase Program, Authorized Amount", "documentation": "Amount of stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock repurchase program, remaining amount", "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount", "documentation": "Amount remaining of a stock repurchase plan authorized." } } }, "auth_ref": [] }, "us-gaap_StockRepurchasedDuringPeriodShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodShares", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Repurchase of common stock (in shares)", "terseLabel": "Shares repurchased (in shares)", "label": "Stock Repurchased During Period, Shares", "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r13", "r77", "r78", "r109", "r510", "r572", "r598" ] }, "us-gaap_StockRepurchasedDuringPeriodValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockRepurchasedDuringPeriodValue", "crdr": "debit", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity", "http://www.vrtx.com/role/StockbasedCompensationExpenseandShareRepurchaseProgramsAdditionalInformationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repurchases of common stock", "verboseLabel": "Value of shares repurchased", "label": "Stock Repurchased During Period, Value", "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock." } } }, "auth_ref": [ "r13", "r77", "r78", "r109", "r513", "r572", "r598", "r665" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.vrtx.com/role/AccumulatedOtherComprehensiveIncomeLossDetails", "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets", "http://www.vrtx.com/role/CondensedConsolidatedStatementsofShareholdersEquity" ], "lang": { "en-us": { "role": { "totalLabel": "Total shareholders\u2019 equity", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r78", "r81", "r82", "r105", "r536", "r552", "r573", "r574", "r650", "r666", "r761", "r778", "r797", "r816" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedBalanceSheets" ], "lang": { "en-us": { "role": { "terseLabel": "Shareholders\u2019 equity:", "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Line Items]", "label": "Subsequent Event [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r429", "r436" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r429", "r436" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTable", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Table]", "label": "Subsequent Event [Table]", "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued." } } }, "auth_ref": [ "r429", "r436" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Axis]", "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r429", "r436" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.vrtx.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event Type [Domain]", "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r429", "r436" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.vrtx.com/role/SubsequentEvent" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r435", "r437" ] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofCashFlows" ], "lang": { "en-us": { "role": { "terseLabel": "Supplemental disclosure of cash flow information:", "label": "Supplemental Cash Flow Information [Abstract]" } } }, "auth_ref": [] }, "vrtx_TRIKAFTAKAFTRIOMember": { "xbrltype": "domainItemType", "nsuri": "http://www.vrtx.com/20240331", "localname": "TRIKAFTAKAFTRIOMember", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "TRIKAFTA/KAFTRIO", "label": "TRIKAFTA/KAFTRIO [Member]", "documentation": "TRIKAFTA/KAFTRIO [Member]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r716" ] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r708" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r715" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r735" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r737" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.vrtx.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsAdditionalInformationDetails", "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r296", "r298", "r407", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r491", "r746", "r747", "r748", "r749", "r750", "r751", "r752", "r773", "r774", "r775", "r776" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } }, "auth_ref": [ "r738" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } } }, "auth_ref": [ "r739" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual Name" } } }, "auth_ref": [ "r737" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual Title" } } }, "auth_ref": [ "r737" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available", "label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r740" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r738" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "US", "presentation": [ "http://www.vrtx.com/role/RevenueRecognitionDisaggregationofRevenueDetails" ], "lang": { "en-us": { "role": { "terseLabel": "United States", "label": "UNITED STATES" } } }, "auth_ref": [] }, "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USGovernmentAgenciesDebtSecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. government agency securities", "label": "US Government Agencies Debt Securities [Member]", "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)." } } }, "auth_ref": [ "r626", "r643", "r810" ] }, "us-gaap_USTreasurySecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "USTreasurySecuritiesMember", "presentation": [ "http://www.vrtx.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesSubjecttoFairValueMeasurementsDetails", "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsSummaryofCashEquivalentsandMarketableSecuritiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "U.S. Treasury securities", "label": "US Treasury Securities [Member]", "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years)." } } }, "auth_ref": [ "r626", "r643", "r645", "r810" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2023", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r734" ] }, "us-gaap_UnrealizedGainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestments", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsNetUnrealizedGainsLossesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrealized (losses) gains", "label": "Unrealized Gain (Loss) on Investments", "documentation": "Amount of unrealized gain (loss) on investment." } } }, "auth_ref": [ "r9" ] }, "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock", "presentation": [ "http://www.vrtx.com/role/MarketableSecuritiesandEquityInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company's Net Unrealized (Losses) Gains on Corporate Equity Securities", "label": "Unrealized Gain (Loss) on Investments [Table Text Block]", "documentation": "Tabular disclosure of unrealized gains and losses on investments." } } }, "auth_ref": [] }, "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate", "crdr": "credit", "presentation": [ "http://www.vrtx.com/role/IncomeTaxesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net unrecognized tax benefits which would affect the tax rate if recognized", "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate", "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate." } } }, "auth_ref": [ "r379" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.vrtx.com/role/BasisofPresentationandAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r42", "r43", "r44", "r125", "r127", "r128", "r129" ] }, "us-gaap_VariableRateAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateAxis", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "VariableRateDomain", "presentation": [ "http://www.vrtx.com/role/CommitmentsandContingenciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]", "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract", "presentation": [ "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of potentially dilutive securities:", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted (in shares)", "totalLabel": "Diluted weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r193", "r201" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome" ], "lang": { "en-us": { "role": { "terseLabel": "Shares used in per share calculations:", "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.vrtx.com/role/CondensedConsolidatedStatementsofIncome", "http://www.vrtx.com/role/EarningsPerShareScheduleofComputationDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Basic (in shares)", "terseLabel": "Basic weighted-average common shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r192", "r201" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "b", "SubTopic": "30", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479613/805-30-35-1" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a),(b),(c)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "405", "Topic": "942", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481047/942-405-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2A" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(i)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(c)(2)", "SubTopic": "20", "Topic": "860", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4D" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-13" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-8" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "320", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "((a)(1),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479668/805-30-25-6" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4A" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a),(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4C" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4D" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-8" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "55", "Paragraph": "182", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480401/815-10-55-182" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "25", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480238/815-25-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "820", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-7" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//220/tableOfContent" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "250", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//250/tableOfContent" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.BB)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480581/330-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481573/470-10-45-12A" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//810/tableOfContent" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "815", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//815/tableOfContent" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.10)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-6" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-7" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "10", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479567/321-10-45-1" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)(1)(ii)", "SubTopic": "20", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org//606/tableOfContent" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-4" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-12" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-12" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-19" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-22" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-23" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-28A" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-5" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480454/718-10-45-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4E" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-5C" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-1A" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-3A" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 8)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 11)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G)(Footnote 8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SX 210.12-13(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5A", "Subparagraph": "(SX 210.12-13A(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5B", "Subparagraph": "(SX 210.12-13B(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5C", "Subparagraph": "(SX 210.12-13C(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 5)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480632/954-210-45-4" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480602/954-210-50-2" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-20" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r636": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r637": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r638": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r639": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r640": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r641": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r642": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r643": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r644": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17" }, "r646": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11" }, "r647": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r649": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r650": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r651": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2" }, "r652": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r653": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r655": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r659": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r660": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r661": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r662": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r663": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "7", "Subparagraph": "(SX 210.12-15(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-7" }, "r664": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r665": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r666": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii", "Section": "6" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r743": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "842", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4H", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(2)", "Publisher": "SEC" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(3)", "Publisher": "SEC" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(c)", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1B" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479424/830-30-S99-1" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480832/942-320-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480109/944-80-50-1" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" } } } ZIP 82 0000875320-24-000139-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000875320-24-000139-xbrl.zip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̂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�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

  •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end XML 84 vrtx-20240331_htm.xml IDEA: XBRL DOCUMENT 0000875320 2024-01-01 2024-03-31 0000875320 2024-04-30 0000875320 2023-01-01 2023-03-31 0000875320 2024-03-31 0000875320 2023-12-31 0000875320 us-gaap:CommonStockMember 2022-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000875320 us-gaap:RetainedEarningsMember 2022-12-31 0000875320 2022-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000875320 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000875320 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000875320 us-gaap:CommonStockMember 2023-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000875320 us-gaap:RetainedEarningsMember 2023-03-31 0000875320 2023-03-31 0000875320 us-gaap:CommonStockMember 2023-12-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000875320 us-gaap:RetainedEarningsMember 2023-12-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000875320 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000875320 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0000875320 us-gaap:CommonStockMember 2024-03-31 0000875320 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000875320 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000875320 us-gaap:RetainedEarningsMember 2024-03-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2024-01-01 2024-03-31 0000875320 vrtx:TRIKAFTAKAFTRIOMember 2023-01-01 2023-03-31 0000875320 vrtx:OtherCysticFibrosisProductsMember 2024-01-01 2024-03-31 0000875320 vrtx:OtherCysticFibrosisProductsMember 2023-01-01 2023-03-31 0000875320 country:US 2024-01-01 2024-03-31 0000875320 country:US 2023-01-01 2023-03-31 0000875320 srt:EuropeMember 2024-01-01 2024-03-31 0000875320 srt:EuropeMember 2023-01-01 2023-03-31 0000875320 vrtx:OtherNonU.S.Member 2024-01-01 2024-03-31 0000875320 vrtx:OtherNonU.S.Member 2023-01-01 2023-03-31 0000875320 us-gaap:NonUsMember 2024-01-01 2024-03-31 0000875320 us-gaap:NonUsMember 2023-01-01 2023-03-31 0000875320 vrtx:CRISPRTherapeuticsAGMember 2019-01-01 2019-12-31 0000875320 vrtx:CRISPRJDCAMember 2024-01-01 2024-01-31 0000875320 vrtx:CRISPRMember 2024-03-31 0000875320 vrtx:CRISPRJDCAMember 2024-01-01 2024-03-31 0000875320 vrtx:CRISPRJDCAMember 2021-12-31 0000875320 vrtx:CRISPRJDCAMember vrtx:CRISPRMember 2021-12-31 0000875320 vrtx:CRISPRJDCAMember 2023-01-01 2023-03-31 0000875320 vrtx:CRISPRT1DMember 2023-03-01 2023-03-31 0000875320 vrtx:EntradaTherapeuticsMember 2023-02-01 2023-02-28 0000875320 vrtx:EntradaTherapeuticsMember 2024-01-01 2024-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-03-31 0000875320 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2024-01-01 2024-03-31 0000875320 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:EquitySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasurySecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CertificatesOfDepositMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2024-03-31 0000875320 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000875320 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2023-12-31 0000875320 us-gaap:EquitySecuritiesMember 2024-03-31 0000875320 us-gaap:FairValueInputsLevel3Member 2019-12-31 0000875320 srt:MinimumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0000875320 srt:MaximumMember us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputDiscountRateMember 2024-03-31 0000875320 us-gaap:USTreasurySecuritiesMember 2024-03-31 0000875320 us-gaap:USTreasurySecuritiesMember 2023-12-31 0000875320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:AssetBackedSecuritiesMember 2024-03-31 0000875320 us-gaap:AssetBackedSecuritiesMember 2023-12-31 0000875320 us-gaap:CertificatesOfDepositMember 2024-03-31 0000875320 us-gaap:CertificatesOfDepositMember 2023-12-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2024-03-31 0000875320 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2024-03-31 0000875320 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2023-12-31 0000875320 vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember 2024-03-31 0000875320 vrtx:MarketableSecuritiesAndOtherNoncurrentAssetsMember 2023-12-31 0000875320 2023-01-01 2023-12-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2024-03-31 0000875320 us-gaap:CashAndCashEquivalentsMember 2023-12-31 0000875320 vrtx:MarketableSecuritiesMember 2024-03-31 0000875320 vrtx:MarketableSecuritiesMember 2023-12-31 0000875320 vrtx:MarketableSecuritiesNoncurrentMember 2024-03-31 0000875320 vrtx:MarketableSecuritiesNoncurrentMember 2023-12-31 0000875320 us-gaap:OtherAssetsMember 2024-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-01-01 2024-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-01-01 2024-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2024-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2024-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2024-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2022-12-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2022-12-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2022-12-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-01-01 2023-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-01-01 2023-03-31 0000875320 us-gaap:AccumulatedTranslationAdjustmentMember 2023-03-31 0000875320 us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember 2023-03-31 0000875320 us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember 2023-03-31 0000875320 srt:MinimumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0000875320 srt:MaximumMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember 2024-01-01 2024-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 currency:EUR us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 currency:CAD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 currency:GBP us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 currency:AUD us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 currency:CHF us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember 2024-01-01 2024-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:NondesignatedMember 2024-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:DesignatedAsHedgingInstrumentMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-01 2024-03-31 0000875320 us-gaap:ForeignExchangeForwardMember us-gaap:NondesignatedMember us-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMember us-gaap:AccumulatedTranslationAdjustmentMember 2023-01-01 2023-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2024-03-31 0000875320 us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 us-gaap:OtherCurrentLiabilitiesMember us-gaap:ForeignExchangeForwardMember us-gaap:CashFlowHedgingMember us-gaap:DesignatedAsHedgingInstrumentMember 2023-12-31 0000875320 us-gaap:RestrictedStockMember 2024-01-01 2024-03-31 0000875320 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0000875320 us-gaap:EmployeeStockMember 2024-01-01 2024-03-31 0000875320 us-gaap:EmployeeStockMember 2023-01-01 2023-03-31 0000875320 us-gaap:CostOfSalesMember 2024-01-01 2024-03-31 0000875320 us-gaap:CostOfSalesMember 2023-01-01 2023-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-03-31 0000875320 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-01 2024-03-31 0000875320 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-01 2023-03-31 0000875320 2023-02-28 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-31 0000875320 us-gaap:LetterOfCreditMember 2022-07-31 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember us-gaap:BaseRateMember 2022-07-01 2022-07-31 0000875320 srt:MinimumMember us-gaap:RevolvingCreditFacilityMember vrtx:SecuredOvernightFinancingRateSOFRMember 2022-07-01 2022-07-31 0000875320 srt:MaximumMember us-gaap:RevolvingCreditFacilityMember vrtx:SecuredOvernightFinancingRateSOFRMember 2022-07-01 2022-07-31 0000875320 us-gaap:RevolvingCreditFacilityMember 2022-07-01 2022-07-31 0000875320 vrtx:AlpineMember us-gaap:SubsequentEventMember 2024-04-01 2024-04-30 0000875320 vrtx:EMorrowMorreyAtkinsonIIIMember 2024-01-01 2024-03-31 0000875320 vrtx:EMorrowMorreyAtkinsonIIIMember 2024-03-31 0000875320 vrtx:JonathanBillerMember 2024-01-01 2024-03-31 0000875320 vrtx:JonathanBillerMember 2024-03-31 0000875320 vrtx:CarmenBozicMember 2024-01-01 2024-03-31 0000875320 vrtx:CarmenBozicMember 2024-03-31 0000875320 vrtx:ReshmaKewalramaniMember 2024-01-01 2024-03-31 0000875320 vrtx:ReshmaKewalramaniMember 2024-03-31 0000875320 vrtx:OuraniaNiaTatsisMember 2024-01-01 2024-03-31 0000875320 vrtx:OuraniaNiaTatsisMember 2024-03-31 0000875320 vrtx:CharlesFWagnerJrMember 2024-01-01 2024-03-31 0000875320 vrtx:CharlesFWagnerJrMember 2024-03-31 0000875320 vrtx:BruceSachsMember 2024-01-01 2024-03-31 0000875320 vrtx:BruceSachsMember 2024-03-31 shares iso4217:USD iso4217:USD shares vrtx:segment vrtx:target pure VERTEX PHARMACEUTICALS INC / MA 0000875320 --12-31 2024 Q1 false P1M P372D P442D P339D P468D P427D P340D P382D 10-Q true 2024-03-31 false 000-19319 MA 50 Northern Avenue Boston MA 04-3039129 02210 617 341-6100 Common Stock, $0.01 Par Value Per Share VRTX NASDAQ Yes Yes Large Accelerated Filer false false false 258053387 2690600000 2374800000 342600000 266900000 789100000 742600000 76800000 347100000 342700000 241100000 -100000 -1900000 1551100000 1595800000 1139500000 779000000.0 181200000 122600000 -10400000 -11400000 -31200000 1300000 1279100000 891500000 179500000 191700000 1099600000 699800000 4.26 2.72 4.21 2.69 258200000 257400000 261100000 260300000 1099600000 699800000 5400000 -800000 -19700000 2900000 -12300000 7400000 44500000 -26800000 6800000 10000000.0 31600000 -13900000 1131200000 685900000 9158000000 10369100000 1013300000 849200000 1793200000 1563400000 813100000 738800000 511100000 623700000 13288700000 14144200000 1172800000 1159300000 1088000000 1088000000 834900000 839900000 1963000000 1812100000 312900000 293600000 4381400000 2497800000 875700000 895300000 23917400000 22730200000 351400000 364900000 2795900000 2655300000 648600000 527200000 3795900000 3547400000 361500000 376100000 359800000 348600000 853600000 877700000 5370800000 5149800000 0 0 0.01 0.01 1000000 1000000 0 0 0 0 0 0 0.01 0.01 500000000 500000000 258296249 258296249 257695221 257695221 2600000 2600000 7284700000 7449700000 17300000 -14300000 11242000000 10142400000 18546600000 17580400000 23917400000 22730200000 257000000.0 2600000 7386500000 800000 6522800000 13912700000 -13900000 -13900000 699800000 699800000 500000 0.0 135600000 135600000 600000 0.0 166600000 166600000 1600000 0.0 13100000 13100000 122800000 122800000 257500000 2600000 7220200000 -13100000 7222600000 14432300000 257700000 2600000 7449700000 -14300000 10142400000 17580400000 31600000 31600000 1099600000 1099600000 300000 0.0 140400000 140400000 600000 0.0 233500000 233500000 1500000 0.0 15900000 15900000 193000000.0 193000000.0 258300000 2600000 7284700000 17300000 11242000000 18546600000 1099600000 699800000 191900000 122400000 53500000 38800000 -158300000 -113400000 -27000000.0 6400000 -100000 -1900000 36300000 -21700000 251600000 90500000 80100000 82600000 -99200000 -46200000 100000 35700000 194100000 140700000 167600000 89400000 1306600000 899900000 2598500000 1816600000 710500000 50000000.0 68400000 42100000 -180000000.0 0 0 24900000 -2136400000 -1833600000 16900000 14200000 131200000 132800000 233500000 166600000 13200000 10600000 3500000 1100000 -357500000 -294700000 -15600000 12000000.0 -1202900000 -1216400000 10372300000 10512000000 9169400000 9295600000 34800000 120300000 10000000.0 11100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Basis of Presentation and Accounting Policies</span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2024 and 2023.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023, which are contained in our 2023 Annual Report on Form 10-K. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K, we did not adopt any accounting standards that had a significant impact on our consolidated financial statements in the three years ended December 31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2023-07”), which requires public entities to disclose significant segment expenses and other segment items. ASU 2023-07 also requires public entities to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for the interim periods starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-07 will have on our segment disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2023-09”), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 becomes effective for the annual period starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-09 will have on our income tax disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our significant accounting policies are described in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Basis of Presentation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements are unaudited and have been prepared by Vertex Pharmaceuticals Incorporated (“Vertex,” “we,” “us” or “our”) in accordance with accounting principles generally accepted in the United States of America (“U.S. GAAP”). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The condensed consolidated financial statements reflect the operations of Vertex and our wholly-owned subsidiaries. All material intercompany balances and transactions have been eliminated. We operate in one segment, pharmaceuticals.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain information and footnote disclosures normally included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 (the “2023 Annual Report on Form 10-K”) have been condensed or omitted. These interim financial statements, in the opinion of management, reflect all normal recurring adjustments necessary for a fair presentation of the financial position and results of income for the interim periods ended March 31, 2024 and 2023.</span></div>The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full fiscal year. These interim financial statements should be read in conjunction with the audited financial statements for the year ended December 31, 2023, which are contained in our 2023 Annual Report on Form 10-K. 1 <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of condensed consolidated financial statements in accordance with U.S. GAAP requires us to make certain estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of our condensed consolidated financial statements, and the amounts of revenues and expenses during the reported periods. We base our estimates on historical experience and various other assumptions, including in certain circumstances future projections that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in estimates are reflected in reported results in the period in which they become known.</span></div> <div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Adopted Accounting Standards</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As noted in Note A, “Nature of Business and Accounting Policies,” in our 2023 Annual Report on Form 10-K, we did not adopt any accounting standards that had a significant impact on our consolidated financial statements in the three years ended December 31, 2023.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Recently Issued Accounting Standards</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Reporting</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2023-07”), which requires public entities to disclose significant segment expenses and other segment items. ASU 2023-07 also requires public entities to provide in interim periods all disclosures about a reportable segment’s profit or loss and assets that are currently required annually. ASU 2023-07 becomes effective for the annual period starting on January 1, 2024, and for the interim periods starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-07 will have on our segment disclosures.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Tax Disclosures</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASU 2023-09”), which requires public entities to disclose in their rate reconciliation table additional categories of information about federal, state and foreign income taxes and to provide more details about the reconciling items in some categories if items meet a quantitative threshold. ASU 2023-09 becomes effective for the annual period starting on January 1, 2025. We are in the process of analyzing the impact that the adoption of ASU 2023-09 will have on our income tax disclosures.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Revenue Recognition </span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Revenue</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Revenues by Product</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other CF products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Product Revenues by Geographic Location</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contract Liabilities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had contract liabilities of $275.8 million and $170.3 million as of March 31, 2024 and December 31, 2023, respectively, related to annual contracts with government-owned and supported customers in international markets that limit the amount of annual reimbursement we can receive for our cystic fibrosis (“CF”) products. Upon exceeding the annual reimbursement amount provided by the customer’s contract with us, our CF products are provided free of charge, which is a material right. These contracts include upfront payments and fees. If we estimate that we will exceed the annual reimbursement amount under a contract, we defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” Once the reimbursement limit has been reached, we recognize the deferred amount as revenue when we ship the free products. Our CF product revenue contracts include performance obligations that are one year or less.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with CF annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">TRIKAFTA/KAFTRIO</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,483.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,096.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other CF products</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">278.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">“Product revenues, net” by geographic region, based on the location of the customer, consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,519.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,403.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Outside of the United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">967.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues outside of the United States</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product revenues, net</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2483600000 2096700000 207000000.0 278100000 2690600000 2374800000 1519900000 1403800000 967400000 807200000 203300000 163800000 1170700000 971000000.0 2690600000 2374800000 275800000 170300000 Upon exceeding the annual reimbursement amount provided by the customer’s contract with us, our CF products are provided free of charge, which is a material right. These contracts include upfront payments and fees. If we estimate that we will exceed the annual reimbursement amount under a contract, we defer a portion of the consideration received for shipments made up to the annual reimbursement limit as a portion of “Other current liabilities.” Once the reimbursement limit has been reached, we recognize the deferred amount as revenue when we ship the free products. Our CF product revenue contracts include performance obligations that are one year or less.<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contract liabilities at the end of each fiscal year relate to contracts with CF annual reimbursement limits in international markets in which the annual period associated with the contract is not the same as our fiscal year. In these markets, we recognize revenues related to performance obligations satisfied in previous years; however, these revenues do not relate to any performance obligations that were satisfied more than 12 months prior to the beginning of the current year.</span></div> <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Collaboration, License and Other Arrangements</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have entered into numerous agreements with third parties to collaborate on research, development and commercialization programs, license technologies, or acquire assets. Our “Acquired in-process research and development expenses” included $76.8 million and $347.1 million for the three months ended March 31, 2024 and 2023, respectively, related to upfront, contingent milestone, or other payments pursuant to our business development transactions, including </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaborations, licenses of third-party technologies, and asset acquisitions that qualify as in-process research and development.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our collaboration, licensing and asset acquisition agreements that had a significant impact on our financial statements for the three months ended March 31, 2024 and 2023, or were new or materially revised during the three months ended March 31, 2024, are described below. Additional agreements were described in Note B, “Collaboration, License and Other Arrangements,” of our 2023 Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In-license Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">CRISPR Therapeutics AG</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRISPR-Cas9 Gene-editing Therapies Agreements</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2015, we entered into a strategic collaboration, option, and license agreement (the “CRISPR Agreement”) with CRISPR Therapeutics AG and its affiliates (“CRISPR”) to collaborate on the discovery and development of potential new treatments aimed at the underlying genetic causes of human diseases using CRISPR-Cas9 gene-editing technology. We had the exclusive right to license certain targets. In 2019, we elected to exclusively license three targets, including CF, pursuant to the CRISPR Agreement. For each of the three targets that we elected to license, CRISPR has the potential to receive up to an additional $410.0 million in development, regulatory and commercial milestones as well as royalties on resulting net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, we entered into a joint development and commercialization agreement with CRISPR (the “CRISPR JDCA”), which we amended and restated in 2021, pursuant to the terms of the CRISPR Agreement. Under the CRISPR JDCA, we and CRISPR were co-developing and preparing to co-commercialize CASGEVY for the treatment of hemoglobinopathies, including treatments for severe sickle cell disease (“SCD”) and transfusion-dependent beta thalassemia. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the CRISPR JDCA, we lead global development, manufacturing and commercialization of CASGEVY, with support from CRISPR. We also conduct all research, development, manufacturing, and commercialization activities relating to other product candidates and products under the CRISPR JDCA throughout the world subject to CRISPR’s reserved right to conduct certain activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CASGEVY was approved by the U.S. Food and Drug Administration in December 2023 for the treatment of SCD. In connection with this approval, we made a $200.0 million milestone payment to CRISPR in January 2024, which we accrued to “Other current liabilities” and recorded within “Other intangible assets, net” on our consolidated balance sheet as of December 31, 2023. Subsequent to receiving marketing approval for CASGEVY, we continue to lead the research and development activities under the CRISPR JDCA, subject to CRISPR’s reserved right to conduct certain activities. We are reimbursed by CRISPR for its 40% share of these research and development activities, subject to certain adjustments, and we record this reimbursement from CRISPR as a credit within “Research and development expenses.” We also share with CRISPR 40% of the net commercial profits or losses incurred with respect to CASGEVY, subject to certain adjustments, which is recorded to “Cost of sales.” The net commercial profits or losses equal the sum of the product revenues, cost of sales and selling, general and administrative expenses that we have recognized related to the CRISPR JDCA.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the three months ended March 31, 2024, we recognized net reimbursements from CRISPR pursuant to the CRISPR JDCA as credits to “Cost of sales” of $15.8 million, related to CRISPR’s share of the CRISPR JDCA’s net commercial loss, and to “Research and development expenses” of $11.7 million, related to CRISPR’s share of the CRISPR JDCA’s research and development activities.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to receiving marketing approvals for CASGEVY in various markets beginning in December 2023, we accounted for the CRISPR JDCA as a cost-sharing arrangement, with costs incurred related to CASGEVY allocated 60% to us and 40% to CRISPR, subject to certain adjustments. In the three months ended March 31, 2023, we recognized net reimbursements from CRISPR as credits to “Research and development expenses” of $17.9 million and to “Selling, general and administrative expenses” of $5.8 million, related to CRISPR’s share of the CRISPR JDCA’s operating expenses.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CRISPR-Cas9 Gene-editing Hypoimmune Cell Therapies Agreement</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2023, we entered into a non-exclusive license agreement (the “CRISPR T1D Agreement”) for the use of CRISPR’s CRISPR-Cas9 gene-editing technology to accelerate the development of our hypoimmune cell therapies for type 1 diabetes (“T1D”). Pursuant to the CRISPR T1D Agreement, we made a $100.0 million upfront payment to CRISPR, and we determined that substantially all the fair value of our upfront payment was attributable to in-process research and development, for which there is no alternative future use, and that no substantive processes were acquired that would </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">constitute a business. CRISPR is eligible to receive up to an additional $160.0 million in research, development, regulatory and commercial milestones for any products that may result from the agreement, as well as royalties on resulting net product sales. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Entrada Therapeutics, Inc.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, we closed a strategic collaboration and license agreement (the “Entrada Agreement”) with Entrada Therapeutics, Inc. (“Entrada”) focused on discovering and developing intracellular therapeutics for myotonic dystrophy type 1 (“DM1”). Upon closing, we made an upfront payment of $225.1 million to Entrada, and purchased $24.9 million of Entrada’s common stock in connection with the Entrada Agreement. We determined that substantially all the fair value of our upfront payment was attributable to in-process research and development, for which there is no alternative future use, and that no substantive processes were acquired that would constitute a business. We recorded the upfront payment to “Acquired in-process research and development expenses” in the three months ended March 31, 2023. We recorded the investment in Entrada’s common stock at fair value on our condensed consolidated balance sheet within “Marketable securities.” In the first quarter of 2024, Entrada earned a $75.0 million milestone, which we recorded to “Acquired in-process research and development expenses” in the three months ended March 31, 2024 and accrued to “Other current liabilities” as of March 31, 2024. Entrada is eligible to receive up to an additional $335.0 million in development, regulatory and commercial milestones for any products that may result from the Entrada Agreement, as well as royalties on resulting net product sales.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Cystic Fibrosis Foundation</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2004, we entered into a collaboration agreement with the Cystic Fibrosis Foundation, as successor in interest to the Cystic Fibrosis Foundation Therapeutics, Inc., to support research and development activities. Pursuant to the collaboration agreement, as amended, we have agreed to pay tiered royalties ranging from single digits to sub-teens on covered compounds first synthesized and/or tested during a research term on or before February 28, 2014, including ivacaftor, lumacaftor and tezacaftor and royalties ranging from low-single digits to mid-single digits on potential net sales of certain compounds first synthesized and/or tested between March 1, 2014 and August 31, 2016, including elexacaftor. We do not have any royalty obligations on compounds first synthesized and tested on or after September 1, 2016. For combination products, such as ORKAMBI, SYMDEKO/SYMKEVI and TRIKAFTA/KAFTRIO, sales are allocated equally to each of the active pharmaceutical ingredients in the combination product. We record expenses related to these royalty obligations to “Cost of sales.”</span></div> 76800000 347100000 3 3 410000000 200000000 0.40 0.40 15800000 11700000 0.60 0.40 17900000 5800000 100000000 160000000 225100000 24900000 75000000 335000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Earnings Per Share</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including performance-based restricted stock units (“PSUs”))</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the computation of basic and diluted net income per common share for the periods ended:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except per share amounts)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,099.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">699.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">258.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of potentially dilutive securities:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:18pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including performance-based restricted stock units (“PSUs”))</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee stock purchase program</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted weighted-average common shares outstanding</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">261.1 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">260.3 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.26 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.72 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net income per common share</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.69 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1099600000 699800000 258200000 257400000 1700000 1600000 1200000 1300000 0.0 0.0 261100000 260300000 4.26 2.72 4.21 2.69 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not include the securities in the following table in the computation of the diluted net income per common share because the effect would have been anti-dilutive during each period:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.864%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.822%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.824%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unvested restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 0 600000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Fair Value Measurements</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following fair value hierarchy is used to classify assets and liabilities based on observable inputs and unobservable inputs used to determine the fair value of our financial assets and liabilities:</span></div><div style="margin-bottom:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Quoted prices in active markets for identical assets or liabilities. An active market for an asset or liability is a market in which transactions for the asset or liability occur with sufficient frequency and volume to provide pricing information on an ongoing basis.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Observable inputs other than Level 1 inputs. Examples of Level 2 inputs include quoted prices in active markets for similar assets or liabilities and quoted prices for identical assets or liabilities in markets that are not active.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.5pt;padding-right:4.5pt;text-align:center;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3:</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable inputs based on our assessment of the assumptions that market participants would use in pricing the asset or liability.</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,921.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">944.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,397.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,636.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,632.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,632.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,286.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,354.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,932.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,382.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,989.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for the carrying amount and related unrealized gains (losses) by type of investment. Our cash equivalents primarily include money market funds and time deposits.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Corporate Equity Securities</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We classify our investments in publicly traded corporate equity securities as “Marketable securities” on our condensed consolidated balance sheets. Generally, our investments in the common stock of publicly traded companies are valued based </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on Level 1 inputs because they have readily determinable fair values. However, certain of our investments in publicly traded companies have been or continue to be valued based on Level 2 inputs due to transfer restrictions associated with these investments.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, one of our investments in publicly traded corporate equity securities was subject to a contractual sales restriction expiring partially in 2024 and partially in 2025 with a total fair value of $23.0 million. We purchased this investment directly from the publicly traded company in the first quarter of 2023, and do not anticipate any circumstances that would cause this restriction to lapse prior to the periods listed above.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Please refer to Note F, “Marketable Securities and Equity Investments,” for further information on these investments.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value of Contingent Consideration</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, we acquired Exonics Therapeutics, Inc. (“Exonics”), a privately-held company focused on creating transformative gene-editing therapies to repair mutations that cause Duchenne muscular dystrophy (“DMD”) and other severe neuromuscular diseases, including DM1. Our Level 3 contingent consideration liabilities are related to $678.3 million of development and regulatory milestones potentially payable to former Exonics equity holders. We base our estimates of the probability of achieving the milestones relevant to the fair value of contingent payments on industry data attributable to gene therapies and our knowledge of the progress and viability of the programs. The discount rates used in the valuation model for contingent payments, which were between 5.1% and 5.3% as of March 31, 2024, represent a measure of credit risk and market risk associated with settling the liabilities. Significant judgment is used in determining the appropriateness of these assumptions at each reporting period.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"></td><td style="width:73.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.854%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables set forth our financial assets and liabilities subject to fair value measurements by level within the fair value hierarchy:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:33.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.894%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.899%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Level 3</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (asset positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,921.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">944.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,397.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,636.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:23.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,632.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,632.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 24.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial assets</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,286.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6,354.1 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,932.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,382.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,989.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4,392.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="48" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Financial instruments carried at fair value (liability positions):</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:29.25pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Foreign currency forward contracts</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other long-term liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 23.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:36.75pt;text-indent:-6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total financial liabilities</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(78.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(111.1)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(77.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5865300000 4921300000 944000000.0 0 7033900000 5397300000 1636600000 0 43400000 43400000 0 0 46000000.0 46000000.0 0 0 1389400000 1389400000 0 0 546500000 546500000 0 0 356700000 0 356700000 0 425200000 0 425200000 0 792600000 0 792600000 0 306000000.0 0 306000000.0 0 42600000 0 42600000 0 33700000 0 33700000 0 2632200000 0 2632200000 0 1802800000 0 1802800000 0 137800000 0 137800000 0 186800000 0 186800000 0 26300000 0 26300000 0 1800000 0 1800000 0 11286300000 6354100000 4932200000 0 10382700000 5989800000 4392900000 0 1400000 0 1400000 0 33700000 0 33700000 0 77300000 0 0 77300000 77400000 0 0 77400000 78700000 0 1400000 77300000 111100000 0 33700000 77400000 23000000 678300000 0.051 0.053 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents a rollforward of the fair value of our contingent consideration liabilities:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:79.315%"><tr><td style="width:1.0%"></td><td style="width:73.946%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.854%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31, 2024</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decrease in fair value of contingent payments</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 77400000 -100000 77300000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:9.4pt">Marketable Securities and Equity Investments</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable debt and equity securities, which are recorded at fair value, is shown below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:25.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,637.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,632.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,794.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable available-for-sale debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,364.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,351.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,288.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,301.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,436.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,394.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,360.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,347.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,301.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,260.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,394.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,380.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above at fair value were classified on our condensed consolidated balance sheets as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">849.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,260.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,380.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,273.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,351.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not record any allowances for credit losses to adjust the fair value of our marketable available-for-sale debt securities or gross realized gains or losses in the three months ended March 31, 2024 and 2023. Additionally, we did not record any realized gains or losses that were material to our condensed consolidated statements of income during the three months ended March 31, 2024 and 2023. As of March 31, 2024, we held marketable available-for-sale debt securities with a total fair value of $4.0 billion that were in unrealized loss positions totaling $19.1 million. Included in this amount were marketable available-for sale debt securities with a total fair value of $53.8 million and total unrealized loss of $0.4 million that had been in unrealized loss positions for greater than twelve months. We intend to hold these investments until maturity and do not expect to incur realized losses on these investments when they mature.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record changes in the fair value of our investments in corporate equity securities to “Other (expense) income, net” in our condensed consolidated statements of income. During the three months ended March 31, 2024 and 2023, our net unrealized (losses) gains on corporate equity securities with readily determinable fair values held at the conclusion of each period were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"></td><td style="width:63.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized (losses) gains</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, the carrying value of our equity investments without readily determinable fair values, which are recorded in “Other assets” on our condensed consolidated balance sheets, was $74.3 million. During the three months ended March 31, 2024, we reduced the carrying value of one of our equity investments without a readily determinable fair value by $24.3 million based on an observable change in price.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of our cash equivalents and marketable debt and equity securities, which are recorded at fair value, is shown below:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:25.874%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.245%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.545%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.253%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gross <br/>Unrealized <br/>Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair </span></div><div style="margin-bottom:1pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Value</span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="45" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Cash equivalents</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Marketable securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. Treasury securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,395.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,389.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">544.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">546.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">U.S. government agency securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">357.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">356.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">424.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">425.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Asset-backed securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">793.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">792.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">304.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">306.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">42.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">33.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,637.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">4.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(9.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2,632.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,794.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">1,802.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Commercial paper</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">137.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">0.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">186.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable available-for-sale debt securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,364.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(19.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,351.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,288.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,301.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Corporate equity securities </span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(28.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">43.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">72.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(26.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">46.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:33pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total marketable securities</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,436.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">5,394.7 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,360.8 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">3,347.0 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Total cash equivalents and marketable securities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,301.6 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">6.2 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(47.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">11,260.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,394.7 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">15.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(29.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">10,380.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in the table above at fair value were classified on our condensed consolidated balance sheets as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,033.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,013.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">849.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,381.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,497.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,260.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,380.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketable available-for-sale debt securities by contractual maturity were as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures within one year</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after one year through five years</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,273.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,495.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Matures after five years</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,351.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,301.0 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 5865300000 5865300000 7033900000 7033900000 1395100000 1100000 6800000 1389400000 544500000 3000000.0 1000000.0 546500000 357700000 100000 1100000 356700000 424800000 900000 500000 425200000 793500000 700000 1600000 792600000 304900000 1400000 300000 306000000.0 42600000 0.0 0.0 42600000 33700000 0.0 0.0 33700000 2637400000 4300000 9500000 2632200000 1794000000 10500000 1700000 1802800000 137900000 0.0 100000 137800000 186800000 100000 100000 186800000 5364200000 6200000 19100000 5351300000 3288700000 15900000 3600000 3301000000 72100000 0 28700000 43400000 72100000 0 26100000 46000000.0 5436300000 6200000 47800000 5394700000 3360800000 15900000 29700000 3347000000 11301600000 6200000 47800000 11260000000 10394700000 15900000 29700000 10380900000 5865300000 7033900000 1013300000 849200000 4381400000 2497800000 11260000000 10380900000 969900000 803200000 4273300000 2495600000 108100000 2200000 5351300000 3301000000 0 0 0 0 4000000000 19100000 53800000 400000 During the three months ended March 31, 2024 and 2023, our net unrealized (losses) gains on corporate equity securities with readily determinable fair values held at the conclusion of each period were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.559%"><tr><td style="width:1.0%"></td><td style="width:63.208%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:16.102%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.086%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.104%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net unrealized (losses) gains</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -2700000 6400000 74300000 24300000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Accumulated Other Comprehensive Income (Loss)</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the changes in accumulated other comprehensive income (loss) by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.519%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.873%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unrealized Holding Gains (Losses), Net of Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency Translation Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Available-For-Sale Debt Securities</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">On Foreign Currency Forward Contracts</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2023</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.5 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2024</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.5 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.3 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.8)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Balance at March 31, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.0)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1100000 9600000 -25000000.0 -14300000 6800000 -20500000 47200000 33500000 0 -800000 2700000 1900000 6800000 -19700000 44500000 31600000 7900000 -10100000 19500000 17300000 -25000000.0 -100000 25900000 800000 10000000.0 2900000 -9600000 3300000 0 0 17200000 17200000 10000000.0 2900000 -26800000 -13900000 -15000000.0 2800000 -900000 -13100000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Hedging </span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a hedging program intended to mitigate the effect of changes in foreign exchange rates for a portion of our forecasted product revenues denominated in certain foreign currencies. The program includes foreign currency forward contracts that are designated as cash flow hedges under U.S. GAAP having contractual durations from <span style="-sec-ix-hidden:f-622">one</span> to eighteen months. We recognize realized gains and losses for the effective portion of such contracts in “Product revenues, net” in our condensed consolidated statements of income in the same period that we recognize the product revenues that were impacted by the hedged foreign exchange rate changes. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We formally document the relationship between foreign currency forward contracts (hedging instruments) and forecasted product revenues (hedged items), as well as our risk management objective and strategy for undertaking various hedging activities, which includes matching all foreign currency forward contracts that are designated as cash flow hedges to forecasted transactions. We also formally assess, both at the hedge’s inception and on an ongoing basis, whether the foreign currency forward contracts are highly effective in offsetting changes in cash flows of hedged items on a prospective and retrospective basis. If we were to determine that a (i) foreign currency forward contract is not highly effective as a cash flow hedge, (ii) foreign currency forward contract has ceased to be a highly effective hedge or (iii) forecasted transaction is no longer probable of occurring, we would discontinue hedge accounting treatment prospectively. We measure effectiveness based on the change in fair value of the forward contracts and the fair value of the hypothetical foreign currency forward contracts with terms that match the critical terms of the risk being hedged. As of March 31, 2024, all hedges were determined to be highly effective.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We consider the impact of our counterparties’ credit risk on the fair value of the foreign currency forward contracts. As of March 31, 2024 and December 31, 2023, credit risk did not change the fair value of our foreign currency forward contracts.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign currency forward contracts - Not designated as hedging instruments</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also enter into foreign currency forward contracts with contractual maturities of less than one month, which are designed to mitigate the effect of changes in foreign exchange rates on monetary assets and liabilities, including intercompany balances. These contracts are not designated as hedging instruments under U.S. GAAP. We recognize realized gains and losses for such contracts in “Other (expense) income, net” in our condensed consolidated statements of income each period. As of March 31, 2024, we did not have any outstanding foreign currency forward contracts where hedge accounting under U.S. GAAP was not applied.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of March 31, 2024, we expect the amounts that are related to foreign exchange forward contracts designated as cash flow hedges under U.S. GAAP recorded in “Prepaid expenses and other current assets” and “Other current liabilities” to be reclassified to earnings within twelve months.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We present the fair value of our foreign currency forward contracts on a gross basis within our condensed consolidated balance sheets. The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> P18M <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the notional amount in U.S. dollars of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign Currency</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Euro</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,305.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canadian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">British pound sterling</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">186.4 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">225.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Australian dollar</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Swiss Franc</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total foreign currency forward contracts</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,854.5 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,392.3 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 1305500000 1720600000 190000000.0 229500000 186400000 225000000.0 122100000 153300000 50500000 63900000 1854500000 2392300000 P1M 0 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, we recognized the following related to foreign currency forward contracts in our condensed consolidated statements of income:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Designated as hedging instruments - Reclassified from AOCI</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Not designated as hedging instruments</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Total reported in the Condensed Consolidated Statements of Income</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,690.6 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,374.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (expense) income, net</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 3400000 22000000.0 -2400000 3600000 2690600000 2374800000 -31200000 1300000 <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the fair value of our outstanding foreign currency forward contracts designated as cash flow hedges under U.S. GAAP included on our condensed consolidated balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:35.209%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Classification</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div> 26300000 1400000 1800000 33700000 The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The following table summarizes the potential effect of offsetting derivatives by type of financial instrument designated as cash flow hedges under U.S. GAAP on our condensed consolidated balance sheets:<div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"><div><span><br/></span></div></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.3 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:34.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.810%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Recognized</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Presented</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Gross Amounts Not Offset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legal Offset</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Foreign currency forward contracts</span></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(33.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 26300000 0 26300000 1400000 24900000 1400000 0 1400000 1400000 0 1800000 0 1800000 1800000 0 33700000 0 33700000 1800000 31900000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:11.61pt">Inventories</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the first quarter of 2024, following positive results we announced related to our two Phase 3 trials for suzetrigine (formerly VX-548) for acute pain and vanzacaftor/tezacaftor/deutivacaftor for CF, we began capitalizing inventories produced in preparation for our planned product launches. We made these determinations based on our evaluation, among other factors, the safety and efficacy results, and expected likelihood of regulatory approval and commercial success. Prior to the first quarter of 2024, we expensed inventoriable and related costs associated with these product candidates as “Research and development expenses.” As of March 31, 2024, these inventories were not material to our condensed consolidated financial statements.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.458%"><tr><td style="width:1.0%"></td><td style="width:44.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.176%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.236%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of March 31, 2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">As of December 31, 2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">601.8 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">525.1 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.6 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813.1 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 95700000 78700000 601800000 525100000 115600000 135000000.0 813100000 738800000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt">Stock-based Compensation Expense and Share Repurchase Programs</span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Stock-based compensation expense</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Share repurchase program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, our Board of Directors approved a share repurchase program, pursuant to which we are authorized to repurchase up to $3.0 billion of our common stock. The program does not have an expiration date and can be discontinued at any time. During the three months ended March 31, 2024 and 2023, we repurchased 335,773 and 459,017 shares of our common stock under the program, respectively, for aggregate repurchases of $140.4 million and $135.6 million, respectively. As of March 31, 2024, we had $2.4 billion remaining authorization under this program.</span></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended March 31, 2024 and 2023, we recognized the following stock-based compensation expense:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by type of award:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units (including PSUs)</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115.9 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP share issuances</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense related to inventories</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in “Total costs and expenses”</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation expense by line item:</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of sales</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76.3 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.7 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.2 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense included in costs and expenses</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.9 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.4 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax effect</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(79.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:2pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense, net of tax</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112.9 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.8 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 187200000 115900000 5800000 5500000 0 1400000 1100000 400000 191900000 122400000 1800000 1900000 119400000 76300000 70700000 44200000 191900000 122400000 79000000.0 40600000 112900000 81800000 3000000000 335773 459017 140400000 135600000 2400000000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:7.73pt">Income Taxes</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to U.S. federal, state, and foreign income taxes. During the three months ended March 31, 2024 and 2023, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the three months ended March 31, 2024 was lower than the U.S. statutory rate primarily due to changes in our unrecognized tax positions as well as excess tax benefits related to stock-based compensation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our effective tax rate for the three months ended March 31, 2023 was higher than the U.S. statutory rate primarily due to an increase in our unrecognized tax positions partially offset by excess tax benefits related to stock-based compensation.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have reviewed the tax positions taken, or to be taken, in our tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2024 and December 31, 2023, we had $301.6 million and $288.7 million, respectively, of net unrecognized tax benefits, which would affect our tax rate if recognized.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We file U.S. federal income tax returns and income tax returns in various state, local and foreign jurisdictions. We have various income tax audits ongoing at any time throughout the world. Except for jurisdictions where we have net operating losses or tax credit carryforwards, we are no longer subject to any tax assessment from tax authorities for years prior to 2015 in jurisdictions that have a material impact on our consolidated financial statements. In 2023, we came to settlement with the United Kingdom’s HM Revenue &amp; Customs (“HMRC”) with respect to our tax positions for 2015 through 2020 and subsequently received Closure Notices for those periods during the three months ended March 31, 2024. Due to the nature of the adjustments, we will be asserting our rights under the U.S./U.K. Income Tax Convention pursuant to the mutual agreement procedures for the relief of double taxation for these matters.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, European Union member states reached an agreement to implement the minimum tax component (“Pillar Two”) of the Organization for Economic Co-operation and Development’s (the “OECD’s”), global international tax reform initiative with effective dates of January 1, 2024 and 2025. In July 2023, the OECD published Administrative Guidance proposing certain safe harbors that effectively extend certain effective dates to January 1, 2027. The assessment of our potential 2024 exposure for the global per-country minimum tax of 15%, based on our forecasted 2024 results, is immaterial to our condensed consolidated financial statements as the effective tax rates in most of the jurisdictions in which we operate are above 15%.</span></div> During the three months ended March 31, 2024 and 2023, we recorded the following provisions for income taxes and effective tax rates as compared to our income before provision for income taxes:<div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions, except percentages)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,279.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179.5 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">191.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:65.815%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:14.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.992%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.847%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21.5 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 1279100000 891500000 179500000 191700000 0.140 0.215 301600000 288700000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.84pt">Commitments and Contingencies</span><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">2022 Credit Facility</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2022, Vertex and certain of its subsidiaries entered into a $500.0 million unsecured revolving facility (the “Credit Agreement”) with Bank of America, N.A., as administrative agent and the lenders referred to therein (the “Lenders”), which matures on July 1, 2027. The Credit Agreement was not drawn upon at closing and we have not drawn upon it to date. Amounts drawn pursuant to the Credit Agreement, if any, will be used for general corporate purposes. Subject to satisfaction of certain conditions, we may request that the borrowing capacity for the Credit Agreement be increased by an additional $500.0 million. Additionally, the Credit Agreement provides a sublimit of $100.0 million for letters of credit.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed under the Credit Agreement will bear interest, at our option, at either a base rate or a Secured Overnight Financing Rate (“SOFR”), in each case plus an applicable margin. Under the Credit Agreement, the applicable margins on base rate loans range from 0.000% to 0.500% and the applicable margins on SOFR loans range from 1.000% to 1.500%, in each case based on our consolidated leverage ratio (the ratio of our total consolidated funded indebtedness to our consolidated EBITDA for the most recently completed four fiscal quarter period). </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any amounts borrowed pursuant to the Credit Agreement are guaranteed by certain of our existing and future domestic subsidiaries, subject to certain exceptions. </span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Credit Agreement contains customary representations and warranties and affirmative and negative covenants, including a financial covenant to maintain subject to certain limited exceptions, a consolidated leverage ratio of 3.50 to 1.00, subject to an increase to 4.00 to 1.00 following a material acquisition. As of March 31, 2024, we were in compliance with the covenants described above. The Credit Agreement also contains customary events of default. In the case of a continuing event of default, the administrative agent would be entitled to exercise various remedies, including the acceleration of amounts due under outstanding loans.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Direct costs related to the Credit Agreement are recorded over its term and were not material to our financial statements. </span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Guaranties and Indemnifications</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As permitted under Massachusetts law, our Articles of Organization and By-laws provide that we will indemnify certain of our officers and directors for certain claims asserted against them in connection with their service as an officer or director. The maximum potential amount of future payments that we could be required to make under these indemnification provisions is unlimited. However, we have purchased directors’ and officers’ liability insurance policies that could reduce our monetary exposure and enable us to recover a portion of any future amounts paid. No indemnification claims currently are outstanding, and we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We customarily agree in the ordinary course of our business to indemnification provisions in agreements with clinical trial investigators and sites in our product development programs, sponsored research agreements with academic and not-for-profit institutions, various comparable agreements involving parties performing services for us, and our real estate leases. We also customarily agree to certain indemnification provisions in our drug discovery, development and commercialization collaboration agreements. With respect to our clinical trials and sponsored research agreements, these indemnification provisions typically apply to any claim asserted against the investigator or the investigator’s institution relating to personal injury or property damage, violations of law or certain breaches of our contractual obligations arising out of the research or clinical testing of our compounds or product candidates. With respect to lease agreements, the indemnification provisions typically apply to claims asserted against the landlord relating to personal injury or property damage caused by us, to violations of law by us or to certain breaches of our contractual obligations. The indemnification provisions appearing in our collaboration agreements are similar to those for the other agreements discussed above, but in addition provide some limited indemnification for our collaborator in the event of third-party claims alleging infringement of intellectual property rights. In each of the cases above, the indemnification obligation generally survives the termination of the agreement for some extended period, although we believe the obligation typically has the most relevance during the contract term and for a short period of time thereafter. The maximum potential amount of future payments that we could be required to make under these provisions is generally unlimited. We have purchased insurance policies covering personal injury, property damage and general liability that reduce our exposure for indemnification and would enable us in many cases to recover all or a portion of any future amounts paid. We have never paid any material amounts to defend lawsuits or settle claims related to these indemnification provisions. Accordingly, we believe the estimated fair value of these indemnification arrangements is minimal.</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Contingencies</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have certain contingent liabilities that arise in the ordinary course of our business activities. We accrue for such contingent liabilities when it is probable that future expenditures will be made and such expenditures can be reasonably estimated. Other than our contingent consideration liabilities discussed in Note E, “Fair Value Measurements,” there were no material contingent liabilities accrued as of March 31, 2024 or December 31, 2023.</span></div> 500000000 500000000 100000000 0.00000 0.00500 0.01000 0.01500 3.50 4.00 0 0 0 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.07pt">Additional Cash Flow Information</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,289.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,372.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,289.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,372.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cash, cash equivalents and restricted cash at the beginning and ending of each period presented in our condensed consolidated statements of cash flows consisted of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.709%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.809%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(in millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,369.1 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,158.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,504.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,289.9 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash per condensed consolidated statement of cash flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,372.3 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,169.4 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,512.0 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,295.6 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 10369100000 9158000000 10504000000 9289900000 3200000 11400000 8000000.0 5700000 10372300000 9169400000 10512000000 9295600000 <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:8.28pt">Subsequent Event</span><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we entered into an agreement and plan of merger (the “Alpine Merger Agreement”) to acquire all of the issued and outstanding shares of common stock of Alpine Immune Sciences, Inc. (“Alpine”), a publicly traded biotechnology company focused on discovering and developing innovative, protein-based immunotherapies, for approximately $4.9 billion in cash. Alpine’s lead molecule, povetacicept, is a highly potent and effective dual antagonist of BAFF (“B cell activating factor”) and APRIL (“a proliferation inducing ligand”). Through Phase 2 development, povetacicept has shown potential best-in-class efficacy in IgA nephropathy (“IgAN”), a serious, progressive, autoimmune disease of the kidney that can lead to end-stage-renal disease. The transaction is expected to close in the second quarter of 2024, subject to certain customary closing conditions, including the completion of a tender offer, the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other conditions. We will account for the acquisition in the period that it closes. We intend to fund the acquisition with our cash and cash equivalents.</span></div> 4900000000 false false false The following table describes the written plans for the sale of our securities adopted by our executive officers and directors during the first quarter of 2024, each of which is intended to satisfy the affirmative defense conditions of Rule 10b5-1 (each, a “Trading Plan”). <div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.179%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.693%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name and Title</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Date of Adoption of Trading Plan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Scheduled Expiration Date of Trading Plan (1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Maximum Shares Subject to Trading Plan</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E. Morrow "Morrey" Atkinson, III</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/22/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,290</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jonathan Biller</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief Legal Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/13/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4/30/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carmen Bozic</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/27/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/31/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,680</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reshma Kewalramani</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer and President</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/7/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/20/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,388</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ourania "Nia" Tatsis</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief Regulatory and Quality Officer</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/29/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5/1/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Charles F. Wagner, Jr.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">EVP, Chief Financial Officer</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/26/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1/31/2025</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,500</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Bruce Sachs</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Director</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/12/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2/28/2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,368</span></div></td></tr><tr><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1) A Trading Plan may expire on an earlier date if all contemplated transactions are completed before such Trading Plan’s expiration date, upon termination by broker or the holder of the Trading Plan, or as otherwise provided in the Trading Plan.<br/>(2) The maximum shares listed has not been reduced by the number of shares of common stock that will be withheld to satisfy tax withholding obligations at future vesting dates because such number of shares is not yet determinable. </span></td></tr></table></div> E. Morrow "Morrey" Atkinson, III EVP, Chief Technical Operations Officer, Head of Biopharmaceutical Sciences and Manufacturing Operations 2/22/2024 true 25290 Jonathan Biller EVP, Chief Legal Officer true 2/13/2024 9825 Carmen Bozic EVP, Global Medicines Development and Medical Affairs, and Chief Medical Officer true 2/27/2024 13680 Reshma Kewalramani Chief Executive Officer and President true 2/7/2024 96388 Ourania "Nia" Tatsis EVP, Chief Regulatory and Quality Officer 2/29/2024 true 9484 Charles F. Wagner, Jr. EVP, Chief Financial Officer true 2/26/2024 6500 Bruce Sachs Director true 2/12/2024 12368